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ABSTRACT 
Stem cells have significant potential to treat many age-related degenerative disorders that 
affect  increasing  numbers  of  people  globally.  This  thesis  investigated  the  capacity  for 
omnicytes  and  human  pluripotent  stem  cells  (hPSC)  to  undergo  directed  differentiation 
towards  neuronal  cell  types  for  the  treatment  of  ischemic  stroke  and  Parkinson’s  disease 
respectively.  
Omnicytes express a range of markers related to pluripotency and plasticity; however they are 
a challenging cell source to use in the development of cell therapies. Variability in omnicyte 
quality was associated with patient source, disease type and cryopreservation, all of which 
affected the reproducibility of data. 
Successful generation of dopaminergic neurons was achieved using a suspension-based hPSC 
culture system, with modified culture medium designed to replicate endogenous signalling 
during  development.  Neurons  expressing  key  markers  of  dopaminergic  neurons  were 
generated and were capable of producing dopamine in response to KCl challenge. The work 
also showed that transfection of saRNA could enhance the expression of key genes i.e. foxa2, 
lmx1a and TH, relative to mock transfected cultures, although not significantly. Results also 
showed that the specific hESC line used (Shef6) had a greater propensity for differentiation 
toward dopaminergic neurons than MSUH001 hiPSC.  
This work successfully used saRNA to enhance gene expression, but shows that transfection 
efficiency is a limiting factor to its use. However, if transfection efficiency can be addressed, 
saRNA will become a powerful tool in the generation of cell therapies, particularly if it can be 
applied to suspension cell cultures. 
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CHAPTER 1 - INTRODUCTION 
1.1  Regenerative medicine and cell therapy 
Regenerative medicine as a discipline includes a number of areas, from the widely known cell 
transplantation element to synthesised biomaterials including; connecting tissues, matrices 
and scaffolds. Within this body of work we will be focusing on the cell therapy element and the 
potential  of  specific  cell  types  in  the  development  of  therapeutically  useful  cells  for  the 
treatment of neurological disorders.  
The  cell  therapy  industry  (CTI)  is  presently  a  very  small  sector  when  compared  with  the 
pharmaceutical industry ($300billion (Bn) per annum (WHO 2013)). There are approximately 
50  publically  listed  companies  across  Asia,  North  America  and  Europe,  with  an  estimated 
worth of $7Bn with an estimated increase in revenues of $1Bn per annum (Mason, McCall et 
al. 2012). This is a rapidly growing and highly lucrative industry that is attracting a lot of 
investment. 
Within the cell therapy sector there is a huge amount of activity. There are a number of adult 
cell-based  and  embryonic  cell-based  products  moving  through  different  regulatory 
frameworks. Within the adult cell arena there a number of key players, for example; Athersys, 
Mesoblast and Osiris (Brindley and Mason 2012), with Athersys currently moving Multistem® 
through Phase 2 studies for the treatment of ulcerative colitis and ischemic stroke, with other 
clinical phase trials on-going for multiple indications (Athersys 2013). There are also number of 
companies approaching the market with embryonic cell-based products and moving through 
clinical trials, including, Advanced Cell Technologies (ACT), BioTime, Cell Cure Neuroscience 
and  Pfizer,  with  ACT,  for  example,  moving  through  Phase  1/2  studies  with  their  human 
embryonic cell-based treatment for Stargardt’s Macular Dystrophy (Trials.gov 2013) and Age 
related macular degeneration (Trials.gov 2013). Recently there has been a set back within the 
embryonic space with Geron exiting this sector to pursue other commercial ventures. Geron 
was considered to be a front-runner, with its product for the treatment of spinal cord injury 16 
 
(Keirstead, Nistor et al. 2005) moving well through Phase 1 clinical trials. Thankfully the exit of 
this player has had limited impact on the market with other companies taking up the mantle.  
For this industry to realise its potential and for it to succeed in the healthcare marketplace a 
number  of  challenges  unique  to  the  CTI  must  be  addressed,  including,  technological 
innovation, infrastructure, manufacturing, development of enabling technologies, regulation 
and reimbursement. This thesis will focus on one of the main challenges of the industry, yield, 
and  the  ability  to  generate  appropriate  volumes  of  the  desired  cell  type  to  allow  the 
generation of a product. This thesis focuses on the potential of specific cell types (stem cells) in 
the  manufacture  of  therapeutically  beneficial  neuronal  cell  types  for  the  treatment  of 
neurological conditions: acute ischemic stroke and Parkinson’s disease (PD).  
This chapter introduces the background to this work, the cells being utilised and the disease 
indications that the technology hopes to address. Specific detail will be provided within the 
various chapter introductions.  
1.2  Stem cells background   
Human stem cells can be broadly placed into three categories: Human embryonic stem cells 
(HESC), human induced pluripotent stem  cells (hiPSC) and human adult stem cells (hASC). 
These  cell  types  can  be  either  defined  as  allogeneic,  non-patient-derived  or  autologous, 
patient derived. These specific cell definitions are explained in more detail below. 
1.2.1  Autologous and Allogeneic 
Cells  have  been  used  in  medical  therapies  since  the  1960’s,  with  the  first  bone  marrow 
transplants  being  carried  out  on  patients  with  depleted  stem  cell  populations  following 
chemotherapy or radiotherapy treatments for cancer. These early therapies were primarily 
performed using donor bone marrow (allogeneic). This in turn meant that the donor cells were 
unlikely to be a perfect genetic match to that of the patient and so immunosuppressant drugs 
were required to prevent rejection of the graft and to subdue adverse immune responses - 
graft versus host disease. This though left the patient immune-compromised and exposed to 17 
 
pathogens and potential secondary complications. More recently autologous cell therapies are 
preferentially used, whereby the cells are collected from the patient prior to treatment and 
then administered following chemotherapy or radiotherapy to initiate the repopulation of the 
bone marrow and the patient’s immune system. The advantage of autologous treatment is 
that  this  removes  the  need  for  immunosuppression,  reducing  the  chance  of  graft/host 
rejection.  It  also  bypasses  any  ethical  barriers  regarding  the  use  of  cells  from  another 
individual.  
1.2.2  Human Embryonic Stem Cells 
Embryonic stem cells were first identified and cultured from mouse models in 1981 (Martin 
1981). Due to the comparative complexity and ethical issues associated with working with 
human  tissues,  it  took  another  two  decades  for  researchers  to  culture  hESCs  (Thomson, 
Itskovitz-Eldor et al. 1998). hESCs are harvested and generated from the blastocyst inner cell 
mass of an embryo, day 4-5 post fertilisation, at which time the cell mass is relatively low (50-
150  cells)(Svendsen  C.  N.  2008).  These  cells  are  then  cultured  and  expanded  under  hESC 
conditions (this is described in detail in Chapter 2).  hESC have the capacity to form all three 
germinal layers: ectoderm; endoderm; and mesoderm. These cells have the potential to form 
any specialised mature cell found in the human body. In normal development they go on to 
form all the various organs and tissues of the body but in-vitro hESC can be cultured and 
expanded indefinitely under the correct stimuli or induced to form specific cell types. 
hESCs present some of the greatest therapeutic potential when looking to generate cell types 
that are not easily obtainable from donor or autologous sources but their use has created 
considerable ethical debate. hESC also possess the potential for tumour formation which is a 
hurdle that needs to be addressed before hESC can be used in any therapeutic intervention. 
Though hESCs are harvested from human embryos supplied surplus to requirement from in-
vitro fertilisation, pro-life activists question the morality of their use in research (Svendsen C. 18 
 
N. 2008). There are strict regulations around the world, with Europe and the USA leading the 
way in developing and reviewing regulatory frameworks (EuroStemCell 2013, Health 2013).  
1.2.3  Human induced pluripotent stem cells 
In  2006  a  new  and  potentially  revolutionary  stem  cell  variation  was  discovered,  hiPSC 
(Takahashi and Yamanaka 2006). These cells are derived from human fibroblasts that have 
been induced through genetic manipulation to behave like hESCs. Rather than having only 
limited differentiation capacity which is characteristic of hASCs, it is thought that they can be 
directed to differentiate into any cell type. It is unlikely that these will be used in therapeutics 
for some time, as research is still required to understand the oncogenic status of this cell type 
and to understand how the genetic manipulation has fully affected the cell. These cells do by-
pass the potential ethical and legal issues associated with hESCs.  
1.2.4  Human Adult Stem Cells 
hASCs are found in the majority of organs in the human body (Henry and Asa 2004). They are 
found  within  populations  of  specialised  cells  but  they  themselves  remain  undifferentiated 
(Health 2009). The main function of adult stem cells is to repair and maintain their tissue type. 
For example, mesenchymal stem cells (MSC) found in bone marrow differentiate and divide to 
form bone, cartilage, fat, tendon and muscle (Institute 2013), maintaining and repairing these 
specific cell types. hASCs can maintain their ability to self-renew and produce specialised adult 
cells even after long periods of inactivity. This quality of senescence is a key characteristic of 
stem cells. 
hASCs have been a focus of research for the last 50 years and were first used in medical 
therapeutics in 1968 for bone marrow transplants (Health 2009). There are no ethical issues 
associated with their use and there is no requirement for immunosuppressant drugs as with 
autologous cells. They also have the potential for differentiation (Watt, Hogan et al. 2000, 
Wagers and Weissman 2004) for example hematopoietic stem cells (HSC) have been shown to 
have the potential to generate cell types outside of their normal linage under the correct 19 
 
stimuli, for example, the generation in-vivo of neurons when implanted into the injured spinal 
cord of chicken embryos (Sigurjonsson, Perreault et al. 2005).  
1.3  Stem Cell Characteristics  
Stem  cells  have  specific,  unique  characteristics  that  make  them  extremely  attractive  for 
incorporation into medical therapies. They are able to undergo self-renewal and retain their 
undifferentiated state when provided with the correct stimuli but can also differentiate to 
produce daughter cells with specialised functions. These traits and abilities possessed by stem 
cells are explained in more detail below. 
1.3.1  Niche dependency 
Whilst  the  intrinsic  genetic  programme  of  the  stem  cell  is  critical  to  its  phenotype, 
environmental  stimuli  are  also  thought  to  be  important  regulators  of  behaviour.  This 
environment  is  commonly  referred  to  as  the  stem cell  niche  microenvironment  (Schofield 
1978, Martinez-Agosto, Mikkola et al. 2007). The niche refers collectively to the chemical and 
biological  signals,  along  with  the  physical  (mechanical)  contact  within  the  immediate 
environment of the cell. These signals allow stem cells to maintain their identity and prevent 
the cells from losing their ‘stemness’. Niche dependency is best demonstrated by removing the 
stem cell from its niche. With the loss of the stimuli associated with the niche the cell divides, 
differentiates  or  become  apoptotic  (Scadden  2006).  Self-renewal,  pluripotency  and 
maintenance/repair are influenced by the stem cell niche, which either maintain the stemness 
of the cell or causes it to differentiate and specialise. There is one known exception to this 
rule, HSCs, which are able to enter the circulatory system and then ‘home’ back to their niche, 
maintaining their own ‘stemness’ (Martinez-Agosto, Mikkola et al. 2007). 
The  characteristics  of  the  niche  are  simulated  or  modified  in  differentiation  or  expansion 
protocols. By including or excluding specific stimuli, the cells can be maintained, expanded as a 
pluripotent cell population or directed towards a desired cell type. 20 
 
1.3.2  Potency  
Potency describes a cell’s ability to give rise to a variety of mature specialised cell types from 
one unspecialised stem cell. hESC and hiPSC are thought to have this ability to the greatest 
degree and are considered to be pluripotent, with the ability to produce over 200 different cell 
types.  
The majority of hASCs are considered multipotent (i.e. HSCs), and are able only to produce a 
limited number of different cell types connected to their particular lineage, under normal, 
niche, conditions. Other tissue specific cell populations are more restricted still, for instance 
neural stem cells (NSC) found within the hippocampus are believed to have the potential to 
produce purely neurones (Martinez-Agosto, Mikkola et al. 2007). 
1.3.3  Cell maintenance and repair 
Through asymmetric division stem cells produce daughter cells to maintain their population to 
repair areas of damage within the tissue. As cells are removed from the niche they mature and 
differentiate into the required cell type through external stimuli (Martinez-Agosto, Mikkola et 
al. 2007).  
1.3.4  Self-renewal  
Where in cell maintenance and repair, stem cells produce specialised daughter cells through 
asymmetric division, they are also able to self-renew, through symmetric division. This process 
enables stem cells to maintain their population and expand it within the niche  (Martinez-
Agosto, Mikkola et al. 2007). The mitotic spinal during division remains parallel to the niche, 
ensuring that the daughter cell maintains in contact with the niche and its stimuli. Through this 
process  the  progeny  produced  are  identical  to  the  parent  cell,  retaining  their  stem  cell 
characteristics.  
1.3.5  Quiescence  
Stem cells are thought to be relatively quiescent, and under normal physiological conditions 
proliferate  and  divide  infrequently  (Morshead,  Reynolds  et  al.  1994).  This  characteristic  is 21 
 
considered important to maintain cell homeostasis and reduce the probability of mutagenic 
events. The molecular pathways that control quiescence are closely related to the stem cell 
niche interaction, when separated from niche stimuli, as is the case for asymmetric division, 
quiescence is interrupted and the cells differentiate.  
1.4  Acute ischemic infarct (Stroke)  
Stroke is the fourth most common cause of mortality in the United Kingdom (UK). There are 
approximately 150,000 incidences of stroke (Association 2013) per annum and stroke accounts 
for approximately 50,000 deaths every year in England (Association 2013). It is also the leading 
cause of long and short term disability globally (Deb, Sharma et al. 2010). There is a 33% 
mortality rate associated with stroke one year post incidence (Foundation 2009) and one third 
of the surviving patients left with disabilities including speech and vision difficulties, difficulty 
with mental processes, tiredness and weakness associated with one side of the body.  The 
financial burden of stroke on the UK National Health Service (NHS) and economy via lost 
productivity is considerable and estimated at £7Bn annually (Excellence 2010). The number of 
incidences  of  stroke  is  only  anticipated  to  increase  in  the  future  due  to  the  global  aging 
population. Therefore, the development of new and innovative therapies for the stroke is of 
paramount importance.  
There  are  a  number  of  risk  factors  associated  with  stroke  which  include;  social,  ethnic, 
pharmacological and physiological factors, resulting from the individual or the environment. 
Social factors include; drug use, drinking, smoking and the use of the contraceptive pill and 
there is evidence to suggest that some ethnic groups may be at higher risk. Other factors 
include but are not limited to hypertension, arterial fibrillation and diabetes (Adina Michael-
Titus 2007, Choices 2012). 
There are two main types of stroke that result in an interruption of the blood supply to the 
brain, ischemic and haemorrhagic, both can lead to infarction and cell death. Ischemic stroke, 
caused by a blockage within a vessel of the brain, accounts for approximately 87% of stroke 22 
 
cases; with haemorrhagic stroke, the bursting of a vessel, accounting for the remainder (Lopez, 
Mathers et al. 2006, Association 2012). 
Due to its prominence and the proposed mechanism of treatment, cell replacement, this thesis 
focuses on acute ischemic stroke, and the development of a cell therapy from omnicytes to 
treat the condition.  
1.4.1  Pathophysiology 
The human circulatory system pumps blood around the body, providing oxygen and nutrient to 
cells and removing metabolic waste products, such as carbon dioxide (CO2). Though the brain 
only constitutes 2% for the body’s mass it utilises 20% of the available oxygen content of the 
circulatory system (Adina Michael-Titus 2007).  This is because the brain is solely dependent on 
aerobic respiration to provide energy to support its intensive metabolism; other organs have 
the  capacity  for  anaerobic  respiration.  This  makes  the  brain  extremely  vulnerable  to  the 
consistent supply of oxygen  (Thwaites, Reebye et al. 2012).  
Ischemic strokes occur when the blood to an area of the brain is restricted (by approximately 
50%) and can be caused by the narrowing of the arteries through atherosclerosis or blocked as 
a result of an embolus. Though these are the primary causes of an ischemic stroke, it can also 
be caused by systemic hypofusion (the blood flow to the whole body is reduced), typically 
caused by heart failure (Association 2012). Atherosclerosis is the build-up of plaque within the 
lumen of the artery, which can lead to the formation of a thrombus, blocking the lumen of the 
vessel and restricting blood flow (Adina Michael-Titus 2007). Atherosclerosis can occur as a 
result of high blood pressure, cholesterol, smoking or high sugar intake. Embolic strokes are 
caused  by the movement  of  an embolus  formed  elsewhere  in  the  body  to the  brain  and 
blocking the vessels. The majority of embolus strokes occur in the morning when the victim 
undergoes a sudden transition from rest state, characteristic of sleep, to the physical activity of 
awake, resulting in fluctuations in blood pressure, dislodging the embolus present. 23 
 
The severity of an ischemic stroke differs depending on the area of the brain that has been 
effected and the duration of the ischemia (Mitsios, Gaffney et al. 2006). An area of the brain 
that  is  starved  of  blood  for  20  seconds  becomes  anoxic  (oxygen  starved)  and  lapses  into 
unconsciousness. If the ischemia continues for up to five minutes, the cells in the effected 
regions  will  die  (Mitsios,  Gaffney  et  al.  2006).  This  is  due  to  the  reduction  in  available 
adenosine triphosphate (energy) which results in reduced energy dependent functions such as 
membrane  ionic  pump  function  triggering  membrane  depolarisation,  failure  of  ion 
homeostasis and release of glutamate (Dirnagl, Iadecola et al. 1999). These processes, which 
happen between 1- 2 hours (hr)  (Mitsios, Gaffney et al. 2006), trigger a cascade of other 
effects which result in cell apoptosis and necrotic cell death. In the immediate region (the 
core), cells are instantly dead. The region surrounding the core (the penumbra) experiences 
significantly  reduced  blood  flow  and  it  is  here  that  energy  dependant  functions  fail  and 
apoptosis occurs. The longer the duration of the incidence the greater the damage in this 
region (Deb, Sharma et al. 2010). The penumbra and the surrounding tissue are the targets of 
cell therapy, to prevent or reduce cell death within these regions or replace the cells lost. 
 1.4.2  Current treatment 
There  is  currently  only  one  Food  and  Drug  Agency  (FDA,  United  States)  approved  drug 
treatment for stroke. Approved in 1996, intravenous recombinant tissue plasminogen activator 
(rt-PA) (Albers, Bates et al. 2000) has a treatment window of 6hrs after stroke onset and is 
ideally administered within 3hrs (Association 2013). This time limit inevitably means that the 
majority  of  patients  cannot  benefit  from  the  treatment.  Pharmaceutical  treatments  in 
development are targeting early onset stroke, and focus on anticoagulants and antiplatelet, 
but have been shown to have limited impact on the revascularisation of the affected area. In 
addition  to  the  pharmaceutical  intervention  techniques  mentioned  there  are  also  two 
mechanical  treatments  available.  These  function  to  attach  to  the  insulting  embolism  or 
thrombus and allow manual removal. FDA approved devices include: the Mechanical Embolus 24 
 
Removal  of  Cerebral  Ischemia  and  the  mechanical  thrombectomy  device;  the  Penumbra 
system (Bose, Henkes et al. 2008, Cohen, Itshayek et al. 2011).   
1.4.3  Cellular therapies for Ischemic Stroke 
With  currently  available  pharmacological  and  surgical  treatments  having  a  number  of 
limitations, namely their short administration window, the advent of cell transplantation and 
the potential for long term regeneration through the use of stem cells is an attractive adjuvant 
to stroke patients. Candidate cell types have the potential to act in two modes; they can 
function in a trophic, neuroprotective capacity to subdue the impact of the ensuing stroke and 
reduce the level of cell death  experienced, otherwise stem cells have the potential to be 
administered at a later stage to replace non-viable cells and tissues and to restore function.  
1.4.4  In-vitro investigation 
The ability to generate neurons in-vitro has evolved from being a niche expertise to a widely 
used  technique  within  many  laboratories.  The  potential  of  stem  cells  in  the  treatment of 
neurological conditions is coming closer to being realised. The ability to generate neurons from 
a number cell sources including; hESC, hiPSC, immortalized cell lines and hASC has been shown 
by different groups around the world. 
hESC are an extremely attractive source of cells for this type of differentiation due to their 
ability for expansion and pluripotency. It was demonstrated by Reubinoff et al. that it was 
possible to generate an enriched population of neuronal progenitors that were capable of 
undifferentiated proliferation from a starting population of HES-1 (Reubinoff, Pera et al. 2000). 
Similarly Chambers et al. described a protocol that claimed to be able to differentiate hESC 
into functional neurons at an efficiency of 80% using two inhibitors of smad signalling; noggin 
and SB431542 (TGF-β inhibitor) (Chambers, Fasano et al. 2009).   
There is a drive to try to avoid the use of hESC in the development of treatments due to their 
ethical status and their potential for tumour formation. With this in mind researchers have 
also started work to investigate other adult cell populations.  25 
 
One promising source of cells includes immortalized cell lines. An example is NTera2 (NT2), 
which was established from a human testicular germ cell tumour and has been shown to be 
exclusively committed to the neuronal lineage upon exposure to retinoic acid (RA) (Andrews, 
Damjanov et al. 1984). The resulting cells, NT2N, display functional neuronal progenitor and 
terminally  differentiated  cell  characteristics  (Pleasure,  Page  et  al.  1992,  Pleasure  and  Lee 
1993).  
hASC have also been shown to have potential within this field, marrow subpopulation MSCs 
have been differentiated successfully into neuron-like cells. These neuron-like cells expressed 
neuron-specific endonuclease, NeuN and Neurofilament-M (Woodbury, Schwarz et al. 2000). 
Hermann et al. (Hermann, Gastl et al. 2004) showed that MSCs could be differentiated into 
neuronal-like  progenitors  when  cultured  in  basic  fibroblast  growth  factor  2  (FGF2)  and 
epidermal growth factor (EGF), which then required maturation using other factors such as 
brain derived neurotrophic factor (BDNF) and RA. It is clear that hASC have potential within 
this field and that they possess some ability to be differentiated towards a neuronal linage; 
however it is also clear that other factors are required to completely commit these cells to the 
relevant differentiation pathways.  
1.4.5  Preclinical investigations 
Specific cell types have been shown to have potential in brain repair following ischemic attack. 
A number of pre-clinical trials have been carried out on autologous derived adult stem cells 
with some success. Groups have shown that the administration of rat derived MSCs into rats 
subjected to middle cerebral artery occlusion (MCAO) resulted in significant recovery over the 
control arms of the investigation (neurological severity scores, adhesion removal and rota-rod 
tests  analysis  techniques  were  assessed).  It  was  also  shown  that  the  administered  cells 
localised to the site of infarct, resulting in an up-regulation of astrocyte and neuronal markers 
as well as reducing scaring levels (Chen, Li et al. 2001, Shen, Li et al. 2007). 26 
 
Bone  marrow  derived  HSC  have  also  been  investigated  for  the  potential  in  brain  repair 
following  ischemic  attack.  HSCs  isolated  from  bone  marrow  biopsies  or  by  mobilisation 
through Granulocyte colony-stimulating factor (GCS-F) stimulation have both been studied. 
HSC have been shown to ‘home’ to a site of injury and to secrete trophic factors such as 
vascular endothelial growth factor (VEGF), FGF2 and insulin-like growth factor 1 (IGF1), which 
promote revascularization and the protection of damaged tissues (Taguchi, Soma et al. 2004). 
Taguchi  et  al.  showed  that  mice  following  MCAO,  injected  with  HSC  showed  enhanced 
angiogenesis and  neurogenesis at the site of infarct. It was also shown that treated mice 
compared to the control showed lower levels of behavioural abnormalities (Taguchi, Soma et 
al.  2004).  Similar  results  were  shown  by  Schwartin  et  al.  who  investigated  the  anti-
inflammatory effects of purified HSC in MCAO treated mice. Post-mortem studies showed that 
administered  HSC  migrated  to  the  peri-infarct  regions  significantly  reducing  the  infarct 
volumes and reducing the level of apoptotic cell death, this was in part thought to be due to a 
subdued immune response caused by the administered HSC (Schwarting, Litwak et al. 2008). 
Human neural stem cells (hNSC) have also been investigated. hNSC are derived from foetal or 
embryonic central nervous system (CNS) and cultured and expanded in-vitro. It was shown in 
rats subjected to MCAO that cultured hNSC administered to the non-ischemic zone migrated 
towards the infarct area and started to express mature neuronal markers. Though this shows 
some potential for this cell type in the treatment of ischemic stroke the use of hNSC in routine 
clinical use is questionable due to their derivation from foetal or embryonic tissues, raising 
ethical issues but also logistic issues in maintaining availability and quality control. 
1.4.6  Clinical trials 
Bone marrow derived and immortalised cell lines are being investigated within clinical trials in 
the  UK  (Catapult  2013).  The  inclusion  of  bone marrow  derived  MSCs  in  the  treatment  of 
ischemic stroke was first reported in 2005 by Bang et al. (Bang, Lee et al. 2005) who performed 
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infarct (MCA). A defined number of autologous cells were injected intravenously and patients 
were examined against the Barthel index and Rankin Score one year post administration. It 
was observed that the treated group steadily improved in both indices and that there was no 
adverse reactions to the treatment. A similar investigation was performed on 52 patients over 
a five year period with similar findings. The improvements were thought to be associated with 
increased Stromal cell-derived factor-1 (SDF-1) levels in the patient serum and the involvement 
of other areas of the brain, namely the sub ventricular region of the lateral ventricle (Lee, Hong 
et al. 2010). Improvements were also observed by Savitz et al. in a patient group injected with 
autologous mononuclear cells (MNC). Patients showed enhanced improvement on the Barthel 
index, with no adverse effects associated with the administration of the cells (Savitz, Misra et 
al. 2011). 
There are two clinical trials associated with stroke that have recently finished in the UK; a 
phase  1  trial  based  at  Hammersmith  Hospital,  Imperial  College  London  finished  in  2014 
(Banerjee,  Bentley  et  al.  2014)  and  a  commercial  trial,  PISCES,  by  ReNeuron  Group  Plc. 
(Therapy  2013).  Imperial  College  London’s  trial  involved  the  administration  of  in-vitro 
expanded Cluster of designation 34 (CD34)
+ cells within 7 days of the event. It involved 10 
patients  and  commenced  in  2007.  PISCES,  authorised  by  the  Gene  Therapy  Advisory 
Committee (GTAC, UK) investigated the safety and feasibility of their immortalized NSC line, 
ReN001, derived from foetal brain tissue. The company has now been awarded £1.5 million 
grant  by  the  Technology  Strategy  Board  (TSB)  to  support  the  Phase  2  trial  of  ReN001 
(ReNeuron 2013). 
1.5  Parkinson’s disease 
PD is a progressive, neurodegenerative disorder first identified in 1817 by James Parkinson 
(Parkinson 1917), caused by the gradual degeneration of neurons in the substantia nigra pars 
compacta (Davie 2008) and results in reduced levels of the neurotransmitter dopamine.  This 
leads to the gradual loss of control over motor function and the ability to initiate movement.  28 
 
PD is not fatal but patients deteriorate physically and mentally over time and so the disease 
has a significant impact on the quality of life for the patient.  
In the UK, approximately 127,000 people suffer from the disease, this equates to 1 in 500 
people nationally (UK 2013). The financial burden of PD including costs incurred from GP visits, 
hospital visits, drugs, and other professional health service, and indirect costs associated with 
loss of  productivity  of  the  sufferer  and  impact  on  those  close  to  sufferers are  significant. 
Depending on the measure and assumptions, Findley et al. estimates the cost of PD to the UK 
to be in a range between £449million and £3.3Bn (Findley 2007). The cost of PD to society is 
anticipated  to  increase  due  to  the  average  age  of  the  population  increasing,  and  the 
prevalence  of  PD  increasing  with  age.  As  the  cost  of  care  increases  with  severity  of  the 
condition, treatments that can reduce symptoms or delay the disorder’s progression will have 
a positive impact on the health service and national economic system. The development of 
new therapies has been recognised by global governments, non-government organisations and 
industry as of paramount importance, with the level of investment and support being moved 
into this area increasing annually.   
PD  symptoms  worsen  as  the  disease  develops  and  are  categorised  as  either  motor  or 
neuropsychiatric  (Massano  and  Bhatia  2012).  Motor  symptoms  include  tremors,  postural 
instability, slowness in movement and physical rigidity. Resting tremors are a characteristic 
symptom  associated  with  the  disease  and  occur  late  in  the  disease  progression.  Early 
symptoms  can  include  but  are  not  exclusive  to expressionless  face,  cramped  handwriting, 
minor shakes and difficulty rising from a chair (UK 2013). Neuropsychiatric symptoms manifest 
in the form of cognitive impairments as well as mood and behaviour problems. As the disease 
advances it can cause cognitive disturbances and can result in problems involving planning, 
rule acquisition and the control of appropriate and inappropriate action, speed of thinking and 
memory (Massano and Bhatia 2012). Later in the stages of the disease, psychotic symptoms 
including hallucinations and delusions can also develop (Friedman 2010).  29 
 
1.5.1  Pathophysiology 
PD can either be idiopathic, arising from an unknown cause, or hereditary, where the patient 
has a genetic predisposition to the disease.  Suffers are typically diagnosed with the disease 
later in life (>50 years old), with only 5% of patients diagnosed below the age of 40 (UK 2013). 
Diagnosis  is often made when  symptomatic  changes  alert  patients  to  consult  their  health 
practitioners; unfortunately by this time, the level of neurological-degeneration is usually in its 
advanced stages and it is estimated up to 80% of the dopamine producing neurons are lost 
(Lees, Hardy et al. 2009). This loss results in one of the most characteristic symptoms of PD, 
the loss of motor function; this symptom is directly linked to the loss of dopaminergic (DA) 
neurons and their presence in the striatum, resulting in the disruption and diminished control 
of the motor circuitry due to reduced levels of dopamine neurotransmitter present (Obeso, 
Rodriguez-Oroz et al. 2000). There are currently no definitive diagnostic tests for Parkinson’s 
disease;  diagnosis  is  primarily  done  through  historical  analysis  of  the  family  and  positron 
emission  tomography  (PET  Scanning)  to  elucidate  the  number  of  surviving  dopaminergic 
neurons; brain scans are also used to rule out other causes of the symptoms (Massano and 
Bhatia 2012).  
1.5.2  Current treatments 
Current treatments for PD involve either drug administration or surgical intervention, with 
treatments  tailored  to  the  individual  patient.  Although  there  are  several  drug  treatments 
available for PD (Lindvall and Kokaia 2006, Lindvall and Kokaia 2009, UK 2010, UK 2013) they 
do not function to slow the progression or cure the disease, they only provide symptomatic 
relief. Surgical techniques such as deep brain stimulation (DBS) have also been found to give 
relief to advanced stage PD suffers (Hellmann, Djaldetti et al. 2006, Lindvall and Kokaia 2006, 
Lindvall and Kokaia 2009) and rehabilitation such as exercise, physiotherapy, speech therapy 
and diet can also help to relieve symptoms (UK 2010).  30 
 
The  gold-standard  pharmacological  treatment  is  a  dopamine  replacement,  a  treatment 
discovered  in  the  1950’s  by  Arvid  Carlsson.  The  treatment  involves  the  administration  a 
dopamine  precursor  L-3,4-dihydroxyphenylalanine  (L-DOPA)  that  passes  through  the  blood 
brain barrier (BBB) and is catalysed by dopa carboxylase to synthesise dopamine, and has been 
found to reduce some of the symptoms of PD (Carlsson, Lindqvist et al. 1958, Cotzias, Van 
Woert et al. 1967). L-DOPA has a vital role currently in the treatment of PD due to its ability to 
pass  through  the  BBB;  dopamine  administered  itself  is  unable  to  do  this  and  so  is  of  no 
therapeutic use. L-DOPA is an effective treatment for reducing the symptoms caused by PD but 
prolonged use of the drug can lead to the development of L-DOPA induced dyskinesia (LID). 
LIDs are a result of abnormal motor outputs from the striatum that result in the involuntary 
movements, caused by the sensitivity of the neurons to the treatment after prolonged use. A 
second  side effect resulting from the use of L-DOPA and the variability in levels between 
administration is known as the ‘on/off’ response (Thanvi, Lo et al. 2007). The on/off response 
is  shown  through  ease  of  mobility  during  the  ‘on’  phase  and  stiffness  and  bradykinetic 
movements during the ‘off’ phase, when the levels of L-DOPA are low.  
Developing on the success of L-DOPA is a new drug, Duodopa, this is a new formulation of L-
DOPA  (carbidopa/levodopa)  which  is  delivered  via  a  novel  intra-intestinal  pump  which  is 
surgically inserted and programmed to deliver a dose which can be modified using an external 
controller, in a non-invasive way (Karlsborg, Korbo et al. 2010).  
Two pharmacological treatments used separately, or in conjunction with L-DOPA have also had 
positive  results.  Dopamine  receptor  antagonists  can  be  used  to  bind  to  the  dopamine 
receptors in the brain and mirror the effect of dopamine (Burton and Calne 1984). Monoamine 
oxidase type B (MOAB) inhibits the breakdown of neurotransmitters and has been shown to 
reduce the breakdown of endogenous dopamine (Ives, Stowe et al. 2004). These treatments 
have some success in reducing symptoms, particularly in the early stages of PD, but neither is 
as effective as L-DOPA in relieving and reducing symptoms.  31 
 
Surgical intervention as an option for treatment involves DBS and was first reported in the 
1980s by Brice et al.  (Brice and McLellan 1980). DBS involves the implantation of electrodes to 
stimulate the neurons within specific regions of the brain, two targets for implantation have 
been identified including to the globus pallidus and the sub thalamic nucleus of the basal 
ganglia motor circuitry. DBS excites or inhibits neurons in the vicinity of the electrodes and is 
controlled  by  the  duration  and  intensity  of  the  stimulation,  which  is  controlled  by  a  DBS 
pacemaker (Vitek 2008).  
1.5.3  Cellular therapies for Parkinson’s disease 
The idea of substituting lost DA neurons with a donor source has been around since the 1970s 
where it was first explored in Sweden and the United States of America (USA) using rats with 
6-hydroxydopamine (6-OHDA) induced lesions. Although, the use of donor human foetal grafts 
was held back for ethical reasons in a number of countries; in 1985 the Lund group received 
permission  to  use  human  foetal  tissue  to  show  good  survival  in  the  stratum  of  6-OHDA 
lessoned rats. It was shown that the introduced donor cells were able to innervate the host 
striatum  and  reverse  lesion  induced  motor  deficits  (Brundin,  Nilsson  et  al.  1986,  Brundin, 
Barbin et al. 1988). In 1986 the Ethical Delegation of the Swedish Society of Medicine endorsed 
the use and issued guidelines for the use of human foetal tissue harvested from aborted foetus 
in transplantation therapies, and shortly afterwards, trials showed significant and sustained 
improvements in a number of parameters associated with dopamine management, including 
improved  [
18F]-dopa  positron  emission  tomography  (PET)  uptake.  The  results  of  the  trial 
indicated good survival and growth of the grafted DA neurons (Lindvall, Brundin et al. 1990, 
Lindvall, Widner et al. 1992) and, further, post mortem studies of the subjects showed good 
graft  survival  and  robust  innervation  (Kordower,  Rosenstein  et  al.  1996).  These  positive 
outcomes supported a change in policy in the USA, where regulation was adapted to allow the 
National Institute of Health (NIH) to fund 2 placebo controlled trials in 1993. Since these initial 
transplantations between 300-400 patients have received this treatment, either in open label 
or placebo surgery controlled trials (Lindvall and Kokaia 2009). Results have shown that cell 32 
 
replacement  of  mesencephalic  dopaminergic  neurons  (mesDA)  neurons  can  be  beneficial. 
Results  have  varied  between  open-label  trials  but  benefits  have  been  witnessed  through 
patient    symptomatic  relief  as  well  as  increased  L-DOPA  intake  indicating  successful 
engraftment and graft survival (Lindvall and Kokaia 2009). 
There  is  currently  one  on-going  open-label  clinical  trial  in  the  UK  based  at  Cambridge 
University in this area. The trial is a Phase 1/2 trial investigating the use of foetal brain tissue in 
40 PD patients. The patients have been pre-screened through the Transeuro observational 
study  and  have  been  selected  to  participate.  Participants  will  be  monitored  for  up  to  36 
months  and  will  be  measured  according  to  outcomes  such  as  Unified  Parkinson's  Disease 
Rating Scale (UPDRS) change, Dyskinesia, L-DOPA usage and PET analysis  (ClinicalTrials.gov 
2013). 
Though findings of cellular replacement therapies for PD are promising, there are a number of 
issues associated with using cells from human foetal tissue; including patient variability, graft-
induced dyskinesia and the consistency of foetal tissue as a material: obtaining source material 
in great enough numbers is difficult; the quality can be highly variable; the cells are almost 
impossible  to  standardize;  and  finally  in  many  countries,  harvesting  tissues  from  aborted 
foetuses is highly controversial and in some cases illegal. These matters have driven a push to 
develop other sources of DA neurons, including via stem cell advances in technology. Cells that 
can be sourced from none ethically controversial sources that can be standardised in number 
and quality controlled; stem cells have been identified as a likely candidate. 
1.5.4  Preclinical Investigations 
The characteristics of PD make it a target for stem cell therapy. If it is possible to replace the 
lost cells with differentiated stem cells, it may be possible to alleviate or even cure the disease 
and achieve long-term, sustainable relief for patients. It is important that any treatment that is 
developed  far  exceeds  the  current  capabilities  of  pharmaceutical  or  surgical  based 
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manner; respond to stimuli; express morphological and genetic similarity to mesDA neurons; 
reverse  symptoms  caused  by  the  disease;  and  be  able  to  integrate  into  existing  circuitry, 
becoming functionally active. Stem cells would also have to be expandable in culture, survive 
long-term  in  the  patient’s  brain  once  engrafted,  and  behave  and  express  all  markers  and 
functional similarities with mesDA neurons in-vitro. It is likely that DA neurons derived from 
stem cells are going to have to be of human origin, due to the risk of inter species disease 
transmission.  
A  number  of  groups  have  shown  the  ability  to  generate  DA-like  neurons  through  the 
manipulation of stem cell populations. Kim et al. (Kim, Auerbach et al. 2002) demonstrated in 
hESC that over-expression of Nuclear receptor related-1 (Nurr1), using plasmid technology and 
electroporation, could differentiate hESC into midbrain neural stem cells. These progenitor 
cells went on to produce tyrosine hydroxylase (TH) positive cells. The resulting cells were 
investigated in-vivo in mice treated with 6-OHDA lesions. Animals were screened to detect the 
graft  placement  and  after  4  to  8  weeks  the  number  of  neurons  present  did  not  change, 
indicating the stability of the graft. Over this period there was also no observation of teratoma 
formation  and  neurons  formed  functional  synapses  and  showed  the  relevant 
electrophysiological properties that are expected of mesDA neurons. The group also tested for 
behavioural improvements and found significant improvements in various behaviour tests in 
the  treated  population.  While  the  study  was  promising  for  cell  therapy,  the  publication 
identified  a  need  for  further  studies  into the  long-term safety  of the  protocol  along  with 
efficacy of implantation. 
Work performed on primate embryonic stem cells (ESCs) by Takagi et al. (Takagi, Takahashi et 
al. 2005) showed that monkey ESCs could be induced to differentiate into dopamine neurons 
through co-culture with stromal cells (P6 stromal cells), supplemented with fibroblast growth 
factor 20 (FGF20) and FGF2 to increase the overall yield. These cells were transplanted into 
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resulting in a primate PD model. At 10 weeks significant improvements in neurological score 
for  treated  animals  were  observed  over  that  of  control  animals  and  imaging  during  the 
experiment  showed  that  cells  were  functioning  as  dopamine  producing  cells  once 
administered. 
Though hESCs have been investigated for this purpose, there are obstacles in their use, their 
ethical  status  is  questionable  and  their  potential  for  teratoma  formation  is  concerning, 
especially in a non-terminal diseases such as PD. These concerns have led research to a move 
towards  hASC  as  a  cell  source.  DA  neuronal  differentiation  is  being  investigated  using  a 
number of sources including, CNS tissue (Shim, Park et al. 2007), bone marrow derived stem 
cells (BMSC) (Dezawa, Kanno et al. 2004) and hiPSC (Chambers, Fasano et al. 2009).  
1.5.5  In-vitro & In-vivo investigation 
Investigators  have  shown  that  over  expression  of  various  transcription  factors  can  induce 
differentiation of cell types into DA neurons. As described previously, the over-expression of 
nurr1 can be used to generate DA precursors from hESCs (Kim, Auerbach et al. 2002) and 
similar findings have been found with other cell sources. Adult CNS derived cells showed that 
with over-expression of nurr1 and the addition of growth factors they could be differentiated 
towards a DA cell type (Shim, Park et al. 2007). Embryonic or foetal CNS cells have also been 
shown to differentiate into DA neurons with the over-expression of either Wnt5a (Parish, 
Castelo-Branco et al. 2008) or Pituitary homeobox 3 (Pitx3) (O'Keeffe, Scott et al. 2008), and 
notch1 over-expression has been found to have the same effect on bone marrow derived cells 
(Dezawa, Kanno et al. 2004) when co-cultured with various growth factors. In the majority of 
these examples the procedure was only investigated using animal stem cells, with further work 
needed to investigate the impact on human stem cells.  
The use of animal products and retroviruses within these studies present their own obstacles 
that  need  to  be  addressed  before  these  protocols  can  move  forwards,  the  risk  of  xeno-
transmission of disease and the genomic instability caused through DNA modification of the 35 
 
genome needs to be investigated. This said, a Phase I trials has previously been done using a 
gene therapy in PD and so may address this concern (Fiandaca, Forsayeth et al. 2008).  
Fu et al. (Fu, Cheng et al. 2006) investigated the use of MSCs isolated from the Wharton’s jelly 
of human umbilical cord as a source for differentiating DA neurons. The group found that 
through culture with neuronal conditioned medium supplemented with growth factors sonic 
hedgehog (SHH) and fibroblast growth factor 8 (FGF8) they were able to differentiate MSCs 
into  DA  neurons.  Cells  cultured  with  the  additional  growth  factors  were  found  to  secrete 
dopamine whereas cells that had not been cultured with them, did not secrete. These cells 
were implanted into rat models treated with 6-OHDA lesions and were found to be viable 4 
months after transplantation without the need for immunosuppression within the animals. No 
tumour formation was identified. Despite this success, behavioural analysis of the animals, 
showed no improvement over the control animals. It was thought this result may be due to 
inadequate cell transplantation, as it contradicted other studies which showed that implanted 
DA  neurons  help  to  alleviate  PD  symptoms.  Fu  et  al.  also  suggest  it  may  take  time  for 
administered cells to integrate into the host brain and there were concerns for the viability of 
the  introduced  cells.  The  group  suggest  further  work  is  needed  to  assess  cell  number 
requirement and a greater understand of the factors being utilised, so to mitigate any toxicity. 
Work  done  by  Wernig  et  al.  (Wernig,  Zhao  et  al. 2008)  demonstrated that iPSC  could  be 
efficiently differentiated into neuronal precursor cells, and once implanted in-vivo, these cells 
were observed to migrate and integrate into the host brain tissue, differentiating into mature 
neurons and glial cells. Wernig et al also demonstrated through electrophysiological recording 
and morphology analysis that iPSC could be directed to differentiate into DA neurons in-vitro 
and once implanted into a PD model improve the behaviour of the host rat when compared to 
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1.6  Thesis aims 
This thesis investigates the potential of both hASC (omnicytes) and hPSC (hESCs and hiPSC) for 
the differentiation of neuronal populations for therapeutic use. Specifically, omnicytes will be 
assessed for their ability to differentiate into neuronal populations through both media and 
molecular manipulation; and hPSCs will be investigated for their ability to form specialised DA 
neurons  through  media  manipulation.  We  will  then  go  onto  investigate  the  use  of  small 
activating  RNA  (saRNA)  to  enhance  gene  expression  of  differentiating  populations  and  to 
increase the yield of DA neurons produced 37 
 
CHAPTER 2 - MATERIALS AND METHODS 
This  thesis  investigates  two  specific  cell  types;  hASC,  namely  omnicytes,  and  hPSC  types 
including hESC and hiPSC. The two bodies of work were carried out at separate locations; UCL 
laboratories  (2
nd  floor,  Robert  building,  London)  and  Omnicyte  laboratories  (Hammersmith 
hospital, London). Due to this work being carried out in different laboratories and on different 
cell types, different protocols were used to culture the cells and analyse the products of the 
experiments. In this materials and methods, general protocols associated with working on 
human pluripotent cell types in the UCL laboratories are described first. Protocols used at the 
Omnicyte Ltd. facility whilst working on omnicytes are described in the second part of the 
chapter. 
In working with both cell types, methodologies and protocols were refined to optimise the 
outcome; this process of optimisation was informed by literature, lab work and collaboration.  
UCL BASED CULTURE AND ANALYTICAL TECHNIQUES 
This  section  describes  the  culturing  and  analytical  techniques  that  were  used  whilst 
experimenting with hPSCs; hESC and hiPSC. 
2.1.  General Human iPSC and ESC Culture Techniques 
2.1.1  Human iPSC and ESC Culture 
Undifferentiated hPSC, MSUH001 (hiPSC, acquired from Michigan State University, USA) and 
Shef6 (hESC, acquired from UK Stem Cell Bank) were cultured in T25 culture flasks (Nunc). 
VWR  International  Ltd,  Leicestershire,  UK).  Cells  were  co-cultured  with  Mitomycin-C 
(0.01mg/mL Sigma-Aldrich, Poole, UK) inactivated mouse embryonic fibroblasts (iMEF, Ref. 
2.1.4) in knockout serum replacement media (KO-SRM) comprising of: KnockOut™ DMEM (KO-
DMEM,  Life  Technologies,  Paisley,  UK)  supplemented  with  20%  KnockOut™  Serum 
Replacement (KO-SR, Life Technologies); 1% Glutamax™ (Life Technologies); 1% non-essential 
amino acids (NEAA,  Life Technologies); 100mM β-Mercaptoethanol (Life Technologies). hESC 38 
 
and hiPSC medias was supplemented with 4 & 10ng/mL basic fibroblast growth factor (bFGF, 
Prospec-Tany Technogene Ltd. East Brunswick, USA) respectively. 
Cells were incubated in a HERAcell 150 incubator (ThermoFisher Scientific, Loughborough, UK) 
at 37
oC and 5% CO2 and media was changed on a 24hrs cycle, replacing spent media with 5mL 
of fresh KO-SRM. Pluripotent cells were passaged onto freshly prepared iMEFs every 3-4days 
by mechanical dissection of colonies into smaller sections using sterile 3mL fine tip pasteur 
pipette (StarLab, Milton Keynes, UK). hESC colonies were dissected using this technique but 
were additionally treated with 0.125mg/mL Collagenase Type IV (Life Technologies) for 5min at 
37
oC  prior  to  dissection.  Dissected  colonies  were  transferred  onto  fresh  iMEF  cultures  at 
typically a 1:2 or 1:3 split. 
2.1.2  Vitrification of hESCs 
To allow long-term storage of hESC, cells were vitrified using the following method.  hESC 
colonies were first treated with 0.125mg/mL Collagenase IV and incubated at 37
oC for 5min 
followed by a rinse with KO-SRM. Colonies were then dissected in 1mL KO-SRM using a sterile 
micro pipette into clumps containing ~100-200 cells each. Vitrification comprised of 4 steps: (i) 
clumps were stored in Holding medium (HM, Table 1), whilst alongside, sterile 4.5mL cryovials 
(Nunc.) were prepared in order to record cell line details, date and passage number; vials were 
also perforated with a sterile hypodermic needle to aid air displacement when submersed in 
liquid nitrogen; (ii) using a 20µL pipette (StarLab) 8-10 clumps were transferred to Vitrification 
solution 1 (VS1, Table 1) and incubated at room temperature (RT) for 1min; (iii) clumps were 
then transferred to Vitrification Solution 2 (VS2, Table 1) and held for 25 seconds at RT; (iv) 
clumps were transferred using a pipette onto the lid of the plate being used with minimal VS2 
transfer; (v) using capillary straws (Corning, Flintshire, UK), cells were drawn into the straws; 
(vi)  straws  were  immediately  plunged  into  liquid  nitrogen  and  transferred  to  the  storage 
cryovials (prepared in step (i)) for long-term storage. The whole process was performed in less 
than 3min. Samples remained cryogenically frozen until use. 39 
 
HM 
D-MEM containing HEPES (10mM HEPES, Life Technologies) 
20% FBS 
VS1 
HM 
10% DMSO (Dimethyl sulfoxide, Sigma-Aldrich) 
10% Ethylene glycol (Sigma-Aldrich) 
VS2 
HM 
20% DMSO 
20% Ethylene glycol 
0.5mol/L Sucrose (Sigma-Aldrich) 
Table 1 - Vitrification solution compositions 
Basic composition of the solutions used in the vitrification of hESC. 
2.1.3  Thawing of vitrified cells 
Straws of cryogenically frozen cells were carefully removed from the liquid nitrogen and the 
cryovials and immediately submerged in HM supplemented with 0.2molar (M) sucrose to expel 
the  cell  clumps.  Cells  were  incubated  in  HM  for  1min  at  RT  and  then  transferred  to  HM 
supplemented with 0.1M sucrose and incubated for 5min. Cells were washed twice in clean 
HM solution and incubated for 5min before being transferred into fresh T25 culture flasks and 
co-cultured  with  iMEF.  Cells  would  typically  attach  to  the  culture  surface  overnight  and 
required passaging within 7 days.  
2.1.4  Inactivated mouse embryonic fibroblast protocols 
To allow co-culture of hESC and hiPSC with iMEF, mouse embryonic fibroblasts needed to be 
isolated, expanded and inactivated. This section will describe the protocols used. 
2.1.4.1  Isolation of mouse embryonic fibroblasts 
Mouse  embryos  from  females  (Strain:  CD-1)  at  embryonic  day  E12.5-13  were  obtained. 
Embryos  were  separated  using  sterile  tweezers  from  the  placenta  and  the  surrounding 
membranes. The embryo sac was cut open using sterile fine surgical scissors and the brain and 
dark organs removed. The embryos were rinsed in distilled phosphate buffer solution (DPBS, 
Sigma-Aldrich)  and  then  transferred  into  0.25%  Trypsin/Ethylenediaminetetraacetic  acid 
(EDTA) (Sigma-Aldrich) for 15min at 37
oC. After incubation the solution and cell suspension 
was  collected  and  mixed  with  mouse  embryonic  fibroblast  (MEF)  media  consisting  of  
Dulbecco's modified eagle medium (DMEM), with 4.5 g/L D-Glucose, 584 mg/L L-Glutamine, 40 
 
(Life Technologies) supplemented with 10% foetal bovine serum (FBS, Life Technologies) and 
NEAA. The FBS contained within the MEF media quenched the trypsin, stalling the enzymatic 
function  of  the  enzyme.  The  cell  suspension  was  then  centrifuged  at  low  speed  (1,200 
revolutions per minute (rpm), Centrifuge 5810 R, Eppendorf, Stevenage, UK) for 3min. The 
supernatant was removed and the pellet re-suspended in fresh MEF media. Cells were then 
split into T75 culture grade T-flasks (Nunc.) and incubated for 4 days at 37
oC and 5% CO2. Once 
cultures reached confluence the cells were prepared for long-term storage in liquid nitrogen. 
Flasks  were  trypsined  in  0.25%  Trypsin/EDTA  for  5min  at  37
oC,  and  then  centrifuged  at 
1,200rpm for 3min. The supernatant was aspirated and the cell pellet re-suspended in freezing 
media:  FBS  supplemented  with  10%  DMSO.  The  cell  suspension  was  then  immediately 
aliquoted into 1mL cryovials (Nunc.) and frozen using ‘Mr Frosties’ (ThermoFisher Scientific, 
Loughborough, UK) in -80
oC for 24hrs. Frozen vials were then transferred to the liquid nitrogen 
stores for long-term storage, denoted as P0 MEF with the date of harvesting. Cell samples 
were  also  taken  to  screen  for  mycoplasm  contamination.  This  screening  process  was 
outsourced. 
2.1.4.2  iMEF preparation 
MEF were cultured from passage 0 (P0) and iMEF were generated from P1 – P6. iMEF were 
produced every 3-4 days and always 1 day prior to hPSC passaging. MEF were inactivated by 
adding 4mL of pre-diluted 0.01mg/mL Mitomycin-C to the flask and incubating for 2hrs at 
37
oC.  Cells  were  washed  3  times  in  DPBS  and  trypsinized  for  3min  at  37
oC.  Trypsin  was 
quenched using MEF media and the cell suspension centrifuged at 1,200rpm for 3min. The cell 
pellet was then re-suspended in 10mL of fresh MEF media and the number of cells found using 
a haemocytometer (Figure 1). iMEF were seeded onto gelatin (Sigma-Aldrich) coated T25 flasks 
at a density of 9.2x10
4 iMEF/cm
2 and cultured overnight at 37
oC and 5% CO2 to allow iMEF to 
adhere to the surface prior to seeding hPSC. 41 
 
 
Figure 1 - Haemocytometer counting strategy 
Cartoon depicting a typical haemocytometer chamber, the pink square denotes a 1mm
2 area; grey circles depict 
distribution of single cell suspension. The average number of cells per large square (i.e. pink square) was found and 
multiplied by 10,000 to calculate the volume of cells per 1mL. 
2.2  Characterisation of hPSC protocols 
2.2.1  Spontaneous differentiation 
hPSCs were co-cultured with iMEF in standard KOSRM supplemented with 10ng/mL bFGF until 
seeding.  Following  mechanical  passage,  clumps  were  seeded  onto  iMEF  in  gelatin  coated 
21cm
2 easy grip culture dishes (BD Falcon) and cultured for 5 days. Media was aspirated and 
replaced with KOSRM without bFGF and cultured for 27 days changing media every two days. 
All incubation steps were carried out at 37
oC and 5% CO2. Cultures were fixed in 4% PFA for 
10min at RT and stored at 4
oC. Cultures were assessed for differentiation into endoderm, 
ectoderm and mesoderm linages using immunocytochemistry (Chapter 2, 2.2.6). 
2.2.2  PA6 co-culture 
Co-culture with PA6 was used to provide proof of concept that the hPSC used within this work 
have the potential to differentiate toward (TH
+) DA neurons. It was reported by Zeng et al. 
(Zeng,  Cai  et  al.  2004)  that  following  co-culture  with  PA6  stromal  cells,  ~87%  of  their 
differentiated hESC colonies contained TH
+ cells.  42 
 
PA6  stromal  cells  (obtained  from  Clinical  Neurosciences,  UCL)  were  maintained  in  DMEM 
supplemented with 10% FBS and 50µg/mL penicillin-streptomycin (Penstrep, Invitrogen). PA6 
cells  were  passaged  using  5min  trypsin  treatment  and  passaged  1:5  into  T75  flasks  and 
expanded for 4 days. PA6 were inactivated using 0.01mg/mL Mitomycin-C and incubated for 
2hrs at 37
oC. Cells were washed three times in DPBS and trypsinized for 3min at 37
oC. Trypsin 
was quenched using MEF media and the cell suspension centrifuged at 1,200rpm for 3min. 
Inactivated PA6 (iPA6) cells were split, one T75 flask into three gelatin coated T25 flasks; this 
produced confluent monolayers of iPA6 cells in each flask. Cultures were incubated overnight 
to allow iPA6 to adhere. 
hPSCs were co-cultured with iMEF in standard KOSRM and supplemented with 10ng/mL bFGF 
until seeding. To start co-culture with iPA6 cells, hPSC colonies were mechanically passaged 
and  seeded  onto  iPA6.  Following  this  transfer,  cells  were  cultured  in  media  consisting  of 
Glasgow  Minimum  Essential  Medium  (GMEM)  supplemented  with  10%  KOSR,  2mM  L-
glutamine, 1mM sodium pyruvate and 0.1mM β-mercaptoethanol. Media was changed after 4 
days post seeding and changed every 2 days thereafter. Cultures were grown for 4 weeks and 
then fixed using 4% PFA for immunocytochemistry staining.  
2.3  Aggregate-based hPSC dopaminergic differentiation 
This  section  will  describe  the  protocol  for  the  aggregate-based  hPSC  DA  differentiation 
programme. Suspension culture was used for the majority of the programme to expand and 
induce the hPSC towards a neuronal and DA lineage. On D24, aggregates were stuck down and 
directed to mature in a chemically defined medium. The individual sections of the process are 
represented  diagrammatically  in  Figure  2  and  described  in  detail  in  the  following  section. 
Media was changed ever 2-3 days or as required by the cultures. 43 
 
 
Figure 2 - Aggregate-base dopaminergic differentiation programme 
Schematic  showing  the  individual  step  performed  during  the  aggregate-base  dopaminergic  differentiation 
programme, indicating the main constituents of  the culture media  and the points at which cell samples were 
harvested.  
2.3.1  Pluripotent cell expansion 
Pluripotent  hESC  (p73-75)  and  hiPSC  (p66-68)  were  cultured  according  to  the  protocols 
described above and passaged mechanically. Upon initiating the investigation, colonies were 
plated onto iMEF in 21cm
2 easy grip culture dishes, approximately 15-20 clumps per dish and 
cultured in KOSRM supplemented with 10ng/mL bFGF at  37
oC and 5% CO2. Cultures were 
expanded  for  up  to  10  days  or  until  colonies  reached  optimal  size  and  morphology  with 
minimal differentiation, an example is shown in Figure 3, B.   
2.3.2  Cell aggregate formation and neural priming 
Differentiation  was  initiated  by  transferring  the  colonies  from  adherent  culture  into 
suspension culture, this processes required colonies from approximately 10x 21cm
2 culture 
plates. hPSC colonies were assessed (Figure 3, B) and a liquid waste trap with a dissecting tool 
attached used to remove differentiated colonies (Figure 3, A). Colonies were kept moist during 
dissection using sterile DPBS and then incubated in collagenase IV (2mg/mL, Invitrogen) at 
37
oC for 10min until colony edges started to detach from the culture surface. Collagenase was 
aspirated and colonies detached using gentle agitation and were transferred to a sterile vial 
after which they were centrifuged at 500g for 5min (Centrifuge 5810R. Eppendorf). Colonies 44 
 
were then transferred to 60x15mm petri dishes (BD Flacon), residual media was aspirated, and 
colonies were dissected using a sterile McIlwain tissue chopper (Mickle Laboratory Engineering 
Company, Guildford, UK) set to 150nm. Colonies were dissected, the plate rotated 90
o, and 
dissected again (Figure 3, C).  
Aggregates were finally transferred into polyHEMA coated T12.5 flasks (DB Falcon) and re-
suspended in KOSRM (~8mL) supplemented with ROCK inhibitor (10nM, Y-27632) to reduce 
apoptosis (Claassen, Desler et al. 2009), 1x Penstrep and incubated at 37
oC at 20% CO2 for 5 
days.  
 
 
Figure 3 - Aggregate-based dopaminergic differentiation - Neuralisation 
A) Schematic of the liquid waste trap and dissecting tool used to dissect differentiated cells from expanded hPSC 
colonies prior to chopping using the McIlwain tissue chopper. B) Representative image of typical hPSC colonies prior 
to  removal  of  differentiated  cells.  All  cells  immediately  outside  of  the  red  circles  were  removed  (Scale  bar  = 
1000µm). C) Bright field image of petri dish post dissection with McIlwain tissue chopper. The blade of the McIlwain 
tissue chopper produced uniform score lines 150nm apart (Scale bar = 400µm). 45 
 
2.3.3  Neural Induction 
Embryo bodies (EB)/cell aggregates were transferred from the T12.5 flask to a 15mL flacon 
tubes post priming and EBs were left to collect at the bottom for 5mins. The media was 
aspirated and replaced with chemically defined neural induction medium (CDM, Table 2) to 
initiate neural induction and cultured for 9 days. Media was changed when its colour indicated 
that the media was spent (yellow/plum colouring), typically every 3 days. From D5 of the 9 
days in CDM, media was supplemented with the following DA factors to condition the cultures 
toward DA differentiation: 
1.  100ng/mL fgf8a (R&D systems)  
2.  2µM Purmorphamine (Cambridge Bioscience) 
3.  0.2mM Ascorbic acid (Sigma) 
 
Reagent  Volume/concentration  
(50mL total) 
Supplier 
IMDM + GlutaMAX  25mL  Invitrogen, UK 
F12 + GlutaMAX  25mL  Invitrogen, UK 
Albumax II (200 mg/mL)  100μL  Invitrogen, UK 
Lipid concentrate  500μL  Invitrogen, UK 
Monothioglycerol (100%)  1.95μL  Sigma, UK 
Insulin (10 mg/mL)  35μL  Sigma, UK 
Transferrin (12.5mg/mL)  60μL  Sigma, UK 
SB431542 (10mM)  20μM  Tocris, UK 
Y27632 (ROCK inhibitor) 
(10mM) 
10μM  Tocris, UK 
Table 2 - Neural induction CDM composition 
Composition of neural induction CDM, with volumes or final concentrations required for a 50mL total volume.  
2.3.4  Expansion stage 
On D9 of neural induction, EBs were transferred to a 15mL falcon tube and the media replaced 
with expansion media (Table 3). Neurospheres were primed and cultured in these conditions 
for an additional 10 days. On D10 of expansion SB431542 and Y27632 were removed from the 
media composition for extended culture. 46 
 
Reagent  Volume/concentration  
 
Supplier 
Neuronal expansion Media 
Base 
(300mL total)   
KODMEM  210mL  Invitrogen, UK 
F12 + Glutamax  90mL  Invitrogen, UK 
Penstrep  3mL  Invitrogen, UK 
Glutamax  2.1mL  Invitrogen, UK 
Expansion Media Supplements     
B27  2%  Invitrogen, UK 
Heparin  5µg/mL  Sigma-Aldrich, UK 
FGF2  20ng/mL  R&D Systems, UK 
FGF8a  100ng/mL  R&D Systems, UK 
Purmorphamine  2mM  R&D Systems, UK 
Ascorbic acid  0.2M  Sigma-Aldrich, UK 
SB431542  20μM  R&D Systems, UK 
Y27632  10μM  R&D Systems, UK 
Table 3 - Expansion media composition 
Composition of neural expansion media for a total volume of 300mL with final concentrations of the supplements. 
2.3.5  Stick down 
Stick down was performed in DA differentiation media (DDM, Table 4). Neurospheres were 
plated onto sterile glass cover slips (VWR) treated with poly-D-Lysine (PDL, Sigma) and coated 
in  laminin  (1:100  dilutions,  Sigma).  Neurospheres  were  plated  in  250µL  DDM  for  16hrs, 
allowing the colonies to settle and adhere. Media was topped up to 400µL at 24hrs and the 
cells were cultured at 37
oC in 20% CO2 for 14 or 28 days. Media was changed every 3 days or 
when the media colour indicated that the media was spent. 
Reagent  Volume/concentration  
 
Supplier 
Neural expansion Media Base  (Table 3)   
Supplements     
FGF8a  100ng/mL  R&D systems, UK 
Purmorphamine  2mM  R&D systems, UK 
Ascorbic Acid  0.2M  Sigma-Aldrich, UK 
BDNF  20ng/mL  Peprotech, UK 
GDNF  20ng/mL  Peprotech, UK 
TGFβ3  1ng/mL  R&D systems, UK 
dbcAMP  0.5mM  Sigma-Aldrich, UK 
DAPT  10nM  R&D systems, UK 
Table 4 - Dopaminergic differentiation media composition 
Composition of dopaminergic differentiation media and final concentrations required.  47 
 
2.4  saRNA experimental protocols 
2.4.1  Designing short activating RNA oligonucleotides 
The proteins; TH, lmx1a and foxa2 were selected for the design and generation of saRNA, with 
the intention for specific activation of their respective genes. saRNA sequences were designed 
and generated by a collaborator of Omnicyte Ltd. and only recently has the method been 
reported within two papers by Reebye et al. (Reebye, Saetrom et al. 2013, Reebye, Saetrom et 
al.  2013).  Briefly  the  algorithm  identifies  the  gene  of  interest,  locates  its  promoter  and 
generates candidate antisense sequences that overlap or are in the close vicinity or in some 
way thought to interact with the gene promoter. This work was done in collaboration with 
another  research  laboratory,  Pål  Sætrom,  Department  of  Cancer  Research  and  Molecular 
Medicine  and  Department  of  Computer  and  Information  Science,  Norwegian  University  of 
Science and Technology. 
2.4.2  saRNA preparation 
saRNA were synthesised by Invitrogen (foxa2) and Eurogentec (TH and lmx1a, Southampton, 
UK) and reconstituted in 5x Universal siMAX siRNA buffer (Eurofins MWG operon, Ebersberg, 
Germany). Stock saRNAs were reconstituted at RT to a concentration of 20µM and aliquoted 
for storage at -80
oC. One working aliquot at a time was utilised, with freeze-thaw cycles kept 
to a minimum, stored at -20
oC. 
Lipid-oligonucleotide complexes were formed through the combination of transfection reagent 
and saRNA oligonucleotides. Briefly, the appropriate transfection reagent: Nanofectin (PAA 
Laboratories Ltd, Staffordshire, UK),  ICAfectin 442 (Eurogentec, Hampshire, UK) or FuGene 
(Roche, Sussex, UK)) (3µL/mL) and saRNA (50nM) were individually diluted in base media (no 
serum) and gently vortexed. The saRNA solution was then added to the transfection reagent 
solution, gently vortexed and complexed at RT for 15min. Following incubation the solution 
was vortexed again and applied to the culture flasks and the flasks mixed gently by rocking 
back and forth and side to side 20 times (Figure 7, B). 48 
 
2.4.3  saRNA transfections 
Cell cultures were prepared and cultured as described above in the experimental materials and 
methods.  Three  investigation  arms  were  created;  un-transfected  (UT),  aggregates  were 
differentiated normally with no addition of saRNA; transfected, aggregates were differentiated 
normally and transfected with saRNA every 3 days; and mock transfected (Mock), aggregates 
were differentiated normally and treated with nanofectin alone. 
2.4.4  hiPSC aggregate formation using Aggrewell 
hiPSC were used to assess the impact of cell aggregate size on transfection efficiency. hiPSC 
colonies  were  disassociated  using  Tryple  Express  into  a  single  cell  suspension  and  passed 
through a 100nm cell strainer prior to manufacture of aggregates using the aggrewell 400EX 
(Stemcell Technologies, Manchester, UK) plate. Cells were then centrifuged (Centrifuge 5810 
R) at 1,200rpm for 3min and the supernatant aspirated. Cells were re-suspended into KOSR 
supplemented with 10nM ROCK inhibitor and the cells counted using a haemocytometer. The 
aggrewell was prepared by dispensing 2mL of 10% pluronic acid into each well and the plate 
centrifuged  at  4,000rpm  for  5min,  to  remove  any  bubbles  found  in  the  bottoms  of  the 
aggrewell units. The pluronic acid was then aspirated and the whole well rinsed with KOSR. 
Cells were seeded into the wells at 4.7x10
6 cells per well to produce 1000 cells/aggregate and 
9.4x10
6 cells per well to produce 2000 cells/aggregate. The plate was centrifuged gently at 
500rpm for 3min to evenly precipitate the cells into each conical unit, as demonstrated in 
Chapter 6, section 6.5, and then incubated at 37
oC and 5% CO2. After 24hrs aggregates were 
harvested by agitating the plate and aspirating the aggregates in suspension. Aggregates were 
transferred to low adherent bacteria culture dishes in KOSR supplemented with ROCK and 
cultured for a further 24hrs. 
2.4.5  hiPSC aggregate transfection assessment  
To  transfect  the  aggregates,  they  were  transferred  to  polyHEMA  coated  T12.5  flasks  and 
treated with siGLO transfection reagent daily for 3 days and incubated at 37
oC and 5% CO2. 49 
 
Every 12hrs, following transfection the media was aspirated and changed prior to the next 
transfection.  At  the  end  of  the  experiment  aggregates  were  aspirated  and  the  cells 
disassociated and processed using flow cytometry. 
2.5  ICSD experimental protocols 
2.5.1  Conditioned media preparation 
iMEF were generated and inactivated as described above. Mitomycin-C was discarded and the 
cells  washed  three  times  in  DPBS.  iMEF  were  then  trypsinised,  centrifuged  (Eppendrof 
centrifuge 5810R) and counted using a haemocytometer and then plated into gelatin-coated 
T75 flasks at a density of 2.0x10
4/cm
2. iMEF cultures were incubated in MEF media for 12hrs to 
allow iMEF to adhere and then the media was removed and replaced with 35mL KSRM media 
supplemented with 4ng/mL bFGF. Cultures were incubated for 3 days at which time media was 
aspirated and replaced, this was repeated three times. The aspirated iMEF conditioned media 
(FC-media) was filter sterilised (Millipore, 0.22µm filter) and stored at -20
oC until use. 
2.5.2  ICSD Differentiation Protocol 
Priming briefly consisted of the hPSCs being expanded using T25 flasks and cultured in KO-SRM 
supplemented  with  bFGF,  until  colonies  compacted.  Upon  initiation of  priming,  cells were 
disassociated into single cell suspension using Tryple Express and passed through a 40µm cell 
strainer  to  ensure  a  single  cell  suspension.  Cells  were  re-suspended  in  filter  sterilised  FC-
media, supplemented with 10ng/mL bFGF and 10nM Y27632 (FC/ROCK media) and plated onto 
gelatin-coated 6 well plates (Nunc) followed by incubation at 37
oC for 1hr. Non-adhered hPSC 
were  aspirated  and  the  wells  rinsed  gently  with  fresh  complete  FC-media  to  remove  any 
remaining  non-attached  cells.  iMEF  remained  adhered  to  the  gelatin-coated  surface. 
Pluripotent cell suspensions were centrifuged at 1,200rpm for 3min, re-suspended in FC/ROCK 
media and then counted using a haemocytometer. The hPSC populations were plated onto 
matrigel (BD) pre-coated 24 well plates (Nunc) at ICSD of 10k/cm
2, 18k/cm
2 and 25k/cm
2 and 50 
 
cultured  in  FC/ROCK  media.  Experimental  ICSD  wells  were  setup  in  duplicate.  Media  was 
changed after 24hrs, removing the Y-27632 supplement. 
On D3 of population expansion the media was changed to initial differentiation media; KO-
SRM  supplemented  with  noggin  (500ng/mL,  R&D  Systems)  and  TGF-β  inhibitor  (10µM, 
SB431542, Miltenyi Biotec), known as priming D0. On D1 media was supplemented with sonic 
hedgehog  (100ng/mL,  SHH)  and  Purmorphamine  (2µM,  Miltenyi  Biotec).  Media  was 
maintained until D3, when CHIR99021 (3µM, Miltenyi Biotec) was added. After an additional 2 
days the media was changed and modified to contain 25% N2, neuronal supplement (PAA,) in 
addition to factors: Noggin, SHH, Purmo and CHIR, but excluding SB4314542. N2 concentration 
was incrementally increased over the following 6 days (to D11) to 25%, 50% and 75% of the 
media constituent, while the media was changed every 2 days. This process is depicted in 
Figure 4. 
 
Figure 4 - Neuronal priming timeline 
Diagram showing the stages of the neuronal priming protocol carried out with hPSC. The days when cells were 
harvested are labelled above the time line. 
2.5.3  Confluence Analysis 
Analysis of confluence was performed using a phase contrast microscope (Nikon, Eclipse TI-E) 
with  an  inbuilt  automated  platform.  20  images  (x10  magnification)  were  taken  of  each 
duplicate well daily. Images were processed using the PHANTAST software (Jaccard, Griffin et 
al. 2014). Briefly, cell regions were characterised by high variations in intensity on the phase 
contrast microscopy images and detected using a local contrast filter. Image confluence was 51 
 
computed as the ratio of the number of cell pixels to the total number of pixels. Images of 
biological duplicates were processed and averages were taken of all readings for a given ICSD.  
Readings were taken over 7 days, to ascertain the growth profile of the two hPSC lines and to 
determine the appropriate time point to commence priming the cells. 
2.6  Pluripotent Cell Analytical Techniques 
2.6.1  Cell Harvesting 
At specific times during an experimental protocol, cells were harvested for extraction of total 
ribonucleic acid (RNA) for subsequent messenger RNA (mRNA) analysis. This was performed 
using quantitative polymerase chain reaction (qPCR) to assess target gene expression relative 
to the starting pluripotent population. 
Cells were mechanically harvested for qPCR using the flat end of a 1mL sterile syringe plunger 
(BD,  Oxford,  UK). Disrupted  cells  were  transferred  immediately  to  RNAse  free  eppendorfs 
(Starlab), centrifuged to 8,000rpm for 5sec, the supernatant was aspirated and the resulting 
cell pellet was snap frozen in liquid nitrogen and transferred to -80
oC until processing. 
2.6.2  RNA extraction  
Total RNA was extracted from the cell pellet using RNAqueous micro kit (Applied Biosystems, 
Warington, UK). Briefly, the pelleted cells were re-suspended in cell lysis buffer (provided by 
the kit) and mechanically disrupted using  QIAshredder columns (Qiagen, Manchester, UK). 
Total  RNA  was  then  precipitated  with  99%  Ethanol  (Sigma-Aldrich),  followed  by  affinity 
separation and elution with RNA columns as provided by the kit. Total RNA content and purity 
was then quantified using a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific). For 
the sample to be valid for analysis a 260/280nanometer (nm) absorbance ratio was required to 
be between 1.9 - 2.1.  RNA samples were kept on ice or immediately stored at -80
oC until 
required for complementary deoxyribonucleic acid (cDNA) synthesis.  52 
 
2.6.3  cDNA Synthesis 
RNA (typically 100-500ng of each sample) was reverse transcribed to cDNA in order that the 
sample could be processed using qPCR. Reverse transcription was achieved using QuantiTect 
Reverse transcription Kit (Qiagen). Briefly, in stage 1, RNA was mixed with gDNA wipeout 
reagent to degrade any contaminating genomic deoxyribonucleic Acid (gDNA) present. The 
mixture was then incubated at 42
oC for 2min as set out in Table 5, stage 1. Stage 2 involved 
mixing the resultant solution with Quantiscript Reverse Transcriptase, Quantiscript RT buffer 
and RT primer mix (Table 5, Stage 2, all reagents are included within the kit), and incubating 
the samples at 42
oC for 15min and at 95
oC for 3min at to inactivate the enzymes. Immediately 
following incubation, the samples were processed using qPCR and then stored on ice or stored 
at -20
oC for short-term use. Temperature cycling was performed using a Veriti 96-well thermal 
cycler (Model 9902, Applied Biosystems). 
 
Stage 1 
Reagent  Volume per reaction 
gDNA Wipeout  2µL 
Molecular grade water  Total 12µL (including RNA volume added) 
Sample RNA  100-1000ng 
Stage 2 
Reagent  Volume per reaction 
RT master mix  1µL 
Quantiscript buffer  4µL 
Quantiscript primer  1µL 
gDNA wipeout treated RNA  14µL 
Table 5 - Table of cDNA synthesis reaction mix 
Table describes the reaction mixes used during the QuantiTect reverse transcription reaction to synthesise cDNA 
from extracted sample mRNA. Stage 1 shows the reagents used during the gDNA wipeout step and Stage 2 shows 
the composition of the cDNA synthesis step (all Qiagen).  
2.6.4  Quantitative PCR  
Gene expression analysis was executed using QuantiFast SYBR Green PCR Kit (Qiagen). Briefly, 
cDNA was diluted (1:5) in molecular grade water (Sigma-Aldrich) and stored on ice ready for 
use. A master mix was composed as described in Table 6 (all reagents provided in the kit). 20µL 
of master mix was aliquoted into each qPCR plate well and 5µL of pre-diluted cDNA added. All 
qPCR  primers  were  purchased  from  Qiagen  and  are  listed  in  Table  7.  qPCR  cycling  was 53 
 
performed  using  a  BioRad  CFX  Connect  Real-Time  System  (BioRad,  Hertfordshire,  UK)  as 
described in Table 6. All samples were processed in duplicate and analysis was performed 
using the CFX manager and gene study programme (BioRad) as described below.  
 
Stage  Temperature  Duration 
Activation  95
oC  5min 
Two-step cycling     
Denaturation  95
oC  10sec 
Combined annealing/extension  60
oC  30sec 
Number of cycles  35-45   
     
Reagent  Volume per reaction 
Quantifast master mix  12.5µL 
Quantitech primer  2.5µL 
Molecular grade water  5µL 
cDNA (1:5 dilution)  5µL 
Table 6 - Table of qPCR reaction mixture + cycling conditions 
Tables describe the cycling conditions used during qPCR analysis of experimental cDNA and the reaction mix used 
per reaction (all Qiagen).  
2.6.5  qPCR data analysis 
qPCR data collected through the BioRad CFX Connect Real-Time System was categorised and 
processed using CFX Manger Data analysis software. The samples were categorised using a 
number of criteria:  
1)  Biological set (biological replicate number) 
2)  Cell type 
3)  Technical replicate  
4)  Target gene 
5)  Sample name  
Statistical  significance  analysis  was  performed  using  CFX  Manager  Data  analysis.  Relative 
quantification/fold-difference  between  samples  was  determined  using  reference  genes, 
namely  GAPDH,  β-Actin  and  UBC  to  normalise  the  starting  template  (cDNA)  volume.  The 
relative quantity was determined by analysing the CT for each sample/target gene/replicate 
and then calculating the relative quantity based on the difference between the CT values of the 
target and reference genes. 54 
 
The  BioRad  CFX  Manager  DATA  analysis  software  automatically  calculated  the  normalised 
relative expression (ΔΔCT) of the target genes (using the criteria listed above to categorise) 
relative to a designated reference gene or sample on the plate. Statistical testing was based on 
the 2-tailed T-test with p-value then calculated to understand the significance of the findings. 
When the p-value was found to be p≤0.05, i.e. the probability of this situation occurring by 
chance being less than 5%, significance was ascertained.  
For further details please refer to the BioRad supporting documentation: CFX96 Touch, CFX96 
Touch  Deep  Well,  CFX  Connect,  and  CFX384  Touch  Real-Time  PCR  Detection  Systems 
Instruction manual. 
Primer target  Primer ID  Function 
Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) 
Hs_GAPDH_2_SG  House keeper gene 
β-ACTIN  Hs_ACTB_2_SG  House keeper gene 
Polyubiquitin-C (UBC)  Hs_UBC_1_SG  House keeper gene 
NANOG  Hs_NANOG_2_S
G 
Pluripotency 
octamer-binding transcription factor 4 
(OCT4) 
Hs_POU5F1_1_S
G 
Pluripotency 
Sex determining region Y-box 2 (SOX2)  Hs_SOX2_1_SG  Pluripotency 
Fibroblast growth factor 5 (FGF5)  Hs_FGF5_1_SG  Epiblast 
BRACHYURY  Hs_T_1_SG  Mesoderm 
Sex determining region Y-box 17 (SOX17)  Hs_SOX17_1_SG  Endoderm 
NESTIN  Hs_NES_2_SG   Ectoderm 
Sex determining region Y-box 1 (SOX1)  Hs_SOX1_2_SG  Ectoderm - early 
neuronal 
Nuclear receptor related 1 (NURR1)  Hs_NR4A2_1_SG  Dopaminergic system 
maintenance 
Orthodenticle homeobox 2 (OTX2)  Hs_OTX2_1_SG  VTA mdDA neurogenesis 
Engrailed-1 (EN1)  Hs_EN1_1_SG  mdDA devlopment 
Forkhead box protein A2 (FOXA2)  Hs_FOXA2_1_SG  DA neuron marker 
Homeoprotein LIM homeobox 
transcription factor 1α (LMX1A) 
Hs_LMX1A_1_SG  DA neuron marker 
Tyrosine hydroxylase (TH)  Hs_TH_1_SG  DA neuron marker 
Dopamine receptor D1 (DRD)  Hs_DRD1_1_SG   Dopamine receptor 
Table 7 - List of primers used in qPCR analysis 
List of qPCR primers used to analyse experimental samples. The table includes the target gene name and descriptor, 
Quantitech  primer  ID  (All  Qiagen)  and  function  of  the  target  gene.  The  qPCR  cycle  recommended  by  the 
manufacturer, Qiagen, was used standardly for all primers. 55 
 
2.6.6  Basic Immunocytochemistry 
Experimental cultures were fixed in-situ with 4% paraformaldehyde (PFA, Sigma-Aldrich) for 
10min before being permibilized in 0.5% Triton X-100/DPBS for 10min and blocked with 5% 
FBS/DPBS blocking solution for 30min (all Sigma-Aldrich). When detecting surface markers the 
permibilization step was omitted from the protocol due to the damage caused to the cell 
membranes by detergents. The samples were incubated with 300µL of primary (1
o) antibody 
(Table 8) and incubated at 4
oC overnight. 1
o antibodies were diluted in blocking solution. Cells 
were then washed in 2mL of DPBS three times to remove any residual 1
o antibody and then 
incubated with 300µL of secondary (2
o) antibodies, diluted in blocking solution (Table 9) and 
incubated  for  1hr.  The  cells  were  then  washed  3  times  in  DPBS  and  incubated  with  4,6-
diamidino-2-phenylindole (dapi, Life Technologies, 1:1000) for 5min. All incubation steps were 
performed  at  RT  unless  otherwise  stated.  Fluorescence  images  were  acquired  using  a 
fluorescence microscope (Eclipse TE2000-U, Nikon, Kingston-upon-Thames, UK) and analysed 
with NIS-element software. This protocol was used throughout this work unless otherwise 
stated. 
Function  Target  Location  Species  Isotype  Dilution 
Nuclei  DAPI  Nucleus      1:1000 
Pluripotency 
OCT3/4  Nucleus  Mouse  IgG2b  1:200 
TRA-1-60  Surface  Mouse  IgM  1:200 
SSEA4  Surface  Mouse  IgG3  1:200 
Early 
differentiation 
SSEA1  Surface      1:100 
Germ Layer 
NESTIN  Cytoplasm  Mouse  IgG  1:100 
BRACHYURY  Nucleus  Mouse  IgG2a  1:200 
Neural 
SOX1  Nucleus  Rabbit  IgG  1:200 
PAX6    Mouse  IgG1  1:200 
β-III-TUBLIN 
(TU-20 clone, C-terminus 
of the neuron specific 
beta III isoform) 
Cytoplasm  Mouse  IgG1  1:200 
Neuronal  EN1  Nucleus  Mouse  IgG2a  1:200 
Dopaminergic 
LMX1A  Cytoplasm  Rabbit  IgG  1:300 
TH  Cytoplasm  Chicken  Polyclonal  1:200 
FOXA2 (HNF-3β)  Nucleus  Mouse  IgG2a  1:100 
Table 8 - List of 1
o antibodies used in immunocytochemistry analysis 
Table showing the 1
o antibodies used to analyse marker expression in cell cultures. Listed are the functions, target 
antigens, species reared in, isotype and the dilution used. Antibodies were supplied by Abcam (Cambridge, UK) or 
Millipore (Merck, Hertfordshire, UK). 56 
 
Secondary raised in  Affinity  Isotype  Excitation 
frequency 
goat  chk  igy  488 
goat  rb  igg (H+L)  555 
goat  ms  igg (H+L)  488 
Donkey  goat  igg (H+L)  488 
goat  mouse  igg (H+L)  555 
Table 9 - Compilation 2
o antibodies for basic immunocytochemistry 
Table  describing  the  antibodies  used  for  immunocytochemical  analysis  during  this  work.  Describing  the  2
o 
antibodies used to in conjunction with the 1
o antibodies, the species it was raised in, the species it has affinity to, its 
isotope and the excitation frequency it is visualised at. 
2.6.7  Bright field microscopy 
Bright field microscopy was typically performed on live cells during an experimental procedure 
using  the  bench  top  AMG  EVOSx1  (Peqlab  ltd,  Sarisbury  Green,  UK)  at  x10  or  x20 
magnification. 
2.6.8  Immunocytochemical staining for confocal imaging 
Confocal imaging was only performed later in the work when differentiating DA neurons using 
a cell aggregate based method. The method used to stain the samples for this process is 
slightly different from the method otherwise used in this work (and described above). 
When differentiating DA neurons, neurospheres were terminally differentiated whilst adhered 
to  a  laminin  coated  coverslip  and  visualised  using  confocal  microscopy.  To  enable  the 
immunocytochemical staining of neurospheres the basic protocol was modified due to the 
highly delicate nature of the samples and the fragility of the filaments protruding from the 
main body. The steps involved in the protocol were reduced significantly to limit agitation and 
the antibodies were applied alongside permibilization solution to aid in the penetration of the 
antibody into the aggregate cell mass. 
Cells were fixed in-situ with 4% PFA for 10min before being permibilized in 0.5% Triton X-
100/DPBS for 20min and blocked with 5% goat serum/DPBS blocking solution for 30min. The 
samples  were  incubated with  300µL  of  1
o  antibody  (Table  10)  and  incubated  for  3hrs.  1
o 
antibodies were diluted in 0.1% triton X-100 solution. Cells were then washed in 1mL of DPBS 
to remove and dilute any residual 1
o antibody and then incubated with 300µL of 2
o antibody 57 
 
(Table 10) for 90min. 2
o antibodies were diluted in 0.1% Triton X-100. The cells were washed 
1mL DPBS  and  incubated  with  dapi  for 3min  and then  washed.  All  incubation  steps were 
performed  at  RT  unless  otherwise  stated.  Images  were  acquired  using  a  Leica  TCS  SP8 
microscope (Leica microsystems, Milton Keynes, UK) and analysed using LIECA LAS AF (Leica 
microsystems) imaging software.  
A. Primary antibodies 
Target  Supplier  Species  Isotype  Dilution  Location 
TH  Abcam  Chicken  Poly  1:200  Cytoplasm 
Foxa2 (HNF-3β)  Santa Cruz Biotechnology  Mouse  IgG2a  1:100  Nucleus 
B. Secondary antibodies 
Target  Supplier  Species  Excitation 
frequency 
Dilution 
Anti-Chicken  Abcam  Goat  Alexa-488  1:200 
Anti-mouse IgG2a  Millipore  Goat  Alexa-555  1:200 
Table 10 - Compilation of 1
o and 2
o antibodies for confocal analysis 
Table A) describes the 1
o antibodies used during confocal analysis of the differentiated neurosphere population, 
listing the target protein, supplier, the species the antibody was raised in, isotype, dilution used and its cellular 
location. Table B) lists the 2
o antibodies used in conjunction with the 1
o antibodies to visualise the proteins, the 
table lists the target species, supplier, excitation wavelength and the dilution used. 
 
 
2.6.9  Confocal Imaging 
Images were taken for both qualitative and quantitative analysis of co-associated staining.  
Quantitative images were taken from representative adhered neurospheres that had been co-
stained for both TH and foxa2. Images were taken for each experimental condition at four 
locations of each neurosphere; top, bottom, right and left (Figure 5). The quantitative images 
taken at these sites maintained a constant Z-stack of the following physical characteristics; 
~30µm in depth, 30 slices of which each layer was ~1µm in depth and the lens, laser, filter 
parameters described in Table 11. To allow direct comparison across the biological replicates 
and experimental conditions the analysis criteria described remained constant. Staining rich 
areas were targeted at each location. 
Analysis of co-associated of TH and foxa2 was processed using an image analysis software, 
Volocity 3D image analysis software (PerkinElmer, Cambridge, UK).  58 
 
Representative  qualitative  images  were  taken  to  demonstrate  the  variety  and  types  of 
morphologies and staining that were observed within the adhered neurosphere culture. 
 
Figure 5 - Schematic of the imaging locations for co-localisation analysis 
The schematic shows a representative neurosphere, depicted onto which are the four locations at which images 
(top, bottom, right and left) were captured for quantitative analysis. At each of these locations the z-stack remained 
constant  to  allow  direct  comparison  with  other  images.  Images  were  taken  for  each  experimental  condition; 
untransfected and saRNA transfected and each condition was processed in triplicate. 
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Microscope  Leica TCS SP8  
Lens  X25 water immersion 0.95NA 
Frequency + magnification  1000Hz x2.95 magnification 
Green filter  Laser power-30% Gain -953% 
Offset-0.14 Leica Alexa 488 
Red filter  Laser power-47.5% Gain -35% 
Leica Alexa 561 
Dapi filter  Laser-8.34% Gain-90% 
Leica Dapi 
Table 11 - Confocal microscope parameters 
The table describes the parameters used during confocal analysis of the adhered neurospheres. Describing the 
microscope and lens utilised as well as the frequency and magnification used. Described also are the three filters 
used, green, red and blue (dapi) and the laser power utilised with each of the individual filters, the gain and the 
filter name/manufacturer. 
2.6.10  Co-association analysis - Volocity 
Volocity  co-association  analysis  was  performed  on  each  quantitative  image  acquired  from 
confocal microscopy. All images were of the same dimensions and were normalised using the 
nuclear stain dapi to control for number of cells analysed in each photo. Certain criteria were 
used within volocity image analysis to allow maximum accuracy (Figure 6, A). Dapi staining 
analysis utilised a maximum size guide allowing the program to differentiate between cells 
that were touching. The software was programmed to disregard dapi staining of <25µm
3, this 
reduced the possibility of DNA fragments obscuring analysis. Similar criteria were used in the 
analysis of foxa2 and TH staining; please refer to Figure 6 for more details. Co-association was 
analysed for nuclei_Foxa2 (Figure 6, B, ii), nuclei_TH (Figure 6, B, iii) and Foxa2_TH (Figure 6, B, 
iv) and the results were normalised and reported using the following equations shown in 
Figure 6, C. 60 
 
 
Figure 6 - Volocity analysis criteria 
The parameters used during Velocity analysis are defined in A, described are the stains analysed, the localisation of 
the stain and the criteria Velocity used in its analysis of dapi, Foxa2 and TH. Shown in B are representative images 
generated using the criteria shown, Bi) shows nuclei identification, where individual nuclei are distinguished from 
touching nuclei using the criteria described in A. Co-association of (Bii) nuclei_Foxa2 and (Biii) nuclei_TH are shown 
in green and pink respectively allowing the total volume of co-association to be elucidated. Image Biv) indicates 
were co-association of Foxa2_TH within the image. C describes the steps undertook to normalise each of the images 
and to calculate the relative total volume of each protein and the co-associated volume.  
2.6.11  Enzyme-Linked Immunosorbant Assay (ELISA)  
2.6.11.1  Dopamine stimulation 
Neurospheres were differentiated for 28 days after ‘stick down’ onto laminin coated cover 
slips in 4 well plates (2 neurospheres per well). Cells were washed once with Hank's Balanced 
Salt Solution (HBSS, containing phenol red, magnesium
+ (Mg) and calcium
+ (Ca), Sigma-Aldrich) 
before 300µL of HBSS was added to each well. To stabilise the dopamine released from the 
neurospheres EDTA was supplemented into the media to a final concentration of 0.1millimolar 61 
 
(mM). Dopamine release was stimulated by supplementing potassium chloride (KCl) to the well 
to a final concentration of 56mM. In each run, one well remained unstimulated to show base 
level dopamine release. Cells were incubated at 37
oC for 15min and the media immediately 
removed and snap frozen in liquid nitrogen and stored at -80
oC until ELISA analysis. 
2.6.11.2  Dopamine assay procedure 
The ELISA was performed using the dopamine ELISA Kit supplied by Abnova (Novus Biologicals, 
Cambridge, UK). Briefly, reagents were equilibrated to RT before use. 10µL of each of the 
standards and controls and 300µL of each of the experimental media samples were pipetted 
into their respective wells of the extraction plate (supplied in the kit). To the standards and 
controls 250µL of distilled water was added. 50µL of assay buffer and 50µL of extraction buffer 
was added to all the wells sequentially and the plate covered with the supplied adhesive foil 
and incubated at RT for 30min on a shaker (600rpm). Following incubation the wells were 
emptied onto an absorbent towel and residual liquid removed by tapping. 1mL of wash buffer 
was added to each well and the plate incubated for 5min at RT on a shaker. Contents were 
again emptied and the wash process repeated. 150µL acylation buffer was added to each well 
followed by 25µL acylation reagent and incubated for 15min at RT on a shaker. Contents were 
emptied from the wells and 175µL hydrochloric acid (HCl) pipetted into each well and covered 
with adhesive foil and incubated at RT for 10min. Following incubation the foil was removed 
and the remaining liquid was used in the dopamine ELISA described next (all reagents were 
provided with the kit). 
2.6.11.3  Dopamine ELISA protocol 
To prepare the wells of the dopamine ELISA strips, 25µL of enzyme solution was pipetted into 
each well. 25µL of the standards and controls and 50µL of extracted experimental media were 
pipetted  into  their  respective  wells  and  25µL  of  HCl  was  added  to  each.  The  plate  was 
incubated at RT for 30min on a shaker. 50µL of dopamine antiserum was added to each well 
and the wells covered with adhesive foil and incubated at RT for 2hrs on a shaker. The foil was 62 
 
removed and the liquid aspirated from the wells. Wells were washed with 300µL wash buffer 
three times and blotted dry to remove any residual liquid. 100µL of enzyme conjugate was 
added to each well and incubated on a shaker for 30min. The enzyme was aspirated and the 
wells washed three times with wash buffer. The wells were emptied and 100µL of substrate 
added to each and incubated on a shaker for 25min (avoiding any direct sun light exposure). 
100µL of stop solution was added to each well and the plate shaken to ensure homogenous 
mixing of the liquids (all reagents were provided with the kit).  
Absorbance was read within 10min of stopping the reaction using a Safire2 microplate reader 
(Tecan, Reading, UK) set to 450nm with a reference wavelength of 620nm.  
2.6.12  Flow cytometry 
Cultures  were  disassociated  into  a  single  cell  suspension  using  Tryple  express  (Life 
Technologies) and flowed through a cell strainer (40µm apertures, BD). Live cells were used for 
all  characterisation  flow  cytometry.  Cells  were  blocked  using  5%  FBS  and  stained  using 
conjugate antibodies (Table 12), cell suspensions were incubated with conjugate antibodies for 
1hr on ice, washed in DPBS and then immediately processed using Coulter Epics XL•MCL flow 
cytometer (Beckman Coulter, High Wycombe, UK). A minimum cell count of 10,000 cells was 
used to ensure a good population representation. Side and forward scatter were adjusted 
according  to  the  experimental  population  but  between  comparable  runs  these  were 
maintained to allow for direct comparison. Readings were made at excitation 488nm. 
Function  Target  Species  Isotype 
Pluripotent 
antibody 
Anti-TRA-1-60 
 
Mouse  IgM, FITC conjugate 
Pluripotent 
antibody 
Anti-SSEA-4-PE  Mouse   IgG3, clone MC-813-70 
Conjugate 
control 
IgM/FITC  Anti-
Mouse 
 
Conjugate 
control 
IgG  Anti-
Mouse 
 
Table 12 - Table of pluripotent conjugate antibodies 
List of pluripotent conjugate antibodies used for flow cytometry and their associated conjugate controls. 
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OMNICYTE LTD. BASED CULTURE AND ANALYTICAL TECHNIQUES 
This  section  describes  the  culture  and  analytical  techniques  utilised  whilst  working  and 
experimenting on the hASC, omnicyte. Within this body of work a number of cancer cell lines 
were also utilised due to the limited availability of the omnicyte cell type. Culturing protocols 
of the cancer cell lines are also described in this section. 
2.7  Omnicyte culture techniques 
2.7.1  Omnicyte isolation and culture 
Omnicytes are a sub population of the HSC population they are isolated from patient samples 
using the same protocol as that used to isolate HSC. The HSCs are then further purified to 
isolate the omnicyte population. 
The HSCs used in this investigation were obtained with the written consent of neutropenic 
patients undergoing therapy for haematological malignancies. Patients were pre-treated with 
G-CSF (Life Technologies) to enhance bone marrow secretion of HSCs into their peripheral 
blood prior to leukapheresis.  
MNCs were  isolated  from  the whole  aspirate,  post  leukapheresis,  by  centrifugation on  an 
isosmotic  medium  (Lymphoprep
TM,  Axis-Shield,  Cambridgeshire,  UK)  and  incubated  with 
magnetically conjugated anti-CD34 antibody (Miltenyi Biotec, Germany). CD34
+ cells were then 
immunoaffinity purified by passing through a magnetic column (MACS Separator LS, Miltenyi 
Biotec). 
Omnicytes  were  isolated  by  re-suspension  in  minimum  essential  medium  eagle  alpha 
modification (αMEM, Life Technologies) media and plated at a density of 2.5×10
5 cells per 
2cm
2 (24 well plate, Nunc.). Following incubation at 37
oC with 5% CO2, non-adherent cells were 
washed away in DPBS. Adherent CD34
+ cells were cultured in serum free medium (CellGro, 
CellGenix, London, UK) with additional cytokine factors,  250ng/mL interleukin-6, 250ng/mL 
stem cell factor, and 250ng/mL interleukin-3 (all Life Technologies or Cellgenix) with 0.5% 64 
 
penicillin/streptomycin antibiotics (Life Technologies), known as expansion media. Cells were 
cultured at 37
oC in 5% CO2. 
2.7.2  Long-term storage for CD34
+ purified cells 
For  long-term  storage,  fresh  media  comprising of 90%  FBS  (PAA,  Austria)  and  10%  DMSO 
(freezing media) was made for each application. CD34
+ cells were pelleted (2,500rpm at RT) 
and the supernatant discarded.  The cells were then gently re-suspended in freezing media at a 
cell density of approximately 1×10
7 cells per mL and transferred into 2mL cryovials. These were 
then wrapped in tissue to allow gradual freezing at -80
oC before being transferred into liquid 
nitrogen storage. 
2.7.3  Defrosting of CD34
+ purified cells from long-term storage 
Although cell survival during the freeze/thaw process is generally low, the method described 
was developed by Omnicyte Ltd. to optimise the number of viable cells recovered following 
cryopreservation.   
Defrosting  was  performed  using  a  ‘thaw  mix’  solution  at  ×5  concentration;  this  solution 
contained Roswell Park Memorial Institute medium (RPMI, Life technologies), antibiotics (Life 
technologies) and Anti-Deoxyribonuclease I (DNase1, Sigma-Aldrich). The frozen sample was 
snap thawed by placing it into a 37˚C water bath before being transferred to the thaw mix 
solution. The cells were then pelleted by centrifugation (Microfuge, Eppendorf, 2,500rpm at 
RT) and the supernatant discarded. The cells were then washed in the thaw mix solution twice, 
centrifuged and re-suspended in αMEM. A viable cell count was established using trypan blue 
(Life Technologies) exclusion and a haemocytometer (Figure 1). Cells there then immediately 
processed for ‘Omnicyte’ isolation using the ‘stick down’ protocol described above. 
2.7.4  Cancer Cell Line Culture 
Undifferentiated  human  neuroblastoma,  SH-SY5Y  cells  (passage  40-49),  were  cultured  in 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12, Life Technologies) 
supplemented with 10% FBS, 0.5% NEAA and antibiotics. Human hepatocarcenoma, HEPG2 65 
 
(passage 10-20) and Human T-Lymphocyte cells, Jurkat (Passage 1-20) were cultured in RPMI 
supplemented with 10% FBS and antibiotics. Cultures were passaged every 3 days when 90% 
cell confluence was achieved, adherent cultures were passaged using 0.25% Trypsin/EDTA for 
5  min  at  37
oC  to  disassociate  the  cell  monolayer  and  split  1:3.  Suspension  cultures  were 
aspirated,  centrifuged  and  re-suspended  in  fresh  media  and  split  1:3.  All  cultures  were 
incubated at 37
oC, 5% CO2. 
2.7.5  Experimental preparation - cancer cell lines 
Cell lines were harvested from the main culture via trypsinisation, if required, and the used 
media removed and cells re-suspended in fresh media. Cell were then seeded into individual 
wells of a 24 well culture plate (Costar, UK) at a seeding density of 2.5×10
5/well (all cell types) 
12hrs following seeding, the culture media was replaced with either serum containing culture 
media (unsynchronised) or  starvation  media  consisting  of  the  appropriate  base media  (no 
phenol red, Life Technologies) and charcoal stripped FBS (csFBS, Life Technologies), cultures 
were  then  incubated  for  another  12hrs.  Starvation  was  used  to  induce  cell  cycle  arrest, 
resetting the entire culture to G0 (Chen, Huang et al. 2012), whereas cells in serum-containing 
media  cultures  remained  unsynchronised,  containing  cells  at  all  stages  of  the  cell  cycle. 
Following  12hrs  of  incubation,  cultures  were  transferred  back  into  normal  media  for  the 
experiment. 
2.7.6  Cell line plasmid transfection optimisation experiment 
Lipid-plasmid  complexes  were  formed  using  the  same  protocol  as  described  for  lipid-
oligonucleotide  complex  formation.  Plasmid  and  lipid  reagent  solutions  were  prepared 
separately and the plasmid solution added to lipid solution carefully. The solution was then 
gently vortexed and incubated for a minimum of 15 min at RT. The complexed solution was 
applied to the culture wells in a spiral motion and the plates agitated side to side to ensure an 
even distribution (Figure 7, B).  66 
 
Cell line transfections were optimised using 200ng GFP-pSG5 plasmid  and pSG5ø negative 
control (Figure 7, A, Omnicyte Ltd., London, UK). Omnicyte transfections were optimised using 
siGLO transfection control reagent (GE Lifesciences, Little Chalfont Bucks, UK). 
 
Figure 7 - GFP containing plasmid and well transfection method 
A) Schematic showing the plasmid used during cancer cell line transfection optimisation, the plasmid was designed 
to contain an EcoR1-GFP-p23-BamH1 element that once taken up by the cell would allow the synthesis of GFP 
within the cell. B) Lipid-oligonucleotide/plasmid complexes were applied to the experimental wells in a circular 
motion and then the whole plate rocked side to side to avoid creating a vortex. 
2.8  Omnicyte Analytical Techniques 
2.8.1  WST-1 cell proliferation assay 
Cells were cultured in micro-plates (96 wells) prior to WST-1 analysis. WST-1 reagent was 
added to cultured cells at 5µL per 100µL culture media and incubated at 37
oC, 5% CO2 for 3hrs 
prior to measuring the absorbance (450nm) with a reference wavelength of >600nm using a 
uQuant microplate spectrophotometer (BioTek, Potton, UK) and analysed with KC4 version 3.4 
(BioTek). Standard curves were produced for each cell type and blank (no cells) controls were 
used to obtain a background/baseline reading. 
2.8.2  Harvesting of cell cultures and RNA extraction 
At specific time points, and at the end of experiments, cells were harvested for extraction of 
total  RNA  for  subsequent  mRNA  analysis.  This  process  allowed  analysis  of  target  genes 
throughout the course of an experiment. 67 
 
Adherent cells were harvested mechanically using a cell scraper to disrupt the cell monolayer. 
Cold DPBS was used to transfer the cells into RNAse free eppendorfs. To harvest suspended 
cells,  the  cell  suspension  was  carefully  transferred  to  RNAse  free  eppendorfs.  For  both 
methods  the  cell  suspension  was  centrifuged  at  8,000rpm  for  3min  and  the  supernatant 
discarded, the cell pellet was snap frozen in dry ice and ethanol and stored at -80
oC until RNA 
processing. 
RNA was extracted using an RNAqueous micro kit (Applied Biosystems). Briefly, the pelleted 
cells were resuspended in cell lysis buffer (provided by the kit) and mechanically disrupted on 
ice using a sonicator (Misosonic Inc) with 3 pulses at output 3. Total RNA was then precipitated 
with  99%  Ethanol  (Sigma-Aldrich)  followed  by  affinity  separation  and  elution  with  RNA 
columns as provided by the kit. Total RNA content and purity was then quantified using a 
Nanodrop 1000 spectrophotometer.  RNA samples were kept on ice at all times or immediately 
stored at -80
oC until required. For very short-term storage, RNA samples were stored at -20
oC 
(but only for a very limited time to avoid damage to the RNA).  
2.8.3  Reverse transcription polymerase chain reaction (rtPCR)  
cDNA  synthesis  was  performed  on  a  CX1000  thermocycler  (Biorad)  using  Omniscript  kit 
(Qiagen)  following  the  manufacturer’s  protocol.  Subsequent  to  this,  semi-quantitative 
polymerase chain reaction (PCR) of the cDNA was performed using Taq Polymerase (Qiagen) 
for the following genes: β-Actin, sox1, otx2, pax6, nestin, TH, lmx1a, foxa2, with β-Actin serving 
as the internal control (Table 13) using the CX1000 thermocycler (Biorad, Hertfordshire, UK). 
PCR cycles and optimal conditions were optimised per primer set.  
Amplified  products  were  visualised  using  2%  agarose  (Sigma-Aldrich)  gels  stained  with 
ethidium bromide (Sigma-Aldrich) enabling labelling of the PCR products. Gels were analysed 
using a UV reader (UVP VisionWorks LS v6.2, Cambridge, UK).  
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  Primer Sequence  PCR conditions 
β-actin  Forward  (37 cycles) 
  5’-GAG AAA ATC TGG CAC CAC ACC-3’  95
oC - 5min 
  Reverse  95
oC - 45sec 
  ATA CCC CTC GTA GAT GGG CAC-3’  60
oC - 30sec 
    70
oC - 45sec 
    72
oC - 10min 
Sox1  Forward  (45 cycles) 
  5’-CAA TGC GGG GAG GAG AGG TC-3’  95
oC - 5min 
  Reverse  95
oC - 45sec 
  5’-CTC TGG ACC AAA CTG TGG CG-3’  58
oC - 40sec 
    60.7
oC - 1min 
    60.7
oC - 10min 
Otx2  Forward  (40 cycles) 
  5’-CAA CAG CAG AAT GGA GGT CA-3’  95
oC - 5min 
  Reverse  95
oC - 45sec 
  5’-CTG GGT GGA AAG AGA AGC TG-3’  55
oC - 30sec 
    62
oC - 45sec 
    62
oC - 10min 
Pax6  Forward  (35 cycles) 
  5’-GGC AAC CTA CGC AAG ATG GC-3’  94
oC - 5min 
  Reverse  94
oC - 45sec 
  5’-TGA GGG CTG TGT CTG TTC GG-3’  64
oC - 1min 
    66
oC - 1min 
    66
oC - 10min 
Nestin  Forward  (45 cycles) 
  5’-GCC CTG ACC ACT CCA GTT TA-3’  95
oC - 5min 
  Reverse  95
oC - 1min 
  5’-GGA GTC CTG GAT TTC CTT CC-3’  57
oC - 45sec 
    60
oC - 1min 
    60
oC - 10min 
Nanog  Forward  (35 cycles) 
  5’-AAT ACC TCA GCC TCC AGC AGA TG-3’  95
oC - 5min 
  Reverse  95
oC - 45sec 
  5’-TGC GTC ACA CCA TTG CTA TTC TTC-3’  60
oC - 30sec 
    66
oC - 45sec 
    66
oC - 10min 
TH  Forward  94
oC - 5min 
  5’-AGC TGT GAA GGT GTT TGA GAC-3’  94
oC - 30sec 
  Reverse  57
oC - 45sec 
  5’-TCG AGG CGC ACG AAG TAC T-3’  62
oC - 45sec 
    62
oC - 3min 
    (39 cycles) 
Foxa2  Forward  95
oC - 3min 
  5’-CCC GCC CAC TCC AAC TAC CG-3’  95
oC - 40sec 
  Reverse  55
oC - 40sec 
  5’-GCG CCC ACG TAC GAC GAC AT-3’  62.5
oC - 40sec 
    62.5
oC - 3min 
    (39 cycles) 
Lmx1a  Forward  95
oC - 3min 
  5’-AAC GAC AGC TTC TGG CAT GA-3’  95
oC - 40sec 
  Reverse  55
oC - 40sec 
  5’-TCA AGA TGG TTC TCG GAC GT-3’  62.5
oC - 40sec 
    62.5
oC - 3min 
    (39 cycles) 
Table 13 - PCR primers, sequences and cycle conditions 
Table describes the PCR primers utilised for mRNA interrogation. Listed are the genes targeted, sequences for both 
forward and reverse primers and the optimised PCR cycling conditions used; melting, annealing, extending and the 
number of cycles performed. 69 
 
2.8.4  Agarose gel manufacture 
Agarose gels were produced in-house to assess the expression of target genes amplified using 
PCR. 1g of agarose was diluted in 49mL double distilled water (ddH2O). Agarose was dissolved 
on a heated stirring platform and then cooled to a workable temperature (~60
oC). 5µL of 
ethidium bromide was pipetted into the solution and mixed well before pouring into moulds 
and allowed to set at RT. PCR products were loaded following mixing with Orange-G loading 
buffer and ran at 70volts for 15min (timing adapted as appropriate) 
Ethidium bromide (Sigma-Aldrich) labelled PCR products were then analysed using a UV reader 
(UVP VisionWorks LS v6.2). 
2.8.5  Quantitative PCR  
Quantification of gene expression was executed using QuantiFast SYBR Green PCR Kit (Qiagen, 
Chapter 2, 2.2.4). Briefly, cDNA was synthesised using Omniscript kit and stored on ice ready 
for use. A quantifast master mix was prepared for the gene of interest and the mix then 
transferred to the PCR wells. Samples were processed in duplicate. 24µL of master mix was 
aliquoted  into  each  well  and  to  this  1µL  of  pre-diluted  cDNA  added.  qPCR  cycling  was 
performed using an Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems). 
Analysis was processed using SDS 2.4 (Applied Biosystems). The same Quantitech primers were 
used as described in Table 7: TH, Lmx1a and Foxa2. 
2.8.6  Immuno-fluorescent staining 
Cells were fixed for 10min at RT using 4% PFA and fixed onto glass cover slides. Cells were 
permeabilised using 0.05% triton-X solution, and blocked with 3% goat serum. Staining was 
performed using the appropriate 1
o antibody i.e. β-III-Tubulin, MAP2 and TH. 2
o antibodies 
(Alexa Fluors®). -488, 594, Cell Signalling Technology, Leiden, Netherlands) were incubated at 
RT for 1hr at a dilution of 1:600. Dapi nuclear staining was incubated for 10min at RT at a 
dilution of 1:1000. Between all staining procedures cells were stored in DPBS. Slides were 
visualised and analysed on a Leica DM4000 (Leica) at x60 magnification. 70 
 
2.8.7  Flow Cytometry Analysis  
Cells  were  fixed  and  permeabilized  using  Fix&Perm®  fixation  medium  according  to  the 
manufacturer’s protocol. Briefly, cells were harvested through trypsin digestion, incubating at 
37
oC for a maximum of 5min, cells were then washed in DPBS and then resuspended in 100μL 
of reagent A (fixation medium), for 15min at RT. Cells were rinsed with DPBS and resuspended 
in 100μL reagent B (permeabilization medium) and incubated  for 10min  at  RT. Cells were 
resuspended in blocking buffer comprising of DPBS, 4% FBS and 3% Bovine serum albumin 
(BSA, Sigma-Aldrich) and incubated for 15min. Finally cells were stored in DPBS at 4
oC for a 
maximum for 48hrs before processing. 
Cells  were  analysed  using  the  BD  LSRII  flow  cytometer  (BD)  to  view  the  Alexa  Fluors®.  A 
minimum of 10,000 cells were collected for each test sample to a maximum of 50,000 to 
ensure a sufficient number of positive stained cells. FlowJo 7.6 software (TreeStar, USA) was 
used for further analysis. 
2.8.9  Automated media analysis 
Media samples were collected from cultures at specific time points during the procedure. 
These were centrifuged at high speed in a microfuge (Eppendorf, 13,000 rpm) to pellet and 
remove any cells and debris in suspension and the supernatant transferred to a sterile storage 
tube and snap frozen in liquid nitrogen and stored at -80
oC until processing. Upon processing 
samples were defrosted in a water bath at 37
oC and immediately analysed using an YSI 2700 
Select Dual Channel Analyser (YSI Bioanalytical Products, Hampshire, UK). This allowed the 
measurement of D-glucose (g/L) and L-lactate (g/L). Values were normalised using the baseline 
measurement of the specific media type being analysed. 
2.8.10  Growth scoring 
Growth scoring was performed by two colleagues who graded growth of specific culture wells 
and scored them between 1-10. Scoring was performed blinded (assessors did not know the 
conditions the cultures were exposed to).  Averages were taken of the awarded scores. 71 
 
CHAPTER  3  -  THE  POTENTIAL  OF  OMNICYTES  IN  NEURONAL 
DIFFERENTIATION  
3.1  Introduction 
As briefly discussed in chapter 1, hASCs may have regenerative capacity within the ischemic 
stroke environment. hASCs regenerative potential lies in their capacity to secret paracrine 
factors (Taguchi, Soma et al. 2004) that aid in endogenous angiogenesis and neurogenesis. 
They have also been shown in-vivo to home to the site of damage and express neuronal and 
glial cells markers reducing scar formation, this will be discussed within this introduction. 
HSCs are one of the best described groups of adult stem cells in mammals and have been 
widely studied. They have a unique ability during early development to leave their tissue of 
origin, circulate in the blood and relocate to other niche environments to develop new pools of 
HSCs (Mikkola and Orkin 2006). They retain this ability during adulthood to an extent, enabling 
them to ‘home’ back to the niche within the bone marrow after being in circulation (Lam and 
Adams 2010). The capacity to mobilise, circulate and return has been exploited for clinical use, 
for example the intravenous infusion of HSCs following myeloablative therapies to repopulate 
the patient’s bone marrow.  
HSCs are a heterogeneous population of cells that express, amongst other antigens, the cell 
surface marker CD34, and are typically non-adherent to culture vessel plastic. Taguchi et al 
(Taguchi, Soma et al. 2004) reported that CD34
+ cells in-vivo enhanced neovascularisation in 
the ischemic brain, this in turn enhanced cerebral blood flow; as well as enhanced cortical 
expansion, likely reflecting endogenous neurogenesis. There was evidence of an increased 
number of neural progenitors migrating to the infarct following treatment and it was also 
noted  that  animals  that  did  not  receive  CD34
+  cells  showed  significant  behavioural 
abnormalities after 90 days, whereas those receiving CD34
+ cells, did not. The conclusion of 
the study was that administration of CD34
+ cells when compared to CD34
- cells and sham 72 
 
treated animals resulted in accelerated neuronal regeneration and improved recovery after 
ischemia. 
3.1.1  Experimental trials using HSC 
The use of HSCs as therapeutic treatments for ischemic stroke has been widely speculated. 
Their characteristics that make them particularly attractive as a cell therapy; including their 
ability to ‘home’ to the area of injury, and their secretion of neuroprotective compounds 
including, VEGF, FGF2, IGF-1, stem cell factor and granulocyte colony-stimulating factor (G-CSF)  
(Taguchi, Soma et al. 2004, Kawada, Takizawa et al. 2006), which aid endogenous repair and 
trigger  the  mobilisation  of  bone  marrow  cells  to  the  brain.  These  characteristics  have 
particularly focused study on the potential of HSCs in both early stage onset stroke as well as 
late stage stroke. Early stage treatment focuses on trying to prevent the wave of damage from 
extending outwards from the infarct site through the provision of trophic, transient support. 
Late stage administration could function to directly replace neurons lost during the stroke. This 
late stage intervention could be achieved in two ways: by differentiating the cells in-vitro prior 
to transplantation or by the direct transplantation of CD34
+ cells followed by specialisation in-
vivo via endogenous signalling (Sigurjonsson, Perreault et al. 2005).  
3.1.2  Omnicytes 
A small sub-population of CD34
+ cells called omnicytes has been identified (Gordon 1994, 
Zuba-Surma, Kucia et al. 2009) with promising characteristics for ischemic stroke therapy. They 
were identified based on their adherence to culture plastic and their expression of the CD34 
antigen.  CD34
+  cells  are  typically  non-adherent,  and  this  property  has  long  been  used  to 
separate CD34
+ from CD34
- cells such as MSCs. However it was discovered by Gordon et al. 
that a sub-population of CD34
+ cells adhered to plastic that constitutes approximately 1% of 
the whole CD34
+ population. Omnicytes have morphology consistent with a primitive stem cell 
population; they have a small lymphocyte-like morphology with high nuclear/cytoplasm ratio, 
attributes that are not characteristic of CD34
+. Once isolated, the adherent population was 73 
 
99% pure with low expression of CD38, CD33 and HLA-DR, differing from their fellow non-
adherent  population  that  had  high  variability  in  expression  of  these  antigens.  It  was 
hypothesised that the regenerative capabilities of the total CD34
+ population lay within this 
small sub-population of cells (Gordon 1994, Gordon, Levicar et al. 2006). 
As well as the primitive morphology, these cells also expressed a number of genes indicating 
their  potential  to  differentiate  towards  different  lineages  and  cell  types  (Cross  and  Enver 
1997). Gordon et al. showed that omnicytes expressed genes associated with all three germ 
layers, including genes associated with cardiovascular, pancreatic, muscle and nerve lineages 
(Table 14). They also expressed genes associated with pluripotency including Nanog and Oct4. 
Evidence suggests that this small sub-population is a putative stem/progenitor cell population 
that may have the potential to form a range of cells from the 3 embryonic germ layers (Gordon 
1994, Gordon, Levicar et al. 2006). 
Stem cell  Pancreas  Cardiovascular  Nerve 
CD34  Pdx-1  Nkx2.5  Endolase 
CD133  NGN-3  MEF-2C  Nestin 
Rex-1  Insulin  MEF-2D  Dopamine 
Oct-4    Phosholamban  Serotonin 
Nanog    VEGF  NGN3 
Tie-2    KDR   
Angiopoietin    PECAM   
TAL-1    VE-cadherin   
CXCR4       
Table 14 - Endogenously expressed genes associated with freshly isolated omnicytes 
Genes observed by Gordon et al. to be endogenously expressed by fresh omnicytes, genetic analysis done using rt-
PCR. 
Omnicytes taken through phase 1 safety trials in liver failure patients were found to be to have 
no  adverse  effects  on  patients  (Gordon,  Levicar  et  al.  2006,  Levicar,  Pai  et  al.  2008,  Pai, 
Zacharoulis et al. 2008). This confirms the safety profile and justifies their use in further human 
trials to investigate their therapeutic potential. 
In  light  of  in-vivo  studies  demonstrating  that  CD34
+  cells  aid  in  angiogenesis  and 
neovascularisation following ischemic stroke (Chen, Zhang et al. 2003, Taguchi, Soma et al. 
2004), it is thought that using omnicytes could aid and enhance patient recovery, as was 74 
 
investigated in a phase 1 trial by Imperial College London in 2013 (Catapult 2013, Banerjee, 
Bentley et al. 2014). 
3.1.3  Neuronal priming through the use of growth factor and cytokine manipulation 
Omnicytes  have  potential  to  differentiate  into  all  three  germ  layers,  including  ectoderm, 
indicated by the endogenous gene expression of nestin, endolase, dopamine, serotonin and 
NGN3 (Gordon, Levicar et al. 2006). This work investigates the effectiveness and impact of 
protocols that were developed for the differentiation of hPSC into neuronal populations on 
omnicytes. With the aim of understanding if omnicytes could be used to generate neuronal 
population for the treatment of ischemic stroke. 
One published protocol that was investigated, reported the ability to produce >80% neuronal 
precursors  (pax6
+)  from  hPSCs  (Chambers,  Fasano  et  al.  2009).  Neuronal  conversion  was 
achieved  by  inhibiting  transforming  growth  factor  beta  (TGFβ)  signalling  by  blocking 
downstream smad signalling pathways using Noggin and SB431542. TGFβ signalling promotes 
differentiation towards endoderm and mesoderm fates, inhibiting these pathways via smad 
inhibition blocks endoderm and mesoderm differentiation thereby encouraging the ectoderm 
lineage.  
Under  a  separate  investigation,  later  stage  growth factor manipulation  was performed on 
omnicyte  cultures  to  investigate  the  hypothesis  that  omnicytes  are  already  primed  for 
neuronal differentiation (Gordon, Levicar et al. 2006). Factors, sonic hedgehog (SHH), fgf8 and 
brain  derived  neurotrophic  factors  (BDNF)  were  used  to  provide  the  appropriate  cues  to 
induce midbrain neuron phenotypes (Jiang, Henderson et al. 2003).  
3.1.4  RNA mediated manipulation of omnicyte neuronal fate 
Neural circuitry has been traditionally studied in the terms of conserved signalling pathways 
and  neurogenic  transcription  factors.  To  exploit  these  pathways  scientist  were  limited  to 
adapting culture media and using growth factors and cytokines. Recently, groups of conserved 
non-coding RNAs that are highly influential post transcriptionally have been discovered, these 75 
 
RNAs  modify  protein  expression  through  the  inhibition  or  degradation  of  messenger  RNA 
(mRNA) and include, Piwi-interacting RNA (pirRNA) (Siomi, Sato et al. 2011), small-interfering 
RNA  (siRNA)  and  RNA  interference  (RNAi)  (Dogini,  Pascoal  et  al.  2014).  Studies  have  also 
shown  the  existence  of  a  highly  conserved  noncoding  regulatory  RNA  group  known  as 
microRNAs, these are discussed in the next section. 
3.1.4.1  MicroRNA background 
MicroRNAs are short noncoding nucleotide sequences that have been found to be essential in 
the regulation of gene expression (Ameres and Zamore 2013). This work investigates whether 
by using microRNAs, omnicytes can be driven towards a neuronal lineage.  
MicroRNA function by targeting mRNA once they are exported from the nucleus, and inhibiting 
their translation into functional protein. MicroRNAs are endogenous 20-24 nucleotide (nt) long 
RNA elements and were originally thought to be possessed only by higher organisms, essential 
only for complex characteristic expression. It has now been found that microRNAs are highly 
conserved across the phylogeny indicating their importance in cellular function (Meza-Sosa, 
Pedraza-Alva et al. 2014). It has been hypothesised through bioinformatics that thousands of 
microRNAs have regulatory functions within the human body and are thought to be involved in 
almost every function and cellular process (Bartel 2004). Expression has been found to be 
highly specific, with microRNA’s being exclusive to particular cell types and some transiently 
expressed during different stages in development. This characteristic suggests an important 
role for microRNAs in cellular homeostasis. 
MicroRNAs  function  by  inhibiting  specific  mRNA  expression  post-transcriptionally,  this  is  a 
result of either degrading of the mRNA or by inhibiting/blocking of translation. The inhibitive 
interaction  between  the  microRNA  and  their  target  mRNA  is  dependent  on  two  factors: 
homology at the 5’ seed region of the microRNA (usually 2-8 nt) target site of the mRNA – 
Watson-Crick  pairing;  and  the  mismatching  and  bulging  at  the  centre  region,  allowing 76 
 
endonucleolytic cleavage of target mRNA by Ago2 (Slicer) (Pillai, Bhattacharyya et al. 2007, 
Filipowicz, Bhattacharyya et al. 2008).  
3.1.4.2  Candidate microRNA  
It is understood that there are distinct microRNA expression profiles during mammalian brain 
development (Martino, di Girolamo et al. 2009) and in the mature brain, these expression 
profiles are tightly regulated. Approximately half the known microRNA identified are found 
within the brain (Shao, Hu et al. 2010), indicating the vital role they play in the brains function 
and development.  
The focus of this work will be two key neuronal microRNAs; microRNA 9 (miR9) and microRNA 
124 (miR124). miR124 is the most abundantly found microRNA in the brain, and accounts for 
approximately  25%  of  the  microRNA  expressed.  It  is  found  to  be  perfectly  conserved 
throughout species, from worms to humans and exists in three forms, 124-a,-b,-c, all resulting 
in identical mature microRNA. In murine models miR124 has been identified to be involved in 
the differentiation of neurons and are predominantly expressed in mature and differentiating 
neurons  (Cheng,  Pastrana  et  al.  2009).  In-vivo  miR124  expression  occurs  with  the  initial 
differentiation  of  neurons  from  neural  progenitor  cells  (Krichevsky,  Sonntag  et  al.  2006), 
indicating miR124 plays a key role in the differentiation of neural progenitor cells into neurons. 
It is thought it does this by repressing the expression of a large number of non-neuronal genes 
(Conaco,  Otto  et  al.  2006,  Cheng,  Pastrana  et  al.  2009).  Knockdown  studies  and  over 
expression studies have shown that increased levels of miR124 drove cells towards a neuronal 
lineage and knockdown showed a 30% reduction in functional neurons produced.  
MiR9 is primarily expressed in the brain as a mediator of neurogenesis (Krichevsky, Sonntag et 
al. 2006, Packer, Xing et al. 2008). The expression of this microRNA is variable throughout 
differentiation  from  neural  progenitor  to  more  mature  cell  types,  the  highest  level  of 
expression is found in mature cell types (Krichevsky, King et al. 2003). A key function of miR9 is 
thought to involve the regulation of TLX, an orphan nuclear receptor involved in proliferation 77 
 
and self-renewal (Zhao, Sun et al. 2009). Over expression of miR9 leads to a down regulation of 
TLX  and  reduced  levels  of  proliferation,  pushing  cells  out  of  proliferation  and  into 
differentiation.  
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3.2  Aim 
The aim of this chapter will be to assess the potential of omnicytes for neuronal differentiation 
and the production of neuronal cells for the treatment of ischemic stroke. Initial work by 
Gordon et al. has indicated the potential of omnicyte for neuronal differentiation. We will 
investigate the potential of this cell type in both neuronal progenitor production and later 
specialised cell induction, forgoing the progenitor stage. The impact of media manipulation 
(smad inhibition and later growth factor modification) and microRNAs will be investigated. 
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3.3  Results 
3.3.1  Omnicyte expansion and endogenous gene expression 
Due to the low yield of omnicytes (~1% of total CD34
+ population) from a primary cell source it 
was important to be able to expand the starting population to a number that could be of 
therapeutic  value  and  of  use  in  differentiation  experiments.  It  was  found  that  by  using 
‘expansion mix’ (Chapter 2, section 2.7.1) it was possible to expand the starting population by 
approximately 6-fold over the course of 6 days (Figure 8, A). This enabled the investigation of 
various  differentiation  protocols  from  a  very  low  starting  population.  Omnicytes  were 
screened at day 0 (D0) for their endogenous gene expression to assess their potential for 
neuronal  differentiation.  It  was  shown  by Gordon  et  al.  that omnicytes  express  ectoderm 
associated genes including; Nestin, Dopamine and Serotonin (Gordon, Levicar et al. 2006). In 
this work omnicytes were assessed for their expression of a number of other neural markers 
and found positive for sox1, sox2, otx2 and nurr1 (Figure 8, B), a number of these were shown 
to be maintained over the 6 days of expansion in expansion media (Figure 8, C). Day 5 was 
deemed to have the greatest potential with the majority of the target genes still expressed 
(Figure 8, C). Omnicytes were found to show negative expression of neural markers pax6, 
foxa2 and TH (Figure 8, B). 
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Figure 8 - Omnicyte expansion and endogenous gene expression 
A)  Representative  bright  field  images  of  omnicytes  expanded  in  expansion  media  over  6  days  showing 
approximately a 6-fold increase in cell number. B) rtPCR primer optimisation and screening of endogenous omnicyte 
gene expression of target genes. C) rtPCR for target neuronal genes during 6 days of expansion of omnicytes in 
expansion media. 
3.3.2  Effects of cryopreservation on omnicyte expansion potential 
Due to the infrequency of patient samples being available for research (Figure 9, C) the effects 
of  retrieval  from  storage  at  -80
oC  on  omnicyte  expansion  potential  was  investigated. 
Cryopreserved and fresh omnicytes were seeded at 3.7x10
4 cells per well (96 well plate) and 
cultured over a 6 day period. WST-1 analysis (Figure 9, A) shows that the sample that had been 
exposed to cryopreservation was severely limited in its ability to stick down and expand over 
the first 6 days when compared with fresh samples.  81 
 
Media analysis was also performed to assess dextrose consumption and lactate production 
over a 9 day culture period. It was shown that over the first 48 hours dextrose consumption 
and lactate production remained low. After 48hrs dextrose levels were observed to drop and 
lactate levels rise in line with omnicyte cell expansion. Media dextrose levels were shown not 
to drop below 2.5g/L over this culture period with only 1 addition of fresh media at day 6 
(Figure 9, B). The same trend was observed in two independent samples characterised over the 
first 5 days. 
 
Figure 9 - Basic omnicyte culture over time 
A)  Shows  WST-1  readings  for  fresh  versus  frozen  omnicytes  over  6  days  (3  hour  WST-1  incubation,  n=1)  B) 
Automated media analysis (Sample 1 & 2, solid and dashed line respectively) under normal culture conditions 37
oC 
5% CO2. Lactate production (g/L) and Dextrose consumption (g/L) is shown over 125hrs (n=2). C) Table showing the 
number CD34
+ patient samples donated to Omnicyte Ltd. over a three year period, categorised by disease type. 
3.4  Growth factor and cytokine manipulation of omnicytes 
3.4.1  Priming omnicytes towards a neuronal lineage using smad signalling inhibition  
Omnicytes were manipulated using conditions similar to those described by Chamber et al. 
(Chambers,  Fasano  et  al.  2009).  Smad  inhibition  was  used  to  drive  omnicytes  down  the 
ectoderm lineage whilst restricting both endoderm and mesoderm differentiation by blocking 
Activin/BMP  signalling  pathways.  The  conditions  described  in  Figure  10,  A,  allowed  the 
screening  of  three  base  media  alongside  the  influence  of  the  smad  inhibition;  DMEM 
(DMEM/KO-SR + Factors), αMEM (αMEM/KO-SR + Factors) and an in-house expansion media 82 
 
(Expansion/KO-SR  +  Factors).  Serum  (+ve  growth  control,  DMEM/FBS)  and  serum-free 
conditions (DMEM/KO-SR) were used as experimental controls.  
Cell cultures were analysed qualitatively (Figure 10, B) and blind scored for morphology change 
and cell culture proliferation following 3 days in the experimental conditions (Figure 10, C).  
Expansion/KO-SR  +  Factors  resulted  in  the  highest  level  of  population  expansion  and  the 
greatest level of morphological change during the 3 days of culture and the serum positive 
control (DMEM/FBS) showed a level of proliferation and morphological change greater than 
the other experiential conditions investigated over the 3 days of culture (Figure 10, B, C). 
 
Figure 10 - Effect of smad inhibition and different media compositions on omnicyte morphology and 
proliferation over 3 days 
A) Schematic of the experimental protocol used to screen initial conditions for the smad inhibition investigation. 
Serum  (DMEM/FBS)  and  serum-free  (DMEM/KO-SR)  controls  were  used  as  controls  to  assess  cell  growth  in 
unmodified  conditions.  αMEM  and  DMEM  +  smad  fact  investigated  base  medium  use  and  expansion  media 
assessed the use of the proprietary in-house expansion mix with omnicytes (factors included noggin (500ng/mL) and 
SB431542 (10µM)). B) Representative bright field images (x20 (DMEM/FBS, Expansion/KO-SR + Fact., scale bars = 
100µm) and x40 (DMEM/KO-SR, DMEM/KO-SR + Fact. and αMEM/KO-SR + Fact., scale bars = 50µm) magnification) 
following  3  days  in  experimental  media.  C)  Blind  scoring  for  proliferation  and  morphology  change  for  each 
experimental condition. 
To further investigate the effects of the previous experiment, 2 experimental conditions were 
taken forward: i) Expansion/KO-SR + factors given the proliferation and morphological scorings 83 
 
observed;  and  ii)  DMEM/KO-SR  +  factors,  so  to  assess  the  impact  of  expansion  media. 
DMEM/KO-SR was used as the experimental control. The culture period was extended to 7 
days to allow the effects of the smad inhibition on cell morphology to be assessed over a 
longer period of time.  
Morphology changes were observed in all conditions (Figure 11, A-H). The greatest level of 
change  was  observed  in  Expansion/KO-SR  +  factors  (Figure  11,  C,  G  and  I),  where 
approximately  11%  of  cells  were  found  to  morphologically  change;  either  elongated  or 
adhered to the culture plastic and extending projections (Figure 11, H, I). 
 
Figure 11 - Effect of smad inhibition on omnicyte morphology after 7 days of culture  
Representative  bright  field  images  of  day  7  (A/D)  DMEM/KO-SR,  (B/E)  DMEM/KO-SR  +  Factors  and  (C/G) 
Expansion/KO-SR + Factors cultures. (x10 and x40 scale bars = 200µm and 50µm respectively). H) Blind scoring of 
observed morphological changes following 7 days culture in experimental conditions. I) Enhanced bright field image 
of Expansion/KO-SR + Factors, red arrows highlight adhered omnicytes with transformed morphologies (Scale bar = 
50µm). 84 
 
3.4.2  Impact of smad signalling inhibition on the neuronal gene expression of omnicytes 
With similarly insignificant morphological changes being  were observed in both DMEM/KO-SR 
with or without smad inhibitors, it was decided that further experiments would focus on the 
use of Expansion media with and without smad inhibition (Figure 12, A).  
Real-time PCR was used to assess the molecular changes induced in culture populations over 
time. It was previously shown that sox1 and otx2 were endogenously expressed by omnicytes 
(Figure  8);  therefore  we  investigated  whether  these  genes  would  be  stably  expressed 
throughout 9 days of culture or whether they would be affected by smad inhibition. We also 
looked to understand whether a longer culture period could result in neuronal progenitor 
marker pax6 expression. 
Analysis showed that sox1 was maintained throughout the 9 days of culture irrespective of the 
condition. Oxt2 was shown only to be maintained in expansion media without smad inhibition 
factors (Figure 12, B). The inclusion of factors resulted in a marked decrease in band intensity 
by D3 and no expression by D9 (Figure 12, B). Pax6 was not expressed at any time point of the 
experiment. Pluripotency marker nanog was found to decrease by D3 but returned to D0 levels 
by D9 in expansion media without smad inhibitors but additions of inhibitors appeared to 
reduce nanog expression (Figure 12, B).   85 
 
 
Figure 12 - Smad inhibition - Molecular analysis at over 9 days (n=2) 
A) Schematic of 9 day smad inhibition investigation using expansion media as the base medium. Factors included 
Noggin (500ng/mL) and SB431542 (10µM) B) rt-PCR for mRNA analysis of target neuronal genes over the 9 days of 
differentiation.  Target  genes  used  include;  β-actin  (housekeeping  gene),  sox1  (early  ectoderm  marker),  otx2 
(sensory  organ  development  and  neuronal  patterning),  pax6  (neuronal  progenitor)  and  nanog  (pluripotency). 
Positive controls were developed for each PCR primer set, for sox1, otx2 and nanog MDA-MB-231 breast cancer cell 
line was used and HEK-293 cell line for pax6. 
3.4.3  Neuronal differentiation of omnicytes using later stage neuronal growth factors 
The effect of specific neuronal growth factors (SHH, FGF8, BDNF) on neuronal differentiation of 
omnicytes were also assessed. This work was modelled on research by Jiang  et al. (Jiang, 
Henderson et al. 2003) that differentiated neuroectoderm from mouse multipotent progenitor 
cells. It was thought that the endogenous expression of early neural markers sox1 and sox2 by 
omnicytes could indicate that omnicytes are already primed for differentiation and that early 
neuronal progenitor manipulation was unnecessary. 
We designed an experiment to determine the effects of different supplements on the seeded 
cells, including +/- neuronal supplement N2 (Life Technologies, Figure 13, A, shaded) and +/- 
fibronectin (5µg/mL, Sigma) coating of plates (Figure 13, A). The experiment was performed 86 
 
over 28 days and non-adherent cells were harvested for PCR analysis. Adherent cells were not 
harvested, due to low cell numbers and with the intention of allowing these cells to mature 
fully over 28 days. 
 
 
Figure 13 - Growth factor manipulation schematic  
A)  Schematic  describing  the  experimental  conditions  used  to  investigate  the  utilisation  of  growth  factors  for 
inducing omnicyte neuronal differentiation. ‘Negative control’ utilised base media only to provide a baseline for 
comparison, unshaded columns (without N2) and shaded columns (with N2) allowed the investigation of the growth 
factors alongside condition types, +/- fibronectin and +/- N2 supplement. B) Depiction of the anticipated protocol 
stages of differentiation. 
3.4.4  Morphological analysis of growth factor manipulation of omnicytes 
Omnicytes were efficiently expanded during the first 6 days (Figure 14, A) and split into wells 
to  investigate  the  effects of  the  experimental  conditions  previously  described.  Bright  field 
images are shown in Figure 14, B-F. During the initial 7 days of differentiation following growth 
in the expansion media (i.e. D6 to D13 of the experiment), the cells were exposed to bFGF. 
Upon stimulation with bFGF, cells started to assume fibroblast-like morphologies, consistent 
with  those  observed  by  Gordon  et  al  during  normal  expansion,  elongated  or  flattened 87 
 
spherical cells. During this time the cell population grew dramatically with cells being released 
into suspension. These non-adherent cells were harvested periodically for total RNA extraction 
and subsequent mRNA analysis but by D11 cell numbers unexpectedly decreased, not allowing 
further  molecular  analysis  (Figure  15,  B).  Progressive  cell  morphologies  were  continually 
observed over culture period (Figure 14, B-F) until D28 where samples were shown to have 
adherent spindle-shaped morphologies (Figure 15, A).  
 
Figure 14 - Growth factor manipulation - cell morphology images 
A) Representiative bright field images of the first 3 days of the initial expansion stage (Scale bars = 1000µm). 
Representiative bright field images of culturing conditions; (B) negaitive control, (C) growth factors only, (D) growth 
factors + fibronectin, (E) growth factors + N2 and (F) growth factors + N2 + fibronectin at day 8, 13,  20 and 28. 
(Scale bars = 200µm). 88 
 
By D23 of the experiment, cells had acquired the various morphologies as shown in Figure 15, 
A. The negative control used exhibited a number of cell types but predominantly adherent 
circular  cells  were  observed  (Figure  15,  A,  indicated  by  the  red  arrow).  Cultures  without 
fibronectin coating also exhibited this cell type but the majority were found to be long spindle 
like cells (Figure 15, A, indicated by the green arrow) with N2 addition reducing the number of 
cells present and stunting the cellular protrusions (Figure 15, A, indicated by the yellow arrow). 
The addition of fibronectin appeared to affect viability, with low cell densities being observed 
in both conditions including the substrate. Growth factors + N2 + fibronectin showed the 
lowest viable cell population.  
PCR analysis revealed that sox1 and otx2 expression was generally stable across the majority of 
conditions, with sox1 increasing or remaining stable over time in all conditions. Otx2 appeared 
to be transiently expressed with reduced levels around D9 of culture. Pax6 analysis indicated 
instability of the cDNA synthesised with unstructured banding observed. At D13 pax6 banding 
could be observed in ‘negative control’, ‘growth factors only’ and ‘growth factors + N2’ but 
was questionable in most conditions. There was also evidence of early expression in ‘growth 
factors + fibronectin’ but this appeared to have dropped by D13 (Figure 15, B). It was not 
possible to analyse cells after D13 due to cell numbers being too low. This experiment was 
repeated with three omnicyte samples; however there was no consistency of gene expression 
or trends observed across the samples.  89 
 
 
Figure 15 - Growth factor manipulation - Enhanced day 23 morphology images and RT-PCR analysis 
A) Enhanced bright field images of day 23 cultures in the different experimental conditions (Scale bars = 200µm). B) 
Composite image of RT-PCR results of mRNA analysis of target neural genes over 13 days of the growth factor 
differentiation. Target genes used include; housekeeping gene, β-actin and neuronal genes, sox1, otx2 and pax6 
(n=1). 
 As  previously  described  non-adherent  cells  were  harvested  for  molecular  analysis  but 
adherent  cells  were  cultured  for  the  full  28  days.  To  analyse  these  adherent  cells 90 
 
immunocytochemistry (ICC) was carried out. Due to the very low cell number PCR was felt not 
to be feasible. 
Cultures were assessed for expression of neuronal markers β-III-Tubulin (microtubule, neuron 
specific)  and  MAP2  (mature  neuronal)  using  ICC  (Figure  16).  It  was  observed  that  on 
fibronectin coated plates β-III-Tubulin
+ cells were present though these were found at very low 
frequencies.    MAP2
+  cells  were  observed  in  Growth  factor  +  N2  cultures.  Unfortunately 
staining was not successful for any of the other experimental condition investigated (Growth 
factors only and Negative control). 
 
Figure 16 - Immunofluorescent labelling of growth factor manipulated omnicytes 
Representative ICC images of β-III-Tubulin (microtubule, neuron specific) staining of (A) growth factors + fibronectin 
and (C) growth factors + N2 + fibronectin. MAP2 (mature neuronal) staining was processed for (B) growth factors + 
N2 (Scale bars = 50µm).   
3.5  Utilisation  of  microRNAs  to  modify  omnicytes  gene  expression  and  drive  them 
towards a neuronal lineage 
The effects of microRNA124 and microRNA9 on the neuronal gene expression of omnicytes 
were  investigated  (Figure  17).  Omnicytes  were  seeded  in  expansion  media  with  SHH 
supplemented, SHH has been shown to have a strong proliferation impact on adult neural 91 
 
progenitors, and it was thought this would prime the cell towards a neuronal lineage (Lai, 
Kaspar et al. 2003). On day 2 and 3 cultures were transfected with microRNAs or microRNA-
negative reagent as a control. The negative control allowed the assessment of the effects of 
transducing cells alone and the two single microRNA transfections allowed the effects of the 
individual microRNAs to be assessed.  
 
Figure 17 - Schematic of microRNA work 
Schematic of the experimental protocol used to investigate the utilisation of microRNAs to modify omnicyte gene 
expression and direct them towards a neuronal lineage, indicating the anticipated stages of the differentiation. 
Cultures were grown over 4 days in expansion media and supplemented with SHH for the first 2 days. Experimental 
cultures were then transfected with  either miR124 or miR9 to assess the effects of the individual microRNAs. 
Transfection with miR-negative reagent (100nM) or untreated (negative control) were used as negative controls.  
PCR  was  used  to  assess  the  effects  of  microRNAs  on  neuronal  gene  expression  in 
cryopreserved  omnicytes.  Initial  experiments  were  performed  to  assess  the  effects  of 
introducing SHH to the cultures over the first 2 days (Figure 18, A). During this stage sox2 was 
found  to  be  stably  expressed,  nestin  was  found  to  be  amplified  in  most  of  the  cultures 
compared  with  the  experimental  negative.  Otx2  expression  was  up  regulated  consistently 92 
 
across all the cultures and Nurr1 only expressed strongly in miR9 transfected cultures. By D4 
following transfection, sox2 and nestin were only expressed in miR9 and miR-negative cultures 
but  conversely  otx2  was  only  expressed  in  miR124  transfected  cultures.  Foxa2  was  not 
expressed by omnicytes under any condition. D0 samples were not collected for this early 
experiment  hindering  gene  expression  analysis  over  time  compared  with  endogenous 
expression, D0 expression this was addressed in later experiments (Figure 18, A). 
The same protocol was repeated using fresh omnicytes and showed differing results. Sox2 and 
nestin  were  expressed  across  all  experimental  conditions.  Otx2  was  up-regulated  in  all 
conditions except miR124 transfected cultures. Nurr1 showed faint banding at D0 but this low 
level of expression was lost by D2. Expression levels of TH were negative (Figure 18, B). 
 
Figure 18 - RT-PCR analysis of microRNA manipulation of omnicytes  
A) RT-PCR analysis of frozen omnicyte expression of target genes (β-actin, sox2, nestin, otx2, nurr1 and foxa2) over 
4 days, investigating four conditions. D2 shows the effects of supplementing the experimental media with SHH, D4 
represent the individual effects of each experimental condition on target gene expression. B) RT-PCR for mRNA 
analysis of fresh omnicyte target gene expression (β-actin, sox2, nestin, otx2, nurr1 and TH). Negative controls 
represent cells cultured in expansion media alone. PCR +ve controls were processed using commercially available 
human foetal temporal lobe DNA. 
To build on the variability observed in the previous two experiments (cryopreserved versus 
fresh), two fresh patient samples received at the same time were used to investigate the 
variability between patients. Nestin was observed to be unaffected by patient variability when 
considering the level of β-actin expression for each sample. Expression across the different 
conditions  showed  that  neither  miR9  nor  miR124  showed  higher  expression  than  the 
microRNA-negative  control.    Sox2  expression  appears  to  be  highly  variable with  sample  A 93 
 
indicating similar expression levels for both miR124 and miR9 transfected cultures and sample 
B showing substantially higher expression in miR9 transfected cultures than miR124. Otx2 also 
showed no consistency with expression levels per conditions varying widely. Nurr1 expression 
was found to be highly variable at D2 and at D4 only miR124 transfected cultures expressed 
nurr1 (Figure 19). TH is consistently not expressed. 
For  both  patient  samples  it  was  observed  that  transfection  with  miR124  resulted  in  the 
greatest increase in target gene expression when compared with miR9 (Figure 19). 
 
Figure 19 - microRNA transfections using fresh cells 
RT-PCR  analysis  of  two  patient  samples  (samples  A  and  B).  Samples  were  cultured  over  4  days  in  identical 
experimental conditions and harvested at D2 and D4 to assess the expression of target genes (β-actin, nestin, sox2, 
nestin,  otx2  and  nurr1)  over  the  course  of  the  experimental  procedure.  One  representative  D0  sample  was 
harvested due  to restricted availability of  samples.  The PCR +ve were achieved through the  use commercially 
available human foetal temporal lobe DNA. 94 
 
We then investigated the expression of target neural genes (sox2, nestin, nurr1 and TH) in the 
two patient samples. Samples were either cultured with expansion media alone or transfected 
with  miR124.  This  was  done  to  understand  the  impact  of  the  culture  media  on  gene 
expression, over that of miR124. miR124 was selected due to the level of expression observed 
in the previous work (Figure 19) when compared with miR9.  
mRNA analysis (Figure 20, A) demonstrated a low consistency in expression of sox2 and nestin 
with  results  shown  to  be  contradictory  to  previous  findings.  The  morphological  effects  of 
transfection were clear, in expansion media only cultures single cells were observed (Figure 20, 
B); but in transfected cultures, cells clumped to form cell aggregates (Figure 20, C). 95 
 
 
Figure 20 - Cell culture with expansion media versus culture expansion media and transfection of 
miR124 
A) RT-PCR analysis comparing the effects of expansion media and expansion media plus miR124 on omnicyte gene 
expression. Representative bright field images of omnicyte cultures in expansion media (B) and expansion media 
transfected with miR124 (C) at day 4 of culture (Scale bars = (B) 100µm (C) 50 µm, n=2). 
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3.6  Discussion 
This  chapter  investigated  the  use  of  omnicytes  (adherent  CD34
+  cells)  as  a  cell  source  to 
generate neuronal populations. It has been shown through in-vivo studies (Taguchi, Soma et al. 
2004)  that  administration  of  CD34
+  cells  post  ischemic  attack  can  have  beneficial  effects; 
reduced scaring, increased neovascularization and increased endogenous neurogenesis. Trials 
are on-going to investigate the benefit of CD34
+ cell mobilisation and administration in humans 
(Therapy 2013, Banerjee, Bentley et al. 2014).  
It  was  thought  that  by  utilizing  omnicytes  as  the  cell  source  for  neuronal  differentiation, 
undifferentiated cells following the differentiation process would have a restorative effect and 
differentiated omnicytes would integrate and have a regenerative effect. 
3.6.1  Endogenous omnicyte gene expression and their ability for expansion 
CD34
+ cells are isolated from patient donated bone marrow aspirates or G-CSF stimulated, 
mobilised bone marrow samples. Omnicytes are a sub-population of this CD34
+ population, 
accounting for around 1% of the whole CD34
+ population (Gordon 1994, Gordon, Levicar et al. 
2006). This presents a challenge as the initial population for investigation is extremely small 
and so requires expansion to be viable for investigation. Omnicyte Ltd. developed a propriety 
expansion media that enabled the expansion of the omnicyte population six-fold over the 
course of 6 days (Figure 8, A).   We found that during these 6 days of expansion in the media, 
seeding remained appropriate for cell growth. However, as the population increased (Figure 9, 
A) lactate levels increase and dextrose levels decrease (Figure 9, B). Cell expansion appeared 
not to be hindered (Figure 9, A).  
Due to the rarity of sample acquisition (Figure 9, C) the majority of experiments were carried 
out on ‘long term’ stored samples and this led us to question how cryopreservation might 
affect cell viability. We found the level of adherence, ‘stick down’ following cryopreservation 
was greatly diminished when compared to fresh samples and that population expansion was 
delayed (Figure 9, A). This needed to be taken into account when initiating experiments.  97 
 
It was found by Gordon et al. (Gordon, Levicar et al. 2006) that omnicytes express a number of 
neural marker genes. We also assessed gene expression and whether these genes continued to 
be expressed during the expansion phase. Omnicytes were found to endogenously express two 
key  pluripotency  markers;  oct4  and  sox2,  affirming  their  identification  as  pluripotent 
progenitors. It was found that omnicytes expressed a number of neural genes including; nestin, 
sox1,  otx2  and  nurr1,  supporting  the  hypothesis  that  these  cells  have  the  potential  for 
neuronal differentiation (Cross and Enver, 1997). Omnicytes were found to not endogenously 
express pax6, fgf5 or TH (Figure 8), indicating that they are not neuronal progenitors (fgf5
+, 
pax6
+), or express genes associated with dopaminergic neurons (TH
+). Expansion was shown to 
support the expression of the pluripotency gene sox2 as well as the neural genes nestin and 
otx2, indicating that with the genes assessed, expansion could support omnicyte’s endogenous 
neural gene expression profile.  
3.6.2  The effect of smad signalling inhibition on omnicyte morphology, proliferation and 
neuronal gene expression 
Due to omnicytes being found to endogenously express a number of neuronal genes it was 
hypothesised that they were primed for differentiation towards a neuronal lineage. To exploit 
this theory smad inhibition was used to try to direct the cultures away from endoderm and 
mesoderm lineages and to differentiate them down the ectoderm lineage. 
Initial work was designed to assess the effects of different conditioning factors on omnicyte 
proliferation  and  morphology  over  3  days.  Morphological  and  proliferation  blind  scoring 
showed that expansion media plus smad inhibition resulted in the greatest proliferation levels 
and morphological changes; this was closely followed by serum (FBS) control (Figure 10). This 
observed proliferation might be expected due to optimised capabilities of expansion media, 
and serum’s common use in cell culture and expansion for this attribute. The use of serum in 
translatable therapy is avoided where possible due to the increased chance of transmission of 
xeno-disease to humans, and also because of its uncontrolled consistency. Where possible, 98 
 
serum is removed from experimentation within this work. Expansion media on the other hand 
is a chemically defined media (described in the chapter 2, 2.7.1) and is manufactured to be 
GMP compliant. Other than expansion media, all other conditions showed little to no effect on 
proliferation of cells, with the exception of DMEM/FBS which was later excluded. 
Culture time was extended to 7 days to further investigate these findings. The conditions taken 
forward included DMEM/KO-SR with/without smad inhibition and expansion media with smad 
inhibition. Serum was withdrawn for the reasons mentioned above and αMEM/KO-SR with 
smad inhibition excluded because it was observed to have no greater impact over that of 
DMEM/KO-SR alone. Findings from this investigation confirmed the observations from the 
previous  screening:  expansion  media  plus  smad  inhibition  resulted  in  the  greatest 
morphological  change  with  DMEM/KO-SR  with/without  smad  showing  no  difference, 
indicating that smad inhibition had no effect over that of the base media alone (Figure 11, A-
G/H).   In the condition expansion media plus smad inhibition cell morphology could be found 
to alter in approximately 11% of the cells observed (Figure 11, H). 
Following  the  finding  that  smad  inhibition  alone  in  basal  media  (DMEM/KO-SR)  led  to  no 
change in morphology over that observed in the negative control, it was decided that the work 
would focus solely on expansion media and the inclusion and exclusion of smad inhibition. We 
investigated the impact of inclusion of smad inhibition over the course of 9 days and assessed 
its inclusion by looking at the effect on neuronal gene expression; sox1, otx2 and pax6 (Figure 
12). Relative to D0, sox1 was found to decrease by D3 but returned to prior levels by D6 then 
increase in level to D9 where expression was observed to be equal in +/- conditions and 
enhanced relative to D0, indicating that the culture  had moved towards an ectoderm lineage. 
Otx2 was expressed at D0 but by D3 otx2 was found only to be expressed in smad inhibitive 
cultures.  This  was  reversed  by  D6,  where  expression  was  shown  to  be  enhanced  only  in 
expansion media (-factors) cultures and lost in smad inhibitive cultures. Expression was found 
to decrease again by D9 to D0 levels in smad negative cultures and was observed not to be 99 
 
expressed in smad inclusive cultures. This indicates that the inclusion of smad inhibition with 
omnicytes does not promote differentiation towards a neuronal lineage. Pax6 (Walcher, Xie et 
al. 2013), an early neuronal progenitor marker, was considered the first milestone in moving 
omnicytes  towards  a  neuronal  cell  type  (Chambers,  Fasano  et  al.  2009).  However  in  this 
experiment  it  was  not  expressed  at  any  time,  under  any  condition.  Screening  of  the 
pluripotency marker nanog showed that expression increased by D9 in smad negative cultures; 
this could potentially corroborate the idea that cultures in this condition are maintained in 
their pluripotent state and not differentiated towards any lineage in particular. 
This investigation into the use of smad inhibition alongside expansion media was repeated 
twice but results were not reproducible. In all experiments, pax6 was not expressed and so this 
method of neuronal induction was perceived as unsuccessful and not continued. 
3.6.3  The effects of growth factor manipulation on neuronal gene expression of omnicytes 
It was hypothesised that the lack of neuronal differentiation witnessed using smad inhibition 
may  be  due  to  intervention  and  manipulation  occurring  too  early  in  the  neuronal 
differentiation process. This section of work focused on using patterning growth factors to 
influence the cells and stimulate neuronal progenitors. 
The growth factor investigation was designed to test the impact of a number of variables 
including the use of fibronectin as surface matrix, N2 supplement and the addition of growth 
factors (Figure 13). It was hypothesised that the addition of the fibronectin would improve cell 
adhesion  and  differentiation,  through  cell-substrate  interaction.  It  has  been  shown  by 
Nakajima  et  al.  that  fibronectin  can  support  neuronal  cell  growth  and  aids  maturation 
(Nakajima, Ishimuro et al. 2007), supporting this hypothesis. N2 was investigated as it has been 
shown to support primary neuronal cultures and it was hypothesised that its addition would 
support the primed omnicytes as they differentiated and matured into neurons. 
Omnicytes were observed to expand over the first 6 days in expansion media prior to being 
split for the experiment (Figure 14). Up to D13, whilst being supplemented with bFGF, the 100 
 
cultures were found to expand dramatically; cells were also observed to adhere to the culture 
surface and assume fibroblast-like morphologies similar to findings by Gordon et al. During this 
time, as cells were released into suspension, they were harvested for mRNA analysis. Adhered 
cells were not harvested as we were limited by the number of experimental replicates and 
harvesting the adhered cells would have impacted on the scope of the work. Following the 
addition of SHH and fgf8a on D13, cell numbers dramatically decreased until D21. Alongside 
this  observation,  in  conditions  including  fibronectin  and  N2  supplement  (Figure  14),  the 
number of adhered cells was greatly reduced when compared with no addition of fibronectin. 
Suggesting that omnicytes do not adhere well to fibronectin and that conditions suitable for 
primary  neuronal  populations  (including  N2)  are  not  beneficial  to  the  omnicyte  derived 
population.  
At D23 a number of different morphologies were observed. The negative control allowed us to 
elucidate the impact of the growth factors and additives. Within the negative control, cells 
adhered  and  assumed  ‘fried  egg’  morphologies  (Figure  15),  with  a  smaller  proportion 
presenting elongated morphologies. Within experimental cultures, elongated cells were shown 
to  be  the  prominent  cell  type,  over  that  of  the  ‘fried  egg’  morphology.  Both  of  these 
morphologies are consistent with observations made by Gordon et al in 2006. The exclusion of 
N2 resulted in the greatest proportion of elongated cells with inclusion of fibronectin resulting 
in this cell type being the dominate morphology (Figure 15). 
Gene expression was assessed over the first 13 days, sox1 appeared to be maintained up to 
D13 in all conditions but with reduced expression around D9 or D10 (Figure 15). This trend was 
also observed with otx2. Pax6 screening did not yield viable results as it appeared that sample 
RNA  or  primer  had  degraded  prior  to  screening  but  slight  banding  was  observed  in  all 
conditions  except  those  including  fibronectin.  This  may  indicate  that  cells  exposed  to 
fibronectin mature faster, passing the neural progenitor (pax6
+) stage and this is supported by 
the  protein  expression  observed.  Maturity  of  the  cells  in  fibronectin  coated  wells  was 101 
 
confirmed  by  staining  of  MAP2  (mature  neuronal  marker)  and  β-III-Tubulin  (neuronal 
microtubule  marker).  MAP2
+  and  β-III-Tubulin
+  were  only  observed  in  fibronectin  coated 
conditions (Figure 16), however it is difficult to draw conclusions from this outcome because 
staining failed in a number of conditions. 
The inability to generate convincing neuronal cell types from omnicytes is consistent with 
literature and other studies that show that the generation of neuronal cells in-vitro from whole 
CD34
+ populations or purified HSC populations is generally unsuccessful (Roybon, Ma et al. 
2006). Other work has shown in chicken that CD34
+ cells can be induced to express neuronal 
markers though only when implanted directly into the injured embryonic CNS (Sigurjonsson, 
Perreault et al. 2005). This suggests that to succeed in differentiating CD34
+ cells in-vitro, 
factors may need to mimic the injured brain rather than signally during development, which 
was attempted in this work. 
3.6.4  The influence of microRNA on omnicyte neuronal gene expression 
Finally, the work investigated molecular manipulation, using microRNA, of omnicyte cultures 
to achieve neuronal differentiation.  
The potential of microRNAs as post-transcriptional controlling elements was only just being 
realised at the time of this work and we attempted to use these elements to modify omnicyte 
gene expression at a molecular level. A review of the literature highlighted the potential of two 
candidate microRNA; miR124 (Conaco, Otto et al. 2006, Cheng, Pastrana et al. 2009) and miR9 
(Krichevsky, Sonntag et al. 2006; Packer, Xing et al. 2008) that had been shown to be highly 
influential in the development of neuronal cell types.  
A protocol was designed that would prime the cells before transfecting with miR124 and miR9 
to  drive  omnicytes  down  a  neuronal  lineage  (Figure  17).  SHH  was  supplemented  to  the 
cultures at D0 and on D2 cultures were transfected with either the experimental microRNA or 
miR-negative  to  assess  the  impact  of  the  transfection  method  and  the  RNA  element.  An 102 
 
untreated arm (no SHH or transfection) was used to assess endogenous gene expression over 
the culture period (Figure 17). 
The initial screen was designed to assess the impact of microRNA transfection (D4) on (fresh) 
omnicyte gene expression. Gene expression was observed to fluctuate between sample times, 
with expression in miR124 transfected cultures showing variable expression of sox2 and nestin 
from D2 to D4. However, when the protocol was repeated, on frozen samples, the expression 
of these genes was found to show the reverse. This experiment was repeated but results were 
found  to  be  highly  variable,  this  was  thought  in  part  to  be  due  to  the  effects  of 
cryopreservation (Figure 18). 
This work then compared the effects of microRNA in two fresh patient samples; this allowed us 
to interrogate the impact of patient variability on results (Figure 19). Results were found to 
vary  between  samples.  Nestin  expression  appeared  to  be  relatively  constant  across  both 
groups of conditions but expression of other genes (sox2, otx2 and nurr1) varied widely. These 
results, though not conclusive, led us to believe that patient variability and sample storage has 
an impact on omnicyte gene expression.   
The  final  experiment  we  performed  assessed  the  effects  of  miR124  transfection  against 
expansion media alone (Figure 20). Once again results varied from those previously achieved 
with expansion media alone enhancing gene expression more than in cultures that had been 
transfected. These findings further supporting the move away from this cell type within the 
work.  
From research performed since this investigation, we now know that miR124 and miR9 can be 
used to differentiate functional neurons. Yoo et al. showed that these two microRNAs can be 
used in conjunction to differentiate fibroblasts into functional neurons (Yoo, Sun et al. 2011). 
This would suggest that this technology could still be used with omnicytes though a consistent 
source of cell needs to be found to reduce the impact of patient variability.  103 
 
3.7  Conclusion 
A number of methods were employed in an effort to drive omnicytes down a neuronal lineage 
including:  varying  the  conditions  used;  the  length  of  culture;  and  the  stage  at  which  the 
manipulation occurred (whether this involved signalling pathway manipulation or molecular 
modification).  In  none  of  these  situations  were  gene  profiles  thought  to  be  indicative  of 
neuronal populations or reproducibly switched on. This finding is in line with other groups that 
have investigated CD34
+ purified populations for the differentiation of neuronal populations 
(Roybon, Ma et al. 2006).  
This analysis was able to show a high level of patient variability associated with omnicytes, 
however, due to the rarity of the samples, analysis was restricted. The scarcity of the cell type 
encouraged the use of cryopreserved samples, further restricted analysis as we were able to 
demonstrate  that  there  was  significant  variability  compared  to  fresh  samples,  further 
impacting on the  consistency of  the  results. These results  are  in  line with  the  findings  of 
Reebye et al. (Reebye, Saetrom et al. 2013, Reebye, Saetrom et al. 2013), that fresh cells yield 
the best results.  
The results of this work challenge the potential of omnicytes as a cell source, certainly under 
these protocols. To develop the overall goal of directing cells towards a neuronal lineage, the 
rest of this thesis focuses on the use of a readily available cell source, hPSCs.   
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CHAPTER  4  -  DIRECT  DOPAMINERGIC  DIFFERENTIATION  OF  HUMAN 
PLURIOPOTENT STEM CELLS 
4.1  Introduction 
Due to the lack of success using omnicytes for the derivation of neuronal populations it was 
decided that the research would move to use different cell types, namely, human embryonic 
stem cells and human induced pluripotent stem cells.  
At  this  stage  in  the  work  the  sponsoring  company,  Omnicyte  Ltd.  was  refocusing  their 
resources to investigate the use of small activating RNAs, and their utilisation in deriving DA 
neuronal  subpopulations. The  intended  purpose of this  work  was  to  improve  the  yield  of 
differentiated DA neurons and so to move research one step closer to the development of a 
treatment for Parkinson’s disease. This work was carried out at the UCL laboratories using the 
methods and protocols available within that facility. 
To allow us to investigate the use of saRNA within a pluripotent population we needed to be 
able to generate DA neurons through conventional means. This functioned to reassure us that 
firstly, the cell types being used (Shef6 (hESC) and MSUSH001 (hiPSC)) could generate DA 
populations and secondly, give us a base level of differentiation that was already primed to 
allow us to assess the function of saRNA in enhancing differentiated yields.  
There  are  a  growing  number  of  research  groups  attempting  to  generate  therapeutically 
beneficial neuronal subsets, including DA neurons from pluripotent cells (Kriks, Shim et al. 
2011, Theka, Caiazzo et al. 2013). One method was of particular interest given its potential 
scalability of expansion of embryo bodies and was developed by a collaborator’s laboratory 
(unpublished). The DA differentiation protocol used by the laboratory was designed to mimic 
signalling pathways that neurons are exposed to during the endogenous generation of DA 
neurons. The protocol was developed to allow the expansion of the pluripotent population  
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using  typical  expansion  techniques,  and  then  induce  neuronal  differentiation,  expand  this 
population and terminally differentiate these primed cells into DA neurons. 
The pluripotent expansion process utilised adhered co-culture with iMEF which mimicked how 
the  cell  populations  had  previously  been  cultured  so  to  avoid  any  adverse  effects.  The 
populations were then assessed for differentiation and any differentiated cells or colonies 
removed prior to being put into suspension as cell aggregates. Neural induction was modified 
from a protocol developed by Joannides’s et al. ((Joannides, Fiore-Heriche et al. 2007))and was 
used to select for a neural lineage using SB431542 to block the endoderm and mesoderm 
lineages and selecting ectoderm as the default (Inman, Nicolas et al. 2002, Laping, Grygielko et 
al. 2002), similar to the investigation and work described in chapter 3 using omnicyte. The 
neuronal primed population was then expanded using bFGF which has elsewhere been shown 
to stimulate proliferation of hPSC-derived neurosphere populations (Gensburger, Labourdette 
et al. 1987), prior to maturation and terminal differentiation. During maturation cultures were 
conditioned towards a DA final population through the addition of fgf8a, purmorphamine and 
ascorbic acid. Both fgf8a and purmorphamine have been shown to be involved endogenously 
in  the  development  of  the  mesencephalon  (Alves  dos  Santos  and  Smidt  2011)  and  the 
generation of ventral midbrain neurons (Roelink, Augsburger et al. 1994, Marti, Bumcrot et al. 
1995). Ascorbic acid was included for its neuroprotective qualities and its ability to increase 
differentiation yields of TH
+ neurons (Cooper, Hargus et al. 2010). This treatment commenced 
on D10 and continued until the neurospheres were terminally differentiated into DA neurons 
after 24 days. Neurospheres were directed finally toward terminal DA differentiation using a 
chemically defined medium including transforming growth factor betas (TGFβ), GDNF, BDNF, 
dbcAMP and DAPT, each with their own function in the differentiation including, cell survival, 
DA neuronal differentiation (TGFβ and GDNF (Krieglstein, Henheik et al. 1998)), promotion of 
TH
+  cell  differentiation  (BDNF  (Hyman,  Hofer  et  al.  1991)),  apoptosis  prevention  (dbcAMP 
(Hartikka, Staufenbiel et al. 1992)) and restriction of differentiation potential (DAPT (Crawford 
and Roelink 2007)).  
 
106 
 
4.2  Aim 
In  this  chapter  we  investigate  the  potential  of  two  human  pluripotent  stem  cell  lines, 
MSHU001  (hiPSC)  and  Shef6  (hESC),  to  differentiate  into  neuronal  subsets  expressing  DA 
markers.  To  do  this  we  firstly  investigated  the  population’s  ability  for  self-renewal  under 
typical culture conditions and their ability to differentiate into the three germ layers. We then 
assessed the cell population’s ability under chemically defined conditions to differentiate into 
neuronal populations that express DA molecular markers and express DA associated protein 
markers.  
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4.3  Results 
4.3.1  Normal hPSC culture and characterisation 
hPSCs were co-cultured with iMEF and passaged mechanically to maintain their pluripotency. 
Both cell types are defined by their ability to self-renew and to differentiate to form cells from 
the three germ layers. Pluripotency of both hiPSC and hESC was assessed at a molecular and 
protein  level  through  the  detection  of  pluripotent  markers  using  qPCR  and 
immunocytochemical assays. The ability of these cell types to generate the three germ layers; 
endoderm,  mesoderm  and  ectoderm  was  assessed  by  allowing  these  cultures  to 
spontaneously differentiate in-vitro and then test for the expression of germ layer markers, 
nestin, sox17 and brachyury using immunocytochemistry. 
4.3.2  hPSC colony morphology 
hPSC  were  typically  expanded  then  passaged  every  3-4days.  The  mechanically  passaged 
clumps were seeded onto fresh iMEF and the progressive colony morphology assessed over 4 
consecutive days (Figure 21). By day 3-4, cell density within the colonies was high and the 
nuclei compacting and becoming visible (Figure 21, D & E).  
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Figure 21 - Representative images of colony morphology during general culture 
Bright field images of typical hPSC colony morphology during culture. A) Initial seeding saw small fragmented cell 
clumps which (B-D) developed and expanded in diameter over time. Once colony mass reached a high level the 
edges of the colonies started to push against the surrounding iMEF resulting in compaction of the colony centre (E) 
(Scale bars A-C = 400µm, D & E = 100 µm). 
4.3.3  Confirmation of pluripotent marker expression in hPSC 
Pluripotent  marker  expression  by  hPSCs  was  assessed  using  immunofluorescent  labelling, 
screening for surface (TRA-1-60, Figure 22, B & D/E) and intracellular (Oct4, Figure 22, A & D/E) 
pluripotent markers. Early differentiation of hESC was visualised through the expression of 
SSEA1 (Figure 22, C) and was typically found expressed by cells that were removed from the 
main colony mass, this population was also observed to express reduced levels of Oct4 (Figure 
22, A).  
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Figure 22 - hPSCs maintained pluripotent surface marker expression in culture 
Representative images of immunofluorescent labelling of pluripotent markers, (A) Oct4, (B) TRA-1-60 and early 
differentiation  marker  (C)  SSEA1  in  hESC  cultures  (Scale  bar  =  100µm).  D-E)  Immunofluorescent  labelling  of 
pluripotent markers, TRA-1-60 and Oct4 for hiPSC (Scale bar = 400µm). 
4.3.4  Quantification of pluripotent marker expression in hPSC  
Conjugate surface pluripotent markers were used to quantify the proportion of hPSC that 
expressed pluripotent markers in culture. SSEA4 and TRA-1-60 can be seen to be expressed in 
≥90% of the cultures screened in hESC and hiPSC (Figure 23).  
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Figure 23 - Flow cytometry analysis of pluripotent surface markers 
Graphs representing flow cytometry data for hESC and hiPSC culture expression of pluripotent surface markers 
SSEA4 (n=3) and TRA-1-60 (n=2). Error bars represent SD±1 
4.3.5  hPSC culture pluripotent gene expression 
Three key pluripotency genes were assessed at the start of each experiment; nanog, oct4 and 
sox2. Pluripotency genes were all expressed in both hESC (Figure 24, A) and hiPSC (Figure 24, 
A) however, relative to the combined housekeeping genes, hiPSC exhibited lower expression of 
the pluripotency genes. 
 
Figure 24 - Endogenous pluripotent gene expression in hPSC 
qPCR data for pluripotency gene expression of nanog, oct4 and sox2 in hESC (A) and hiPSC (B) cell lines. Data was 
normalised against β-Actin, GAPDH and UBC. Error bars = SEM±1 (n=3) 
4.3.6  Spontaneous differentiation of hPSC can generate cells of all germ layer lineages  
Cultures were spontaneously differentiated to examine the pluripotent nature of both hESC 
and hiPSC. This was done by removing bFGF from the culture media (KOSRM) and culturing 
cells for 27 days without passage. hPSC cultures were shown to express mesoderm marker, 
Brachyury (Figure 25, A & D), ectoderm marker, Nestin (Figure  25, B & E) and endoderm  
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marker, Sox17 (Figure 25, C & F), demonstrating the ability of hESC and hiPSC to form cells 
from all three germ layers.  
 
Figure 25 - Immunocytochemistry staining of spontaneously differentiated hPSCs 
Representative images of immunofluorescent labelling of hPSC cultures for mesoderm, ectoderm and endoderm 
markers; Brachyury, Nestin and Sox17 in hESC (A-C) and hiPSC (D-F) (Scale bar = 400µm).  
4.3.7  Neuronal differentiation of hPSC through co-culture with PA6 stromal cells 
hPSC’s ability to differentiate towards (TH
+) DA neuron specification was examined through co-
culture with mouse PA6 stromal cells. After 4 weeks in co-culture, colonies were screened for 
evidence of DA neuron differentiation (i.e. the co-localisation of β-III-Tubulin and TH) (Figure 
26, A & D). In addition, the general neural marker Nestin was assessed in hESC (Figure 26, B-C).  
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The  cell  colonies  expressed  all  these  specialised  markers  confirming  their  ability  to 
differentiate along the neuronal lineage towards specialised TH
+ cell types. 
 
Figure 26 - Immunocytochemistry staining of PA6 co-cultured hPSC  
A) Representative immunocytochemistry images of β-III-Tubulin and TH co-staining and B-C) neuronal marker 
Nestin in hESC cultures. Immunocytochemistry images for and neuronal markers D) β-III-Tubulin, TH staining in 
hiPSC (Scale bars = 400µm). 
4.4  Differentiation of hPSC-derived dopaminergic neurons from hPSCs 
Following the characterisation work we investigated the potential of hPSCs to generate DA 
neurons. hPSCs were cultured according to the protocol described in Chapter 2, section 2.3. 
Briefly, cells were expanded normally, co-cultured with iMEF to achieve sufficient pluripotent 
cell numbers. Cultures were then dissected and cultured in suspension (feeder-free) whilst 
being exposed to a number of different culture conditions as shown in Figure 2. Cell samples 
were harvested for each major stage in the protocol; D5, D9, D13, D23 and D30, allowing the 
influence of each stage of the protocol to be assessed. The method also allowed the analysis of 
extended culture past D24 (the typical termination point) which will be discussed later in this 
chapter. 
4.4.1  Aggregate morphology during hPSC dopaminergic differentiation 
Aggregate morphology of the cultures was assessed over the 24 days prior to stick down 
(Figure 27). We found that neurospheres from both hESC and hiPSC formed aggregates which  
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increased in diameter over time (Figure 27). Although the McIlwain tissue chopper was used to 
provide uniform aggregate formation variation was observed at D4 onwards (Figure 27). 
 
Figure 27 - hPSC suspension culture dopaminergic differentiation 
Representative  images  showing  the  growth  of  hPSC  derived  neurospheres  during  the  aggregate-based 
dopaminergic differentiation process (24 days) (Scale bars = (Day 4 & 24) 1000µm, (Day 10 & 19) 400 µm and (Day 
6) 200µm). 
4.4.2  Differentiation  of  hPSC-derived  aggregates  towards  dopaminergic  neurons: 
pluripotent gene expression 
To assess the impact of the protocol on the pluripotency of hPSC, the relative expression of 
pluripotent genes nanog, oct4 and sox2 were measured. By D5 both nanog and oct4 were 
observed to significantly drop in expression in both hESC (Figure 28, A & B) and hiPSC (Figure 
28, D & E), except in the case of hiPSC, where  oct4 expression only significantly dropped 
following neural induction (D9) (Figure 28, E, p≤0.01). Sox2 expression significantly increased in 
hESCs during neural induction (Figure 28, C) and was maintained until D23, where expression 
dropped. Sox2 expression in hiPSC culture was observed to significantly decrease during EB 
expansion (Figure 28, F) and was never found to significantly exceed that of D0 levels.  
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Figure  28  -  qPCR  analysis  of  pluripotent  gene  expression  during  aggregate-base  dopaminergic 
differentiation of hPSC  
qPCR analysis of pluripotent mRNA expression over the course of aggregate-base dopaminergic differentiation. 
hESC and hiPSC derived neurosphere expression of  nanog (A/D), oct4 (B/E) and sox2 (C/F) are shown relative to D0 
expression. Data was normalised using GAPDH expression (* p< 0.05, ** p<0.01, ***p<0.001 and **** p<0.0001. 
Bars = Mean ± SEM. n=3). 
4.4.3  Differentiation of hPSC-derived aggregates towards dopaminergic neurons: epiblast 
fgf5 gene expression 
Analysis of fgf5 expression over time showed expression in hESC cultures did not significantly 
change during the differentiation programme (Figure 29, A); however, hiPSC expression was 
found  to  drop  during  EB  expansion  (Figure  29,  B)  and  thereafter  significantly  increase 
throughout the protocol. (Figure 29, B).  
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Figure 29 - qPCR analysis of fgf5 gene expression during aggregate-base dopaminergic differentiation 
of hPSC 
qPCR analysis of fgf5 mRNA expression over the course of aggregate-base dopaminergic differentiation. hESC and 
hiPSC derived neurosphere expressions of  fgf5 (A/B respectively) are shown relative to D0 expression. Data was 
normalised using GAPDH expression (* p< 0.05, ** p<0.01, ***p<0.001 and **** p<0.0001. Bars = Mean ± SEM. 
n=3). 
4.4.4  Differentiation  of  hPSC-derived  aggregates  towards  dopaminergic  neurons:  germ 
layer gene expression 
Analysis of germ layer genes indicated that  brachyury (mesoderm) was down-regulated in 
hESC, yet underwent transient up-regulation in hiPSC ( 
Figure 30, A&D) during the protocol. Sox17 (endoderm) was constantly down-regulated for 
both cell types ( 
Figure 30, B&E) whereas sox1 (ectoderm) was up-regulated significantly over time ( 
Figure 30, C&F). 
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Figure  30  -  qPCR  analysis  of  germ  layer  gene  expression  during  aggregate-base  dopaminergic 
differentiation of hPSC 
qPCR analysis of germ layer mRNA expression over the course of aggregate-base dopaminergic differentiation. hESC 
and hiPSC derived neurosphere expression of brachyury (A/D), sox17 (B/E) and sox1 (C/F) are shown relative to D0 
expression. Data was normalised using GAPDH expression (* p< 0.05, ** p<0.01, ***p<0.001 and **** p<0.0001. 
Bars = Mean ± SEM. n=3). 
4.4.5  Differentiation of hPSC-derived aggregates towards dopaminergic neurons: neuronal 
gene expression 
Analysis of neuronal genes revealed an up-regulation in all genes screened in hESC cultures 
(Figure  31,  A-C).  However  nurr1  expression  (not  statistically  significant)  was  observed  to 
fluctuate throughout culture; increasing throughout neuronal induction (D9), decreasing with 
addition of DA factors (D13) then increasing on neurosphere expansion (D23) (Figure 31, A). 
Otx2 levels significantly increased during neural induction (D9), after which time, continued to 
decrease in expression (Figure 31, B). En1 levels remained increased relative to D0 throughout 
the whole culture period (Figure 31, C) but fluctuated in alignment with nurr1. In hiPSCs, nurr1 
and otx2 decreased during the culture period (Figure 31, D&E), whereas, expression of en1 
increased during EB expansion and remained increased for the duration of the culture (Figure  
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31, D). Due to the number of biological repeats no statistical significance could be ascertained 
for nurr1 and en1 qPCR results. 
 
Figure  31  -  qPCR  analysis  of  neuronal  gene  expression  during  aggregate-base  dopaminergic 
differentiation of hPSC  
qPCR analysis of neuronal mRNA expression over the course of aggregate-base dopaminergic differentiation. hESC 
and hiPSC derived neurosphere expression of  nurr1 (A/D, n=1), otx2 (B/E, n=3) and en1 (C/F n=2) are shown 
relative to D0 expression. Data was normalised using GAPDH expression (* p< 0.05, ** p<0.01, ***p<0.001 and **** 
p<0.0001. Bars = Mean ± SEM). 
4.4.6  Differentiation  of  hPSC-derived  aggregates  towards  dopaminergic  neurons: 
dopaminergic neuron gene expression 
Analysis of DA neuron genes showed that all genes generally increased in hESC cultures over 
time (Figure 32, A-D). Lmx1a expression declined following D13 (Figure 32, B) and TH and DRD 
had the greatest expression at later time points (Figure 32, C&D). Foxa2 was the most delayed 
DA gene assessed with expression increasing only following neurosphere expansion (Figure 32, 
A, D23).  
hiPSC generally mirrored this pattern, particularly with expression for both TH and DRD (Figure 
32, G&H).  Foxa2 expression was found to decease during culture and was never up-regulated 
relative to D0 (Figure 32, E).  
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Figure  32  -  qPCR  analysis  of  dopaminergic  gene  expression  during  aggregate-base  dopaminergic 
differentiation of hPSC  
qPCR analysis of dopaminergic mRNA expression over the course of aggregate-base dopaminergic differentiation. 
hESC and hiPSC derived neurosphere expression of  foxa2 (A/E), lmx1a (B/F), TH (C/G) and DRD (D/H, n=2) are 
shown relative to D0 expression. Data was normalised using GAPDH expression (* p< 0.05, ** p<0.01, ***p<0.001 
and **** p<0.0001. Bars = Mean ± SEM. n=3). 
4.4.7  Morphology assessment of adhering neurospheres upon ‘stick down’ 
To assess the morphology of neurospheres during the ‘stick down’ maturation protocol, bright 
field images were taken over 14 days. Neurospheres from both hESC and hiPSC cultures were 
observed to adhere to the laminin surface substrate and by D7 projections extend away from 
the main body of the neurosphere resulting in extensive projections by D14, as shown in Figure 
33.  
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Figure 33 - Stages of 14 day stick down protocol 
Representative bright field images of hPSC derived neurospheres during the ‘stick down’ process (14 days), whilst 
being patterned through the addition of dopaminergic differentiation media (Scale bars = (x4) 1000µm and (x20) 
200µm). 
4.4.8  Confocal imaging of 14 day differentiated neurospheres following ‘stick down’ 
Cultured neurospheres were plated onto laminin coated coverslips on D24 of neurosphere 
expansion  and  cultured  in  DDM  for  14  days.  Colonies  were  then  fixed  using  4%  PFA  and 
immunofluorescent labelling performed to assess neuronal differentiation and the efficiency in 
producing DA neurons (TH
+/foxa2
+). 
First  differentiation  of  hPSC  towards  a  neuronal  lineage  was  confirmed  using  Nestin 
immunofluorescent labelling. Both hESC and hiPSC were confirmed as Nestin
+ (Figure 34). Cell 
projections  were  seen  projecting  from  the  main  neurosphere  body,  connecting  different 
bodies of cells.  
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Figure 34 - Confocal images of Nestin stained differentiated neurospheres 
Representative confocal images of neural marker, Nestin, in 14 day differentiated neurospheres for (A) hESC (Scale 
bar = 100µm) and (B) hiPSC (Scale bar = 50µm). 
To  ascertain  whether  DA  neurons  had  been  produced  during  the  protocol,  adhered 
neurosphere cultures were assessed for TH (green) and Foxa2 (red) markers. hESC cultures 
could be shown to contain TH
+ cells and Foxa2
+ cells. TH was found in the cytoplasm of the 
cells whilst Foxa2 was co-localised with dapi to the nuclei (Figure 35, A-E). The majority of cells 
were found to be TH
-/Foxa2
- but pockets of cells were Foxa2
+ (Figure 35, D). Association of 
Foxa2 and TH within a single cell was very limited. hiPSCs appeared to have a slightly higher 
level of co-labelled cells (Figure 35, H) though more commonly cells were defined as either TH
+ 
or Foxa2
+ (Figure 35, F & G).  
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Figure 35 - Confocal images of TH and foxa2 stained differentiated neurospheres 
Representative  confocal  images  of  hESC  (A-E)  and  hiPSC  (F-H)  adhered  neurosphere  cultures.  Differentiated 
neurospheres were staining for Foxa2 (red), TH (green) and dapi (blue). Scale bars = 50nm (A-B & F-G), 100nm (C-D) 
and 10nm (E & H).  
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4.5  Dopamine release from hPSC-derived differentiated neurospheres 
To  verify  whether  the  differentiated  hPSC-derived  neurospheres  were  functional  and 
contained cells that were able to synthesise dopamine, two neurospheres were plated onto 
laminin coated coverslips at D24 and differentiated for 4 weeks in DDM. Neurospheres were 
then stimulated using potassium chloride (KCl) and the media collected and stored at -80
oC 
until processing.  
ELISA  analysis  revealed  that  basal  level  dopamine  was  ~7.8ng/mL  in  hESC,  increasing  to 
~18.6ng/mL on stimulation with KCl (Figure 36, A). Basal dopamine levels from hiPSC were 
shown to be ~5.8ng/mL, increasing to ~12.9ng/mL on stimulation (Figure 36, B). 
 
Figure 36 - Dopamine release from 4-week matured neurospheres 
Dopamine release from two hPSC-derived 4-week matured neurospheres, showing dopamine release from both un-
stimulated (control) or stimulated with the addition of 56mM KCl. Detection was performed using ELISA for hESC (A) 
and hiPSC (B). C) A standard curve was generated from using standards provided in the ELISA kit, R
2 = 0.9969.   
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4.5.1  Effect of extended neurosphere culture on resulting dopaminergic gene expression 
Neurospheres were cultured for an extended period before ‘stick down’ to assess its effect on 
DA gene expression. Gene expression was assessed at D0 and D14 of adherent culture relative 
to experimental D0 levels. Expression of foxa2 by hESC was observed to drop to negative levels 
when seeded at times after D24 (Figure 37, A). The ability to express foxa2 gradually decreased 
following  extended  periods  of  culture  and  by  D55  no  recovery  of  foxa2  expression  was 
observed following culture in DDM. hESC expression of lmx1a and TH was observed to increase 
in expression following stick down at all seeding time points (Figure 37, B&C). Both genes were 
seen to consistently increase to D14 following culture in DDM except at D55 where  lmx1a 
showed reduced expression. 
Expression  of  foxa2  in  hiPSC  was  shown  to  be  lower  than  the  experimental  control  (D0 
pluripotent cells) for all stick down time points except D55 which showed enhanced expression 
(Figure 37, D). Lmx1a and TH expression as with hESC were shown to increase following stick 
down, though hiPSC expression of lmx1a did not consistently increase following 14 days in 
DDM (Figure 37, E). TH was shown to mirror the pattern on hESC with enhance expression 
following 14 days in culture (Figure 37, F).   
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Figure 37 - qPCR analysis of dopaminergic gene expression following ‘stick down’ at different time 
points 
qPCR analysis of dopaminergic mRNA expression following extended suspension culture (24days, 30days, 41days 
and 55days) then followed by 14 days of stick down and culture in DDM. hESC and hiPSC derived neurosphere 
expression of  foxa2 (A/D), lmx1a (B/E), and  TH (C/F) are shown relative to control (experimental D0) expression. 
Data was normalised using GAPDH expression (n=1). 
4.5.2  The effect of extended ‘stick down’ culture on dopaminergic gene expression 
To assess the effect of extended culture in DDM on DA gene expression, neurospheres were 
adhered for a prolonged period of time (up to 28 days). In hESC, the expression of all the genes 
increased relative to the control up to D14, but then tailed off to D28 (Figure 38, A). Expression 
of target genes in hiPSC followed a similar path to hESC, with all genes showing increased 
expression relative to control, but reducing following stick down (D0). Again, an exception was 
with expression of TH which increased consistently to D28 whilst in culture with DDM (Figure 
38, B).  
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Figure 38 - qPCR analysis of dopaminergic gene expression during extended stick down 
qPCR analysis of dopaminergic mRNA expression during extended stick down culture (up to 28 days) in DDM. hESC 
(A)  and  hiPSC  (B)  derived  neurosphere  expression  of    foxa2,  lmx1a,  and    TH  are  shown  relative  control 
(experimental D0) expression. Data was normalised using GAPDH expression. 
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4.6  Discussion 
4.6.1  Pluripotent hPSC culture and expansion 
It is essential in the development of new and innovative cell therapies based on the use of 
stem cells that we are able to confirm the identity of the pluripotent base population. This 
work showed that we are able to co-culture hPSCs with iMEFs to maintain an Oct4
+/TRA-1-60
+ 
cell population in both hESC and hiPSC (Figure 22). We were also able to confirm that as cells 
migrated  out  of  the  colony  they  became  SSEA1
+  and  showed  reduced  levels  of  Oct4 
expression, indicating a loss of pluripotency. To quantify these findings, TRA-1-60 and SSEA4, 
both surface markers, were used for live cell flow cytometry. Results confirmed that cultures 
were maintained so that the majority of cells (≥90%) were positive for the pluripotent markers 
investigated (Figure 23). 
Finally, pluripotency was confirmed at the molecular level. Gene expression analysis showed 
that both hESC and hiPSC cultures were positive for pluripotent markers; nanog (Chambers, 
Colby et al. 2003, Mitsui, Tokuzawa et al. 2003), oct4 and sox2 (Masui, Nakatake et al. 2007) 
(Figure  24),  all  considered  to  be  essential  for  pluripotent maintenance  and used  regularly 
within research literature to confirm population pluripotency. 
Although  it  is  widely  considered  that  pluripotency  can  only  be  confirmed  using  in-vivo 
teratoma assays to determine products of all three germ layers (Wesselschmidt 2011), in this 
study  we  assessed  the  ability  to  produce  cell  types  of  all  three  germ  layer;  ectoderm, 
mesoderm and endoderm lineages following spontaneous differentiation for 27 days (Figure 
25) and showed that both hESC and hiPSC were able to form Nestin
+ neural rosettes indicative 
of ectoderm. Rosettes were shown to be present in high density 3D structures within the 
colonies  under  staining.  Brachyury  was  also  abundantly  present  indicating  mesoderm  was 
present at the edges of the colonies in a monolayer tiled formation. Staining was found to be 
located to the nuclei, characteristic of Brachyury staining. Sox17 was also present at high levels 
in  the  cultures  and  like  brachyury,  localised  to  the  edges  of  colonies  as  very  distinctive  
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spherical cells. This work confirmed that the hPSCs being utilised were pluripotent and able to 
form all three germ layers (Figure 25). 
Directed differentiation of hPSC was also performed by co-culturing hPSC with iPA6 mouse 
stromal cells. iPA6 cells were used instead of iMEF because they have been shown to generate 
TH
+ cells from hESC (Zeng, Cai et al. 2004). We used this method to confirm that the hPSC used 
within this investigation were capable of differentiating to a neuronal lineage and further 
towards a TH
+ cell specification. Results confirmed that hPSCs were capable of differentiating 
toward a neuronal cell type (Nestin
+) and acquired a β-III-Tubulin
+ and TH
+ phenotype (Figure 
26). These results indicate that hPSC had differentiated into TH
+ neurons and they imply that 
the cells are capable of differentiating towards specialised DA neurons.  
4.6.2  Differentiation of dopaminergic neurons from hPSC 
The  investigation  attempted  to  differentiate  hPSC  towards  a  DA  phenotype  using  an 
aggregate-based protocol adjusted with growth factors and media modification to mimic the 
endogenous signalling that DA neurons are exposed to during development. This method was 
chosen due to the potential for scale-up, by incorporating bioreactors within the process. We 
showed that it was possible to form cell aggregates following colony segmentation using the 
McIlwain  tissue  copper  and  culture  these  aggregates  in  suspension  over  a  24  day  period 
(Figure 27). Aggregates were shown to increase in diameter over time, reaching up to 1mm by 
D24.  In  spite  of  the  even  spacing  (150µm)  of  the  cutting  blade  incisions,  the  resulting 
aggregate  diameters  were  heterogeneous,  illustrating  a  key  process  variable  that  would 
benefit from better control. If this protocol was to be used for longer than the 24 days of this 
investigation, aggregates should be passaged using the McIlwain tissue chopper to reduce the 
size within the population, though this is an open process and risks infection. The size of the 
aggregate is important as it has a significant impact on oxygen transfer and growth factor 
diffusion to the centre of the aggregate (Van Winkle, Gates et al. 2012). The effect of the size 
of aggregates on culture differentiation efficiency was not investigated within this body of  
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work but will be discussed in the final discussion of the thesis for its potential within future 
work. 
4.6.3  qPCR analysis of target genes during dopaminergic differentiation 
Molecular  analysis  of  harvested  cultures  showed  that  pluripotency  genes  nanog  and  oct4 
significantly  decreased  in  hESC  and  hiPSC  cultures  following  EB  formation  and  expansion 
(Figure 28). This signified that the cultures were moving away from a pluripotent state and 
differentiating.  Sox2,  also  a  marker  of  pluripotency  because  of  its  role  in  regulating  oct4 
(Masui, Nakatake et al. 2007), rather than decreasing, significantly increased in hESC following 
neural induction (Figure 28). This may be due to the role of sox2 in maintaining the neural 
progenitor  state  (with  its  further  loss  associated  with  neuronal  differentiation)  (Graham, 
Khudyakov et al. 2003), however, hiPSC results did not mirror this pattern. In hiPSC,  sox2 
expression dropped significantly during EB expansion and then gradually increased, although 
never significantly exceeding levels of D0 pluripotent cells. This increase in sox2 expression 
might reflect neural progenitors in culture. 
The assessment of fgf5 expression also supported the theory that neuronal precursors were 
present within the experimental populations. Fgf5 is associated with early stages of lineage 
commitment (Lowell, Benchoua et al. 2006) and is also reported to be a neural precursor 
marker, found in primitive ectoderm (Hitoshi, Seaberg et al. 2004).  Similar results were seen 
for  both  hESC  and  hiPSC  with  initial  fgf5  expression  being  reduced  but  then  increasing 
significantly compared to D0 levels over the culture period (Figure 29). For both hPSC types, 
the initial drop may indicate lineage commitment of pluripotent cells and the following up-
regulation  suggest  neural  precursors  in  the  population.  The  increase  in  sox1  expression 
following EB expansion (Figure 30) further corroborates the generation of neural precursors, as 
sox1, like sox2 and fgf5 is an early neuronal marker (Brafman 2014). 
Following EB expansion, expression of brachyury and sox17 fell in the hESC cultures confirming 
that  the  protocol  directs  ectoderm  specification  and  inhibits  mesoderm  and  endoderm.  
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However in hiPSC,  brachyury expression increased following EB expansion, suggesting that 
contaminating  mesoderm  cells  were  present  in  culture.  Expression  of  sox17  in  hiPSCs 
decreased following EB expansion suggesting that endoderm lineage cells were not present in 
culture (Figure 30). 
The expression of nurr1, otx2 and en1, key neuronal patterning genes important to DA neuron 
specification were also investigated. Nurr1 plays a key role in the maintenance of the DA 
phenotype  (Sacchetti,  Carpentier  et  al.  2006);  otx2  is  considered  the  ‘master’  anterior-
posterior  patterning  module  gene  (Omodei,  Acampora  et  al.  2008)  confirming  that  the 
protocol mimics conditions found at the midbrain-hindbrain boundary; and en1 is associated 
with proliferation and survival of the ventral midbrain neurons and is also midbrain marker 
(Gale and Li 2008).  
Results from hESC analysis indicated that expressions of all three genes were increased over 
time.  Nurr1  appeared  to  be  transiently  expressed  with  expression  peaking  during  neural 
induction (D9) and neurosphere expansion (D23) (Figure 31). Otx2 expression increased then 
dropped  away  to  D24  (Figure  31)  suggesting  that  the  cells  produced  were  not  of  the 
appropriate  phenotype.  Initial  enhancement  in  expression  does  suggest  the  protocol  was 
directing them correctly but following neural induction the marker was lost; inclusion of DA 
factors appeared to change the course of expression. Expression of en1 was shown to increase 
significantly  throughout  the  duration  of  the  experiment  for  both  cell  types  (Figure  31) 
suggesting a midbrain phenotype was achieved. It is difficult to draw a solid conclusion from 
this data, though it is appears that this protocol is driving the cells down a midbrain lineage, 
results suggest that it is not generating the desired A9 DA neurons. Further optimisation of the 
patterning procedure is required.  
A number of key identifiers have been recognised for the characterisation of therapeutically 
valuable DA neurons and have been assessed within this work, these include: foxa2 lmx1a and 
TH. Foxa2 has been found to be important in the differentiation of DA neurons and associated  
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with  a  loss  of  proliferative  neuronal  precursors  (Lee,  Bae  et  al.  2010),  it  also  works 
synergistically with nurr1 in the development of the DA phenotype. Lmx1a is an early regulator 
of  midbrain  dopamine  neural  progenitor  phenotype  specification  and  has  been  shown  in 
mouse  embryonic  development  to  regulate  maturation  of  DA  neurons  (Chung,  Kim  et  al. 
2012). Finally, TH is a key rate limiting enzyme in the synthesis of dopamine and so an essential 
marker  for  any  viable  DA  neuron.  Also  assessed  was  dopamine  receptor  D1  (DRD)  gene 
expression; the most abundant dopamine receptor in the central nervous system and found to 
regulated neuronal growth and development (O'Keeffe, Barker et al. 2009).  
Results from hESC analysis showed that DA genes (foxa2 lmx1a and TH) were significantly up-
regulated by D23 of the protocol (Figure 32). Lmx1a was observed to significantly rise during 
EB expansion and peak during neural induction. DRD was observed to increase significantly 
during neural induction, with inclusion of DA factors enhancing this further to D23. This may 
corroborate lmx1a’s involvement in early regulation of DA development and the expression of 
DRD  following  neural  induction.  The  increase  in  DRD  was  mirrored  by  that  of  TH,  which 
increased  significantly  following  neural  induction  and  was  maintained  throughout  the 
experiment. Foxa2 was transiently expressed, initially dropping during neural induction only to 
significantly increase to D23. This is in line with our collaborators findings (unpublished), that 
foxa2 expression requires longer culture to be induced. hiPSC’s expression of lmx1a appeared 
more stable than in hESC cultures, expression was observed to increase significantly during EB 
expansion, rising to D9 levels and remaining at significantly high levels for the remainder of the 
protocol. TH mirrored this, increasing following neural induction and remaining stable until the 
end of the protocol. DRD levels were significantly up-regulated following DA factor additions 
although this was delayed compared to hESCs. Contrary to these other positive results foxa2 
levels  decreased  throughout  the  protocol,  this  indicated  that  although  a  number  of 
appropriate makers were switched on during directed differentiation of hiPSC, the protocol 
requires significant optimisation to correctly specify DA neurons from MSUH001 cells. Timing 
of delivery of certain factors may need to be altered for this particular cell line.   
 
131 
 
Confocal  imaging  confirmed  Nestin
+  cells  were  generated  (Figure  34)  indicating  that 
neurospheres were correctly directed towards a neuronal lineage. Neurospheres were also 
assessed for TH and Foxa2 expression and although both markers were shown to be expressed 
by different individual cells, co-expression was rare. It was interesting to see the level of co-
localisation in hiPSC as qPCR data had suggested a lack of gene expression for foxa2. Even 
though gene expression is important for protein synthesis, ultimately it is protein expression 
and localisation that enables function. 
Extending culture of the neurospheres past D24 resulted in a varying ability of neurospheres to 
adhere and produce transcripts for foxa2/lmx1a/TH (Figure 37). All stick down days up to D41 
resulted in high expression of foxa2/lmx1a/TH relative to D0. Both lmx1a and TH expression 
increased following stick down (Figure 37) suggesting prolonged culture of hESC is possible. 
Due to time constraints the experiment was only performed once and so solid conclusions 
cannot be drawn. This would be an interesting extension to this work if long-term culture 
within bioreactors were to become an option.  
4.6.4  Gene expression and dopamine release from differentiated neurospheres 
Gene expression analysis of the extended stick down neurospheres for the purpose of ELISA 
showed that hESC and hiPSC expression of key genes, lmx1a, foxa2 and DRD all decreased to 
D28 of extended culture. This suggests that this time point may be too late for ELISA analysis as 
neuronal function may have been compromised.  
Though gene expression analysis suggested a reduction in DA markers, ELISA analysis at D28 
revealed that cells in both hESC and hiPSC cultures responded to stimulation and released 
dopamine. Resulting in background levels of 7.8ng/mL and 5.8ng/mL respectively, increasing 
to  18.6ng/mL  and  12.9ng/mL  (Figure  36)  after  stimulation.  This  result  combined  with  the 
molecular  and  protein  analysis  suggests  that  dopamine  releasing  neurons  were  generated 
under this protocol. 
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4.7  Conclusion 
The work in this chapter shows it is possible to direct neuronal specification in hPSC types 
using a feeder layer and subsequent aggregate-based differentiation procedure. This might 
enable scalable production using 3D bioreactor based method in the future. 
The  experiments  also  show  that  it  is  possible  to  produce  neuronal  phenotypes  with 
characteristics of DA neurons. Although we did not conclusively produce a valid DA neuronal 
product that could be tested in-vivo, we did show we were able to generate cell types that 
express the genes of interest, enabling the incorporation of saRNA. 
Systematic  optimisation  of  the  long,  complex  culture  method  and  assessment  of  other 
pluripotent cell lines would inevitably improve the production of DA neurons and future work 
could follow these avenues.  
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CHAPTER 5 - OPTIMISATION OF SMALL ACTIVATING RNA USING CANCER 
CELL LINES AND OMNCIYTES 
5.1  Introduction 
Though our ability to generate specific cells types including DA neurons in-vitro has become a 
widely used research methodology, the ability to generate large and consistent yields of target 
cell types remains elusive, hindering the movement of this technology toward a therapeutically 
beneficial product. Groups have reported variable efficiencies of generating TH
+/Tuj
+ cells (TH
+ 
neuronal cells) of between 3 - 30% from hPSC, using media conditioning and smad inhibition 
(Yan, Yang et al. 2005, Stanslowsky, Haase et al. 2014). To address the issue of yield and 
consistency, researchers are investigating a number of methods, including bioreactor culture 
(Van Winkle, Gates et al. 2012) and genetic modification (Park, Lim et al. 2012). Within this 
chapter we will investigate the potential of saRNA for enhancing target gene expression and 
identify the optimal saRNA candidate for use in collaboration with the aggregate-based DA 
differentiation protocol investigated in Chapter 4. 
Since the publication of the human genome (Lander, Linton et al. 2001) and the development 
of RNA interference (RNAi)(Agrawal, Dasaradhi et al. 2003), our ability to  understand and 
manipulate gene and protein expression has greatly increased. It was previously thought that 
there were few mechanisms of gene regulation, for example chromatin remodelling and DNA 
methylation (Geiman and Robertson 2002). However it is now recognised that a new powerful 
class of regulators in the form of small RNA elements exists.  What were once thought to be 
non-coding  ‘junk’  RNA  sequences  have  now  been  demonstrated  to  play  key  roles  in  the 
regulation of gene expression through the repression of transcription or translation.  
Recently there has been the discovery of a new regulatory element, saRNA. saRNA are able to 
modify gene expression at the transcription stage, targeting activation sites and amplifying the 
expression  of  specific  genes.  These  molecules  allow  the  directed  up-regulation  of  specific  
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target  genes  within  cell  populations  without  the  use  of  plasmids  and  viral  transfection 
(Reebye, Saetrom et al. 2013, Reebye, Saetrom et al. 2013). This approach is preferable to the 
DNA- and viral-based approaches as synthetic mRNA modifications are thought not to impact 
on the genetic integrity of the cell genome (Steichen, Luce et al. 2014). 
saRNAs were identified and developed as part of this investigation to specifically target genes 
with an  expression associated with DA neuronal specification. Within this work we focused on 
three  genes;  forkhead  box  protein  A2 (foxa2),  Homeoprotein  LIM  homeobox  transcription 
factor  1α  (lmx1a)  and  tyrosine  hydroxylase  (TH)  (Caiazzo,  Dell'anno  et  al.  2011,  Pfisterer, 
Kirkeby et al. 2011). 
Lmx1a  has  been  shown  to  promote  neuronal  midbrain  DA  neuron  differentiation  by 
repressing other neuronal differentiation pathways (Cai, Donaldson et al. 2009), for example 
down-regulating the floor plate marker Nkx6  which is involved in ventral neural patterning 
(Sander,  Paydar  et  al.  2000,  Cai,  Donaldson  et  al.  2009,  Kriks,  Shim  et  al.  2011). 
Forkhead/winged helix transcription factor, foxa2, has been shown to be influential in the 
specification  of  DA  neurons  (Ferri,  Lin  et  al.  2007,  Lin,  Metzakopian  et  al.  2009)  and  the 
determination of mesencephalon floor plate cell fate in cooperation of lmx1a/b (Akashi, Traver 
et al. 2000). Lastly, TH is essential in the normal functioning of the nervous system and is a rate 
limiting component of the pathway that produces an important group of hormones called 
catecholamines  (Figure  39)  and  is  involved  in  the  synthesis  of  dopamine,  essential  in  a 
functional DA neuron.  
 
Figure 39 - Dopamine synthesis pathway 
L-Tyrosine  is  converted  into  L-Dihydroxyphenlalanine  by  an  enzymatic  reaction  involving  Tyrosine  Hydroxylase. 
DOPA  decarboxylase  Aromatic  L-amino  acid  decarboxylase  then  converts  L-Dihydroxyphenlalanine  into  the 
functional neurotransmitter dopamine which is the essential for the normal functioning of the nervous system.  
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5.2  Aim 
This chapter investigates the use of saRNAs and their efficiency in up-regulating three target 
genes; foxa2, lmx1a and TH. The initial assessment was done through the use of epigenetically 
positive cell lines to illuminate the best variant saRNA. It then investigates the potential to 
transfer these findings into omnicytes, a cell type considered to have great potential within the 
cell therapy environment.  
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5.4  Results 
5.4.1  Cell line culture and lipid-based transfection reagents optimisation 
The ability of candidate saRNA to modify target gene expression were first assessed using cell 
lines SH-SY5Y (Figure 40), HepG2 (Figure 42) and Jurkat (Figure 44). Due to their anticipated 
endogenous expression of the target genes TH, foxa2 and lmx1a respectively, it was thought 
that the cells would be amenable to gene manipulation and not be hindered by any epigenetic 
fingerprint.  
To  allow  analysis  of  the  impact  of  the  saRNAs,  PCR  primers  (forward  and  reverse)  were 
designed in-house or taken from peer reviewed papers and optimal PCR cycling conditions 
established by cycle optimisation of the annealing temperature (Ta). TH and foxa2 PCR cycling 
conditions were optimised against SH-SY5Y (Figure 40, C/D) and HepG2 synthesised cDNA from 
total extracted RNA (Figure 42, C/D). Lmx1a primers were optimised against foetal temporal 
lobe (Figure 44, B/D). 
To optimise the impact of the saRNA transfections, SH-SY5Y seeding density and growth rate 
were initially assessed. WST-1 analysis revealed that 2.5x10
4 cells/well (microplate) resulted in 
optimal  growth  over  72hrs  and  provided  the  maximum  number  of  cells  for  lipid-
oligonucleotide endocytosis. Higher seeding at 5x10
4cells/well resulted in growth inhibition by 
50hrs and viable cell reduction to 72hrs (Figure 40, B). Visual analysis showed that 2.5x10
4 
resulted  in  good  surface  coverage  and  allowed  continuous  proliferation  over  the  culture 
period. 
  
 
137 
 
 
Figure 40 - SH-SY5Y seeding density and TH PCR optimisation 
A)  Representative  images  showing  SH-SY5Y  at  varying  seeding  densities  at  24hrs  (x4  magnification).  B)  WST-1 
analysis of SH-SY5Y at different seeding densities over a 72hr culture period (n=2). C) Optimisation of Tyrosine 
hydroxylase PCR primers against SH-SY5Y total RNA, with primer dimers observed in the -ve control (D) Table 
showing primer sequences for TH PCR primers and optimal thermo cycling conditions 
It was thought that the individual cell types may exhibit different behaviours in each lipid 
transfection reagents and for this reason we investigated the use of three reagents for each 
cell line. To allow us to visualise and assess the efficiency of each transfection reagent we used 
a green fluorescent protein (GFP) labelled plasmid provided by Omnicyte Ltd., pSG5-GFP. The 
non-fluorescent, GFP -ve plasmid, øpSG5, was used as the negative control. Efficiency of the 
transfection of SH-SY5Y was assessed using flow cytometry, the difference between pSG5-GFP 
(+ve) and øPSG5 (-ve) represented transfection efficiency (Figure 41, A). Data indicated that 
ICAfectin  was  the  most  efficient  at  transfecting  the  pSG5-GFP  plasmid  into  SH-SY5Y  cells 
(Figure  41,  B)  with  28.0%  (σ  ﾱ0.23)  of  cells  showing  positively  for  GFP.  Confocal  analysis 
showed that the neuroblastoma cell line was capable of producing GFP (Figure 41, C).   
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Figure 41 - SH-SY5Y transfection reagent optimisation  
A)  Flow cytometry results for SH-SY5Y transfection reagent optimisation, cells were either transfected with a GFP 
containing plasmid, GFP-pSG5 or the negative, pSG5. B) Compilation of transfection optimisation results (n=3). C) 
Representative confocal microscopy images of ICAfectin transfected SH-SY5Y cells with the plasmid, pSG5-GFP. 
Images show DAPI nuclear staining, pSG5-GFP expression and merged images. Images were taken at both at x20 
and x60 magnification (Scale bar = 10µm).  
HepG2  density  and  proliferation  were  assessed  to  find  the  maximum  cell  seeding  density 
whilst  allowing  viable  cell  proliferation  over  the  72hrs  of  culture  and  maximising  lipid-
oligonucleotide endocytosis. WST-1 analysis revealed that 2.5x10
4 cells per well resulted in 
optimal growth over 72hrs. A seeding density of 2.5x10
4 resulted in a similar end absorbance 
result to that of the higher seeding density and made setting up of experiments more efficient 
when done alongside the SH-SY5Y cell line (Figure 40, B). Visual analysis showed that 2.5x10
4 
resulted in good culture surface coverage and allowed continuous proliferation during culture. 
PCR  primers were confirmed  against  HepG2 with the  cycling  conditions  optimised  for  the 
primer set (Figure 42, C/D).  
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Figure 42 - HepG2 seeding density and foxa2 PCR optimisation 
A) Representative bright field images showing HepG2 at varying seeding densities at 24hrs (x4 magnifications). B) 
WST-1 analysis of HepG2 at different seeding densities over a 72hr culture period (n=3). C) Foxa2 PCR primers were 
optimised against HepG2 total RNA and the cycling conditions shown in D. 
HepG2 cell line transfection efficiency under this protocol was less than 1.9% (Figure 43, A/B) 
for each reagent. Confocal imaging however, showed that GFP was being generated by the 
cells in isolated pockets (Figure 43, C) throughout the cytoplasm and surrounding the cells, 
suggesting that the HepG2 cells generated and secreted the GFP protein. The presence of GFP 
indicates that transfection had been successful but it was not possible to quantify.   
 
140 
 
 
Figure 43 - HepG2 transfection reagent optimisation  
A)  Flow cytometry results for HepG2 transfection reagent optimisation, cells were either transfected with a GFP 
containing plasmid, GFP-pSG5 or the negative, pSG5. B) Compilation of transfection optimisation results (n=3). C) 
Representative  confocal  microscopy  images  of  ICAfectin  transfected  HepG2  cells  with  the  plasmid,  pSG5-GFP. 
Images show DAPI nuclear staining, pSG5-GFP expression and merged images. Images were taken at both at x20 
and x60 magnification (Scale bar = 10µm).  
Jurkat  density  and  proliferation  was  also  assessed.  WST-1  analysis  revealed  that  2.5x10
4 
cells/well resulted in optimal growth over 72hrs (Figure 44, C) with reasonable cell density 
observed that would allow continuous proliferation over the experimental time frame. Lmx1a 
PCR primers were optimised against foetal temporal lobe because Jurkat was found not to 
express lmx1a (Figure 40, B/D). The absence of lmx1a expression was not expected as Jurkat 
lysate is commonly used as a positive control for lmx1a protein assays (abcam 2014). Despite 
this finding, we continued to use this cell type to assess lmx1a saRNA efficiency with the 
expectation that the saRNA technology could overcome this barrier. Transfection efficiency 
experiments were not carried out due to time constraints.  
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Figure 44 - Jurkat seeding density and TH PCR optimisation 
A) Representative bright field images showing Jurkat at varying seeding densities at 24hrs (x 4 magnifications). C) 
WST-1 analysis of Jurkat at different seeding densities over a 72hr culture period (n=3). B) lmx1a PCR primer was 
optimised against foetal temporal lobe DNA and the optimal cycling conditions are shown in D. 
5.4.2  PCR analysis of saRNA transfected cell lines 
Cells  were  transfected  with  their  relevant  saRNA  at  24hrs  and  48hrs  alongside  ‘Un-
transfected’, lipid transfection reagent alone and ‘Scramble’, random RNA sequences that have 
no specific target, using ICAfectin. Scramble acted as a true negative, allowing assessment of 
the effects of the transfection reagent and the RNA molecule without a targeted impact on the 
gene of interest.  These controls also worked to assess the component’s effect on cell viability. 
Transfections were performed on cultures that were either unsynchronised or synchronised. 
Total RNA was harvested at 72hrs and rtPCR performed to assess the expression levels of the 
genes  of  interest.  Unsynchronised  cells  were  found  to  produce  variable  results  with  no 
consistency  across  repeated  experiments  (Figure  45,  A-B,  n=2).  Cultures  were  then 
synchronised as it was thought the inconsistencies might be a result of different cell cycle 
positions  throughout  the  populations  of  unsynchronised  cells  (Figure  45  A-B).  Following 
synchronisation, cultures were found to be uniform in expression for foxa2. TH results are not  
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shown as these were inconclusive, thought to be due to RNA or primer degradation. There was 
no observable impact of saRNA. Lmx1a was not observed to be expressed by Jurkat under any 
condition, with the performance of the lmx1a PCR primers confirmed using foetal temporal 
lobe DNA (Figure 46, D/E).  
 
Figure 45 - RT-PCR mRNA analysis of transfected cell lines 
rtPCR mRNA analysis of HepG2, SH-SY5Y and Jurkat expression of target genes; (A) foxa2 and (B) lmx1a respectively. 
Cultures were treated with different conditions; untransfected, scramble and the available saRNA variants for that 
target gene (PR1-PR3). The figure shows a comparison of results from unsynchronised (n=2) and synchronised (n=1) 
cultures. TH results are not shown as these were inconclusive. PCR primer functionality was confirmed using cDNA 
from target gene positive sources; HepG2, SH-SY5Y and foetal temporal lobe DNA respectively. 
5.4.3  Lipid-base transfection reagent optimisation for omnicytes  
Due to the inconclusive results using cell lines it was agreed that the saRNA candidates would 
be  screened  using  omnicytes.  The  efficiency  of  the  transfection  reagents  at  transfecting 
omnicytes was investigated using siGLO green fluorescent transfection. This is a small molecule 
of a similar size to that of siRNA and saRNA elements (~20nt) and is used regularly in RNAi 
experiments;  it  was  thought  that  this  would  give  a  more  accurate  representation  of 
transfection efficiency of the reagents. SiGLO allowed the visualisation of transfected cells and 
quantification using flow cytometry.  
Flow  cytometry  data  showed  that  efficient  transfection  could  be  achieved  using  both 
nanofectin  (99.1%)  and  ICAfectin  (92.6%)  (Figure  46,  A/B).  Confocal  imaging  following  
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transfection with nanofectin confirmed that siGLO was internalised and was located to the 
cytoplasm (Figure 46, C). 
 
Figure 46 - Optimisation of omnicyte transfection 
A) Omnicyte transfection reagent optimisation using a frozen lymphoma sourced omnicyte cell sample. Cells were 
transfected  with  siGLO  fluorescent  transfection  control  and  efficiency  assessed  using  flow  cytometry  B)  Table 
showing the compiled transfection efficiencies for omnicytes using different lipid-based transfection reagents (n=1). 
C) Confocal images of omnicyte transfected cells at x60 magnification (n=1) (Scale bars = 10µm).  
 
During this stage of the investigation an opportunity arose to work with two known disease 
type  omnicyte  samples.  This  allowed  us  to  investigate  the  impact  of  disease  type  on 
transfection efficiency, gene expression and the efficacy of the saRNA.  
The omnicyte disease samples were transfected twice with candidate saRNA, as depicted in 
Figure  47,  A.  Briefly,  CD34
+  were  seeded  at  a  density  of  2.5x10
5cells/well  and  omnicytes  
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isolated,  then  expanded  for  24hrs  in  proprietary  expansion  media.  Cultures  were  then 
transfected  twice  over  a  48hrs  period  using  nanofectin  and  cultured  for  a  further  24hrs. 
Cultures were then mechanically harvested and gene expression assessed using qPCR. Parallel 
to  the  saRNA  experimental  transfections,  both  myeloma  and  lymphoma  cell  types  were 
transfected with siGLO allowing visualisation of the transfection efficiency. It was observed 
that  myeloma  cells  showed  significantly  better  transfection  ability  when  compared  with 
lymphoma (Figure 47, B). 
 
Figure 47 - Transfection protocol schematic and siGLO of omnicytes 
A) Omnicytes were seeded into wells (24 well plate) and expanded in expansion media and expanded for 24hrs. 
Cultures were then transfected with saRNA over the next 48hrs and mechanically harvested for mRNA analysis at 
72hrs. B) Myeloma and lymphoma omnicyte samples were transfected over 72hrs with siGLO transfection control, 
figures show representative x10 and x20 magnification fluorescent images of the cell populations (Scale bars = 
100µm).  
5.4.4  Molecular analysis of omnicyte target gene expression following saRNA transfection 
qPCR data was collected for both myeloma and lymphoma omnicyte samples and interrogated 
for the target genes of interest for each transfection set. As a general trend it was found that 
myeloma sourced omnicytes showed greater variation when transfected with the relevant 
saRNA when compared with lymphoma, with the exception of lymphoma when transfected 
with  TH  saRNA.  TH  expression  in  lymphoma  following  TH  saRNA  transfection  showed  the 
greatest enhancement in PR1 (Figure 48).  
Through this experiment it was observed that lymphoma and myeloma sourced omnicytes 
responded differently to the addition of saRNA. It was therefore decided that the use of this  
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cell type for the work would be unproductive until a consistent non-disease-type omnicyte cell 
source could be obtained.  
 
Figure 48 - qPCR analysis of saRNA transfected lymphoma and myeloma omnicyte samples 
Lymphoma  and  myeloma  sourced  omnicyte  cells  were  transfected  with  TH  (A/B  respectively),  foxa2  (C/D 
respectively) and lmx1a (E/F respectively) saRNAs and harvested and analysed after 72hrs. Results were normalised 
against β-actin expression and controlled against ‘untransfected’, transfected with Nanofectin alone, ‘scramble’, 
transfected with Nanofectin and scramble RNA and saRNA variants (PR1 - 3)(n=1). 
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5.5  Discussion 
Due to the limited availability of omnicytes, it was decided that initial optimisation of the 
saRNA candidates would be done using cell lines that were thought to endogenously express 
the genes of interest. This was done as it was thought that these cells would contain no 
epigenetic factors that might inhibit the transcription of the target genes and obscure the 
impact of the saRNA. 
Two cell lines, HepG2 and SH-SY5Y, were found to be positive for the targets foxa2 (abcam 
2014)  and  TH  (abcam  2014)  at  a  protein  level.  The  expression  of  the  target  genes  was 
confirmed at a molecular level using rtPCR for both cell types (Figure 40/Figure 42). A similar 
search was used to identify Jurkat as being positive for lmx1a expression (abcam 2014) though 
confirmation  at  a  molecular  level was  negative.  Lmx1a  PCR  cycling  was  optimised  against 
foetal temporal lobe RNA that was purchased commercially.  
A seeding density of 2.5x10
4cell/well (24 well plate), as determined by WST1 analysis, was 
used as the standard density for all of the cell lines, allowing continuous cell proliferation over 
72hrs culture. Through visual assessment, this initial seeding density also resulted in a good 
cell density at 24hrs when the cells were transfected using a lipid-base reagent, maximising 
lipid-cell  interaction  and  endocytosis  (Figure  40/Figure  42/Figure  44)  (Ziello,  Huang  et  al. 
2010).  
Cell lines were individually assessed for their efficiency to be transfected using three reagents; 
ICAfectin, Nanofectin and FUgene, using a GFP containing plasmid, pSG5-GFP, and non-GFP 
containing control, øpSG5, to visualise and quantify the efficiency of the transfection reagents. 
pSG5-GFP is approximately 4kb in size, significantly larger than the candidate saRNA (20nt) 
elements, providing a rigorous test of transfection efficiency. Following optimisation it was 
decided that ICAfectin would be used for all cell types, because SH-SY5Y showed the greatest 
efficiency  using  ICAfectin  (28.7%  efficiency)  and  the  HepG2  assessment  was  inconclusive  
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although  GFP  was  present  in  ICAfectin  transfected  cultures  when  assessed  using  confocal 
microscopy (Figure 41/Figure 43).  
PCR results from both Jurkat and SH-SY5Y based transfection experiments were inconclusive. 
Unsynchronised cells, showing variability across all variants and controls assessed. This was 
thought to be due to cells within culture being at different stages of the cell cycle, impacting 
on efficiency of the saRNA and the expression of target genes, this is supported by findings of 
Chen et al. (Chen, Huang et al. 2012). Chen et al. found retroviral infection was significantly 
affected  by  cell  culture  synchronisation.  To  overcome  this,  cells  were  synchronised  using 
starvation media which resulted in uniform expression across all experimental conditions. This 
was thought to be a result of endogenous gene expression masking the effects of the saRNA. 
The lack of conclusive results was thought to be, in part, a result of the insensitivity inherent to 
the rtPCR method. We expect that changes in the expression levels of the target genes were 
too subtle and could not be distinguished. At this stage of the work the use of qPCR became 
available, allowing sensitive and quantitative analysis of any molecular changes within the 
cells.  
It was decided further optimisation of saRNA would be carried out using omnicytes as this was 
a potential cell source for use within the development of a therapeutic product.  
Transfection optimisation work  was  performed  using  a  green  fluorescent molecule,  siGLO, 
which better represented the saRNA molecules (Figure 45, C). Transfection was found to be 
most efficient when using nanofectin (Figure 46) and so this reagent was used in all further 
investigations.  
The omnicytes available for screening of the saRNAs at this stage of the work were sourced 
from  two  diseased  donors,  one  myeloma  and  one  lymphoma.  Following  the  discovery  in 
Chapter 3 that disease type influenced cell behaviour and molecular gene expression it was 
decided that these cell types would be ran in parallel and their results assessed separately. 
Transfection efficiency was found to be affected by disease type with  lymphoma showing  
 
148 
 
significantly lower transfection efficiency than that of myeloma (Figure 47, B). qPCR data also 
showed a high degree of variability depending on which disease type was transfected, with 
both TH and lmx1a saRNAs producing distinctive results dependant on disease type (Figure 48, 
A/B & E/F). Foxa2 transfected cells showed some consistency with PR1 showing an increase in 
expression for both disease types though the expression level difference was dramatic with 
lymphoma and myeloma showing 0.05 and >175 fold increases in expression, respectively. This 
could be a result of disease modification of the gene activation sites, as it has been found by 
another group that only 9% of small nucleotide polymorphisms (SNPs) associated with disease 
are found in the protein coding region the rest are found in the activation sites (Hindorff, 
Sethupathy et al. 2009), this could impact on the binding of the saRNA at the activation site 
and their functionality. This limitation of diseased cells should be investigated if this work is to 
be taken forwards (Figure 48, C/D). 
Due to the lack of availability of ‘normal’, non-disease omnicyte cells and the variability of the 
results from disease types and patient variability (discussed in Chapter 3) observed, it was 
decided that for this work to progress a different experimental cell type would need to be 
used. This thesis continues this work on saRNA using hPSCs, hESC and hiPSC, in conjunction 
with the DA differentiation protocol described and investigated in Chapter 4.  
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5.6  Conclusion 
SaRNAs were shown in these limited experiments to have variable impact on gene expression 
when source cells were of different disease types. As the experiment was only repeated once 
due to limited sample availability these results should be interpreted with caution. It was 
found that the use of rtPCR to screen and understand the effects of saRNA in cell types is 
unsuitable due to the low sensitivity of this method. 
Due to the lack of availability of the omnicytes and the variability observed across all the work 
done  with  this  cell  type,  whether  because  of  patient  variability  or  the  disease  type, 
experimental  work  with  this  cell  type  is  challenging  and  could  not  be  addressed  in  the 
timescale of this doctorate.  
In the following chapter (Chapter 6) we show how saRNAs can be included into an hPSC-based 
DA  differentiation  protocol  and  we  will  investigate  if  saRNA  can  have  an  impact on  gene 
expression and differentiation yield.  
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CHAPTER  6  -  POTENTIAL  OF  SARNA  FOR  ENHANCING  TARGET  GENE 
EXPRESSION  DURING  AGGREGATE-BASED  DOPAMINERGIC 
DIFFERENTIATION 
6.1  Introduction 
Our  ability  to  derive  specific  neuronal  cell  types  from  hPSCs  has  developed  from  niche 
expertise based on the fundamentals of developmental biology into a widespread laboratory 
methodology increasingly adopted by translational scientists. It is now possible to stimulate a 
cell population to express DA genes, TH, lmx1a and foxa2, through a number of protocols 
(Chambers, Fasano et al. 2009, Kriks, Shim et al. 2011); however as discussed in Chapter 5, the 
efficiency  of  these  protocols  remains  low.  The  lack  of  an  efficient  protocol  has  hindered 
progress to clinic and the development of robust cell lines for drug screening. The low purity of 
the differentiation process means, additional purification and packaging steps and increased 
input cell numbers at the initial stages of the process will be required. Contaminating cell 
types, including pluripotent, germ layer and incorrectly differentiated cells, also need to be 
removed  from  the  dose  to  eliminate  tumorigenic  risk,  again  reducing  the  output  of  the 
process.  
We know through the work presented in Chapter 4, that the generation of specific, DA-like 
neuronal cell types from hPSC populations is possible using a suspension-based culture system. 
Within  the  differentiated  populations  pluripotent  and  non-ectoderm  germ  line  marker 
expressions were shown to reduce and the expression of key DA marker genes, including, 
lmx1a, TH and DRD to increase. This work also showed that while we can now generate cell 
populations  that  express  the  desirable  markers  required,  we  cannot  achieve  efficient  co-
expression of the target proteins in all the cells. Through collaboration with Omnicyte Ltd. this 
project was able to use the novel technology, saRNA, to modify targeted gene expression 
transiently and attempt to enhance the efficiency of the protocol. Pilot work was performed  
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on cancer cell lines and omnicytes as described in Chapter 5. This work proved inconclusive on 
these  cell  lines,  however  the  technology  has  been  shown  to  influence  genes  and  protein 
expression and proof of principal confirmed through work done to improve liver function, 
inhibit live carcinogenesis in-vivo and target and modify the specific Islet beta-cell transcription 
factor  MafA  in  CD34
+  cells  (Reebye,  Saetrom  et  al.  2013,  Reebye,  Saetrom  et  al.  2013); 
indicating that there is potential for this technology to be used to enhance hPSC differentiation 
yields. 
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6.2  Aim 
Having generated hPSC products that express DA genes, and given the reported stimulatory 
effect  of  saRNAs  on  differentiation  and  reprogramming,  the  aim  of  this  chapter  was  to 
determine  whether  combination  effects  of  standard  differentiation  protocols  and  neuron-
specific saRNA treatment can enhance the expression of key markers TH, lmx1a and foxa2 in 
hPSC cell lines. 
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6.3  Results 
6.3.1  saRNA transfection optimisation 
Transfection of hESC and hiPSC with nanofectin, a lipid-base reagent, was assessed using the 
transfection  control  reagent,  siGLO,  which  fluoresces  green  for  visual  confirmation  of 
transfection. Both hESC and hiPSC were successfully transfected with siGLO relative to UT and 
Mock transfected controls (Figure 49, C & F). Transfection with siGLO appeared to impact on 
cell  growth  with  lower  colony  density  observed  when  compared  with  both  mock  and  UT 
cultures. 
 
Figure 49 - Nanofectin transfected hPSC with fluorescent element siGLO 
Representative bright-field and fluorescent images of hPSC cultures transfected using nanofectin. hESC and hiPSC 
were  negative  for  green  fluorescence  when  cultured  un-transfected  (A/D)  and  mock  transfected  (B/E).  Cells 
transfected with siGLO (C/F) emitted green fluorescence (495nm/519nm, n=1) (Scale bar = 100µm).   
To assess the impact of the candidate saRNAs on target gene expression, saRNAs were tested 
in hiPSC. hiPSC were transfected, using nanofectin, with either individual saRNA or all three 
saRNA  together.  Cultured  cells  were  mechanically harvested  for  qPCR  analysis  72hrs  after 
transfection. All the genes showed the greatest expression increase following transfection with 
all three candidate saRNAs (Figure 50, A-C). Transfection at the higher concentration resulted  
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in a greater increase in expression for foxa2 (Figure 50, A), and a slight increase in TH (Figure 
50, C). Lmx1a expression was not impacted by saRNA concentration (Figure 50, B).  
 
Figure 50 - saRNA optimisation using hiPSC 
qPCR analysis of mRNA expression in saRNA transfected hiPSC cultures. hiPSC were transfected with A) foxa2, B) 
lmx1a and C) TH saRNA either individually or combined over 72hrs (3 x transfections) at two concentrations; 25nM 
or 50nM. Foxa2 (A) was assessed for two candidates (v1 & v2); volume was used to alter concentration levels (2.5µL 
or 5µL). Investigations were controlled against UT cultures, cultured in KOSRM. 
6.3.2  Impact  of  combined  saRNA  addition  during  dopaminergic  differentiation  at  the 
molecular level 
The impact of saRNA transfection was assessed at a molecular level using qPCR. Pluripotent, 
germ layer, neuronal and DA marker gene expression levels were assessed at a population 
level throughout the differentiation process. Samples were harvested at D0, D24 and D38, i.e. 
before differentiation, following suspension culture and following adhered maturation of the 
neurospheres. Transfection of the hPSC aggregates was confirmed in hiPSC using the siGLO 
transfection control. Control suspension cultures were transfected over the course of 24 days, 
mimicking the transfection regime of the saRNA samples. Qualitative analysis of the cultures 
confirmed that the aggregates positively fluoresced when transfected with siGLO whilst UT 
aggregates did not fluoresce (Figure 51).   
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Figure 51 - Representative image of siGLO transfected hiPSC neurospheres 
Representative bright field and  fluorescent images of  transfected (siGLO) and UT hiPSC aggregates (Scale bars 
1000µm). 
6.3.3  Impact  of  transfecting  saRNAs  during  the  dopaminergic  differentiation  protocol  - 
pluripotent gene expression 
Pluripotency genes, nanog and oct4, were significantly down-regulated over time in hESC and 
hiPSC  (Figure  52,  A-B  &  D-E);  however  the  addition  of  saRNA  did  not  induce  substantial 
changes  when  compared  to  mock  or  UT.  Indeed  in  hiPSC,  mock  transfected  conditions 
appeared  to  result  in  the  greatest  measurable  down-regulation,  though  not  statistically 
significant. 
In the case of sox2, gene expression was up-regulated at D24 relative to D0 in hESC but by D38 
sox2 was significantly down-regulated in all conditions (Figure 52, C). Sox2 expression in hiPSC 
was found not to change substantially from D0 levels at any point during culture (Figure 52, F).  
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Figure  52 - qPCR analysis of pluripotent gene expression following the inclusion of saRNA during 
dopaminergic differentiation and maturation 
qPCR  analysis  of  pluripotent  mRNA  expression  following  dopaminergic  differentiation  (D24)  and  adhered 
maturation in DDM (D38). hESC and hiPSC derived neurosphere expression of  nanog (A/D), oct4 (B/E) and sox2 
(C/F) are shown relative to D0 expression. Data is normalised using GAPDH, β-Actin and UBC expression (* p< 0.05, 
** p<0.01, ***p<0.001 and **** p<0.0001. Bars represent Mean ± SEM. All UT and saRNA cultures n=3, hESC mock 
culture n=1 and hiPSC mock culture n=2). 
6.3.4  Impact  of  transfecting  saRNAs  during  the  dopaminergic  differentiation  protocol  - 
fgf5 gene expression 
Expression of fgf5 in both hESC and hiPSC significantly increased in all experimental conditions 
relative to D0 over the duration of culture, though hiPSC was shown to increase faster than 
hESC by D24 (Figure 53, A & B). Transfection with saRNAs was not observed to increase the 
expression of fgf5 compared with control arms in either cell type.   
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Figure 53 - qPCR analysis of fgf5 expression following the inclusion of saRNA during dopaminergic 
differentiation and maturation 
qPCR analysis of fgf5 mRNA expression following dopaminergic differentiation (D24) and adhered maturation in 
DDM (D38). hESC and hiPSC derived neurosphere expression of  fgf5 (A/B respectively) is shown relative to D0 
expression. Data is normalised using GAPDH, β-Actin and UBC expression (* p≤0.05 and ** p≤0.01. Bars represent 
Mean ± SEM. All UT and saRNA cultures n=3, hESC mock n=1 and hiPSC mock n=2). 
6.3.5  Impact  of  transfecting  saRNAs  during  the  dopaminergic  differentiation  protocol  - 
germ layer gene expression 
Contaminating germ layer markers brachyury and sox17 were shown to be down-regulated in 
both hESC and hiPSC following differentiation (Figure 54, A-B & D-E). Sox17 was shown to be 
significantly  reduced  in  hESC  by  D38  and  in  hiPSC  by  D24.  Nestin  expression  increased 
significantly in all conditions by D24 (Figure 54, C & F) for hiPSC, and in hESC it was shown to 
decrease by D38. Transfection of saRNA did not reduce expression of brachyury and sox17 or 
increase the expression of nestin over that of the control arms.  
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Figure  54  -  qPCR  analysis  of  germ  layer  expression  following  the  inclusion  of  saRNA  during 
dopaminergic differentiation and maturation 
qPCR analysis of germ layer mRNA expression following dopaminergic differentiation (D24) and adhered maturation 
in DDM (D38). hESC and hiPSC derived neurosphere expression of  brachyury (A/D), sox17 (B/E) and nestin (C/F) are 
shown relative to D0 expression. Data was normalised using GAPDH, β-Actin and UBC expression (* p≤0.05, ** 
p≤0.01, ***p≤0.001 and **** p≤0.0001. Bars represent Mean ± SEM. All UT and saRNA cultures n=3, hESC mock 
n=1 and hiPSC mock n=2). 
6.3.6  Impact  of  transfecting  saRNAs  during  the  dopaminergic  differentiation  protocol  - 
neuronal gene expression 
Assessment of neuronal gene expression during differentiation showed sox1 and en1 to be 
significantly increased over the course of the differentiation process in both hESC (Figure 55, A-
B) and hiPSC (Figure 55, E-F). Expression of sox1 and en1 was slightly increased in saRNA 
transfected hESC cultures relative to the controls, at D24; no difference was observed in hiPSC 
relating to culture condition.  Nurr1 expression in both hESC and hiPSC increased significantly 
by D38 in all conditions (Figure 55, D & H), with expression being greater in saRNA transfected 
hESC culture. Expression of otx2 was shown in both cell types to decrease across all conditions 
(Figure 55, C & G).  
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Figure  55  -  qPCR  analysis  of  neuronal  gene  expression  following  the  inclusion  of  saRNA  during 
dopaminergic differentiation and maturation 
qPCR analysis of neuronal mRNA expression following dopaminergic differentiation (D24) and adhered maturation 
in DDM (D38) alongside the inclusion of saRNA. hESC and hiPSC derived neurosphere expression of  sox1 (A/E), en1 
(B/F), otx2 (C/G) and nurr1 (D/H) are shown relative to D0 expression. Data was normalised using GAPDH, β-Actin 
and UBC expression (* p≤0.05, ** p≤0.01, ***p≤0.001 and **** p≤0.0001. Bars represent Mean ± SEM. All UT and 
transfected cultures n=3, hESC mock n=1 and hiPSC mock n=2). 
6.3.7  Impact  of  transfecting  saRNAs  during  the  dopaminergic  differentiation  protocol  - 
dopaminergic gene expression 
Expression of DA marker genes, foxa2, TH and DRD were shown to significantly increase in all 
conditions by D24 in hESC (Figure 56, A, C-D) with expression of  foxa2 being significantly 
greater  in  saRNA  transfected  cultures  than  UT  cultures  by  D24.  Expression  of  lmx1a  was 
delayed until D38 where expression in saRNA transfected cultures appeared to be greater 
(Figure 56, B), though not significantly. Expression of lmx1a, TH and DRD also rose significantly 
in hiPSC cultures by D24 (Figure 56, F-H) but no difference was observed associated with 
treatment. Expression of foxa2 was shown in both UT and mock transfected to decrease in 
hiPSC culture, only saRNA transfected culture increased slightly over the course of the protocol 
(Figure 56, E).  
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Figure 56 - qPCR analysis of dopaminergic gene expression following the inclusion of saRNA during 
dopaminergic differentiation and maturation 
qPCR  analysis  of  dopaminergic  mRNA  expression  following  dopaminergic  differentiation  (D24)  and  adhered 
maturation in DDM (D38) alongside the inclusion of saRNA. hESC and hiPSC derived neurosphere expression of  
foxa2 (A/E), lmx1a (B/F), TH (C/G) and DRD (D/H) are shown relative to D0 expression. Data was normalised using 
GAPDH, β-Actin and UBC expression (* p≤0.05, ** p≤0.01, ***p≤0.001 and **** p≤0.0001. Bars represent Mean ± 
SEM. All UT and transfected cultures n=3, hESC mock n=1 and hiPSC mock n=2). 
6.3.8  Confocal imaging of UT versus saRNA transfected cultures 
Immunofluorescent staining and confocal imaging confirmed the presence of neuronal marker 
β-III-Tubulin in both hESC and hiPSC cultures. No visual difference in expression of β-III-Tubulin 
could be distinguished between UT and saRNA transfected cultures in either cell type (Figure 
57). DA marker, TH, was also assessed with expression being observed in both cell types and 
conditions (Figure 57). A greater number of TH
+ cells were seen to be present in hESC saRNA 
transfected  cultures  when  compared  with  UT  and  hiPSC  cultures  though  this  was  not 
quantified (Figure 57, C-D). 
TH
+/Foxa2
+  cells  were  confirmed  in  both  UT  and  saRNA  culture  conditions  and  cell  types 
(Figure 58). TH staining was observed to be located to the cytoplasm of the cell whereas Foxa2 
was located to the nuclei, co-stained with dapi. The majority of cells were shown to be TH
-
/Foxa2
- but in pockets, cells could be observed to be Foxa2
+ with granular red staining in the 
nuclei. Co-association of Foxa2 and TH within a single cell was found to be low in both hESC  
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and  hiPSC  cultures.  No  difference  in  abundance  of  Foxa2
+/TH
+  cells  could  be  discerned 
between UT and saRNA transfected cultures.  
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Figure  57  -  Confocal  imaging  of  hPSC  β-III-Tubulin  and  TH  staining  of  untransfected  and  saRNA 
transfected cultures 
Representative confocal images of hESC (A-D) and hiPSC (E-H) UT and saRNA transfected cultures after 14 days in 
DDM. Cultures were affinity stained for β-III-Tubulin (red) and TH (green) antibodies. Dapi (blue) stained the nuclei 
(Scale bars A-G = 50µm, except H scale bar = 25µm).  
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Figure 58 - Confocal imaging of hPSC foxa2 and TH staining of untransfected and saRNA transfected 
cultures 
Representative confocal images of hESC (A-D) and hiPSC (E-H) cultures after 14 days UT and saRNA transfected 
culture in DDM stained with TH (green) and foxa2 (red) antibodies. Dapi (blue) stained the nuclei  (All scale bars 
represent 50µm).  
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6.3.9  Co association analysis of Foxa2 and TH immunocytochemistry staining 
To fully assess the ability of the DA differentiation protocol, with and without saRNA, to derive 
TH
+/Foxa2
+ neurons, confocal microscopy and Volocity software were used to quantify co-
association  of  staining  in  matured  neurospheres.  Images  were  processed  as  described  in 
Chapter 2, section 2.6.9. Unfortunately due to noise, for both hESC and hiPSC experimental 
groups no statistical difference between UT and saRNA could be ascertained (Figure 62).  
Neurospheres (UT and saRNA transfected) derived from hESC and hiPSC (Figure 59/Figure 60) 
were shown to include Foxa2
+ and TH
+ cells. Data indicated that Foxa2 was enhanced in saRNA 
transfected cultures for both cell types but no significance could be identified due to noise 
(Figure 62). TH staining displayed the opposite trend, revealing a slight decrease in the volume 
of  expression.  Comparison  with  2
o  only  confocal  images  in  Figure  61  shows  that  each 
population contains Foxa2
+ and TH
+ cells but few were co-associated.  
 
 
  
 
165 
 
 
Figure 59 - hESC foxa2 and TH confocal imaging of neurospheres 
Representative maximum intensity images of confocal images of hESC derived neurospheres cultured for 14 days in 
DDM.  A  -  D)  Representative  UT  neurospheres  images.  E  -  H)  Representative  images  of  saRNA  transfected 
neurospheres.  Foxa2
+ (red) and TH
+ (green) can be observed in all conditions with co association found to be 
minimal (Scale bars = 50µm).   
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Figure 60 - hiPSC foxa2 and TH confocal imaging of neurospheres 
Representative maximum intensity images of confocal images of hiPSC derived neurospheres cultured for 14 days in 
DDM.  A  -  D)  Representative  UT  neurospheres  images.  E  -  H)  Representative  images  of  saRNA  transfected 
neurospheres.  Foxa2
+ (red) and TH
+ (green) can be observed in all conditions with co association found to be 
minimal (Scale bars = 50µm).   
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Figure 61 – Confocal imagaes of foxa2 and TH 2
o only control staining 
Representative maximum intensity images of 2
o only staining for both Foxa2 and TH staining (Scale bar = 50µm). 
 
Figure 62 - hiPSC associated volume of foxa2 and TH staining in hPSC derived neurospheres 
Graphs showing the associated volumes of positive staining for both TH and foxa2 in (A) hESC and (B) hiPSC derived 
neurospheres following Volocity analysis. Data is shown as volume (µm
3) per nuclei (Bars = SEM, n=3).  
6.4  Investigating the impact of using a reduced number of saRNAs in enhancing target 
gene expression during dopaminergic differentiation  
Next, we investigated the impact of the individual saRNA; we did this by reducing the number 
of saRNAs from the 3 target genes to 2, now targeting only TH and lmx1a and removing foxa2. 
The same transfection regime as previously used was utilised. 
6.4.1  Impact  of  transfecting  a  reduced  number  of  saRNA  during  dopaminergic 
differentiation - pluripotent gene expression 
Analysis of mRNA expression showed pluripotent genes, nanog and oct4, in hESC and hiPSC 
decreased following neural induction (Figure 63, A/B & D/E). hESC, transfected with saRNA, 
appeared to show a greater reduction in oct4 expression when compared with UT (Figure 63, 
B).  
Expression of sox2 in hESC and hiPSC marginally increased but then decreased to D0 levels by 
D24 in all conditions (Figure 63, C & F). With the exception of oct4 in hESC, transfection with 
saRNA appeared to have little impact on pluripotent gene expression.  
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Figure 63 - qPCR analysis of pluripotent gene expression following dopaminergic differentiation, with 
and without inclusion of TH and lmx1a saRNA  
qPCR analysis of pluripotent mRNA expression following dopaminergic differentiation and the inclusion with TH and 
lmx1a saRNA. hESC and hiPSC derived neurosphere expression of  nanog (A/D), oct4 (B/E) and sox2 (C/F) are shown 
at D5, D13 and D24 relative to D0. Data was normalised using GAPDH, β-Actin and UBC expression. (n=1) 
6.4.2  Impact  of  transfecting  a  reduced  number  of  saRNA  during  dopaminergic 
differentiation - fgf5 gene expression 
Expression  of  fgf5  expression  in  both  hESC  and  hiPSC  were  observed  to  decrease  for  all 
conditions relative to D0 over the course of the protocol (Figure 64, A & B).  Transfection with 
saRNA did not enhance the expression of fgf5 by D24 when compared with D0 in either cell 
line.  
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Figure 64 - qPCR analysis of fgf5 gene expression following dopaminergic differentiation, with and 
without inclusion of TH and lmx1a saRNA 
qPCR analysis of fgf5 mRNA expression following dopaminergic differentiation and transfection with TH and lmx1a 
saRNA. (A) hESC and (B) hiPSC derived neurosphere expression of fgf5 was shown at D5, D13 and D24 relative to D0 
expression. Data was normalised using GAPDH, β-Actin and UBC expression. (n=1) 
6.4.3  Impact  of  transfecting  a  reduced  number  of  saRNA  during  dopaminergic 
differentiation - germ layer gene expression 
Germ layer markers brachyury and sox17 were shown to reduce in both hESC and hiPSC by D24 
(Figure 65, A/B & D/E) except in the case of saRNA transfected hiPSC expression of brachyury 
which was increased slightly, relative to D0. Expression of nestin was shown to increase in both 
cell types though only marginally, with hiPSC showing greater expression than that of hESC at 
both time points (Figure 65, C & F). hiPSC transfected with saRNA showed a marginal increase 
in nestin expression compared with UT by D24 (Figure 65, F).    
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Figure 65 - qPCR analysis of germ layer expression following dopaminergic differentiation, with and 
without inclusion of TH and lmx1a saRNA 
qPCR analysis of germ layer mRNA expression following dopaminergic differentiation and transfection with TH and 
lmx1a saRNAs. hESC and hiPSC derived neurosphere expression of  brachyury (A/D), sox17 (B/E) and nestin (C/F) 
are shown  at D5, D13 and D24 relative to D0 expression. Data was normalised using GAPDH, β-Actin and UBC 
expression. (n=1) 
6.4.4  Impact  of  transfecting  a  reduced  number  of  saRNA  during  dopaminergic 
differentiation - neuronal gene expression 
Analysis of neuronal genes showed that nurr1 and en1 increased in expression to D24 in both 
hESC and hiPSC (Figure 66, A/C & D/F). Nurr1 expression in both cell types was delayed, only 
showing a significant increase relative to D0 at D24. En1 also showed a stepwise increase with 
expression in hESC by D24, with saRNA transfected cultures showing slighting increased levels 
of expression relative to UT. Expression of otx2 was shown to decrease in both cell types 
though the decrease was observed to be greater in hiPSC (Figure 66, B & E).  
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Figure 66 - qPCR analysis of neuronal gene expression following dopaminergic differentiation, 
with and without inclusion of TH and lmx1a saRNA 
qPCR analysis of neuronal mRNA expression following dopaminergic differentiation and transfection with TH and 
lmx1a saRNAs. hESC and hiPSC derived neurosphere expression of  nurr1 (A/D), otx2 (B/E) and  en1 (C/F) are shown 
at D5, D13 and D24 relative to D0 expression. Data was normalised using GAPDH, β-Actin and UBC expression. (n=1) 
6.4.5  Impact  of  transfecting  a  reduced  number  of  saRNA  during  dopaminergic 
differentiation - dopaminergic gene expression 
The expression levels of the DA genes assessed in the experiment increased relative to D0 in 
both cell types. Lmx1a in hESC and hiPSC at D24 showed greater expression in cultures that 
had been transfected with saRNA (Figure 67, B & F). This was also observed in foxa2 expression 
with hiPSC, though in hESC this increase was only marginal (Figure 67, E & A). Expression of TH 
and DRD in both hESC and hiPSC gradually increased to D24 levels but no distinction could be 
made between expression level according to culture conditions (Figure 67, C-D & G-H).    
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Figure  67  -  qPCR  analysis  of  dopaminergic  gene  expression  following  dopaminergic 
differentiation, with and without inclusion of TH and lmx1a saRNA 
qPCR analysis of dopaminergic mRNA expression following dopaminergic differentiation and transfection with TH 
and lmx1a saRNAs. hESC and hiPSC derived neurosphere expression of  foxa2 (A/E), lmx1a (B/F), TH (C/G) and DRD 
(D/H) are shown at D5, D13 and D24 relative to D0 expression. Data was normalised using GAPDH, β-Actin and UBC 
expression. (n=1) 
6.5  Assessing the efficiency of transfecting cell aggregates in suspension 
Transfection  of  saRNA  was  shown  to  have  little  impact  on  gene  expression  and  so  an 
investigation  was  developed  to  investigate  the  ability  of  nanofectin  to  transfect  cell 
aggregates. This was to test the hypothesis, only the surface cells of the aggregates were 
affected by the saRNA. If this was the case the majority of the cells within the aggregate were 
not being influenced, and so the impact of the saRNA in our previous experiments would have 
been overshadowed.  
To  assess  the  efficiency  of  transfecting  cell  aggregates  in  suspension  we  used  aggrewell 
technology. This technology generated uniformly sized aggregates which allowed us to tightly 
control and assess the impact of aggregate size on transfection efficiency (Figure 68).  
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Figure 68 - Aggrewell EB formation  
A/B) Representative aggrewell formation images, a single cell suspension has been applied to the aggrewell well 
and centrifuged to evenly distribute the cells across the wells, uniform sized EBs are generated (Scale bar = 200µm). 
Representative image of aggrewell generated EBs in suspension at 1kb (C) and 2kb (D) sizes (Scale bar = 1000µm). E) 
Shows EB diameter distribution of EBs of 1kb and 2kb cells (Error bars = ±SD)  
6.5.1  Quantification of aggregate transfection efficiency 
Aggregates were generated that contained 1,000 and 2,000 cells per aggregate; these were 
then transfected over 3 days and assessed using flow cytometry. Aggregates treated with 
nanofectin  and  siGLO  were  shown  to  be  positively  transfected  relative  to  UT  aggregates, 
confirming that nanofectin was appropriate for transfecting hPSC aggregates (Figure 69, A - D). 
Flow cytometry analysis showed a material difference in transfection efficiency associate with 
aggregate size. Transfection was shown to be more efficient in smaller 1k cell aggregates 
(1.57%) than in the larger aggregates of 2k (0.05%, Figure 69, E).   
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Figure 69 - Analysis of siGLO transfected cell aggregates 
Representative images of 1kb (A) and 2kb (B) siGLO transfected cell aggregates and UT controls (C & D) (Scale bars = 
1000µm). E) Flow cytometry data collected following disassociation of cell aggregates at varying sizes and the 
number of viable transfected cells in the population minus the negative control. 
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6.6  Discussion 
6.6.1  Transfection of hPSC using Nanofectin 
Nanofectin was selected as the transfection reagent for this research; this was the favoured 
reagent by Omnicyte Ltd. and would allow them to continue to develop this work in the future. 
hPSC transfection efficiency was assessed using a transfection control (fluorescence emitting 
siGLO), and resulted in positive emission at 488nm in both hESC and hiPSC (Figure 49, C & F). A 
degree of cell death in the siGLO transfected cultures (absent in the UT and mock transfected 
cultures) indicates that the siGLO element may contribute to greater cell death (Figure 49, B & 
E). It is important to recognise this potential impact of the cyctoxcity of saRNAs, however if a 
higher efficiency of derivation of target cell populations is achieved at the expense of a small 
degree of cell death, the trade-off is tenable.  
Results  observed  using  fluorescent  microscopy  on  the  suspension-based  culture  system 
showed that cell aggregates were 488nm positive relative to the UT control (Figure 51). This 
indicated that the transfection method used for adherent cultures could be translated to our 
suspension differentiation system, which would be important for translating the process to 
industry-ready bioreactor technologies. 
6.6.2  saRNA function confirmed using hPSC 
hiPSC cultures were transfected with the candidate saRNA to assess their effect on target gene 
expression (Figure 50). It was shown that all target gene expression levels increased relative to 
UT  following  transfection,  though  TH  expression  increased  only  marginally.  Foxa2  and  TH 
saRNA  transfected  cultures  increased  in  target  gene  expression  relative  to  saRNA 
concentration increase (Figure 50, A & C) suggesting that the activity of these saRNAs was not 
saturated and could be further optimised. For the purposes of this work and with limited 
resources  and  time,  and  given  the  positive  correlation  between  concentration  and  gene 
potency, it was decided that work should progress using the highest saRNA concentration 
(50nM)  for  transfection.  All  target  genes  were  found  to  have  the  greatest  increase  in  
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expression  following  transfection  with  all  three  saRNA  candidates  (Figure  50,  A-C).  These 
investigations were performed in duplicate and confirmed previous findings by Omnicyte Ltd. 
(unpublished).  
This work shows that using the combination of saRNA produces superior results to transfecting 
with the individual saRNAs. From this point all transfections were carried out in combination 
and at the higher concentration of 50nM. 
6.6.3  Molecular analysis of saRNA transfected cultures versus UT cultures 
Analysis of pluripotent markers was performed to assess the relative impact of saRNA inclusion 
compared  with  UT  (statistically  significant)  and  mock  (indicative  due  to  low  replicative 
numbers) transfected cultures. The expression of both  nanog and oct4 in hESC and hiPSC 
cultures were shown to be substantially down-regulated following 24 days of differentiation 
culture (Figure 52, A/B & D/E) but no difference was observed between treatments, except in 
the case of hESC oct4 expression where saRNA transfection resulted in a greater reduction. 
These  results  indicate  that  cultures  are  moving  away  from  a  pluripotent  state  and 
differentiating (Pan and Thomson 2007), although the qPCR methodology does not allow us to 
assess what proportion of the population remains pluripotent. Sox2 expression was found to 
increase in both hESC and hiPSC up to D24 and then drop to D38 (Figure 52, C & F). Although 
sox2  was  assessed  as  a  pluripotency  marker,  it  is  also  a  marker  for  neuronal  progenitors 
(Graham, Khudyakov et al. 2003), and the increase in expression may indicate that cultures to 
D24 contain a greater proportion of neuronal progenitors,  but these may be lost by D38, as 
the neurons develop and mature. The move from a pluripotent state is further confirmed 
through  the  expression of  fgf5.  Significantly  increased  expression  of  fgf5  in  hiPSC  by  D24 
(Figure 53, B) and hESC by D38 (Figure 53, A) indicates early differentiation and the presence of 
a  primitive  fgf5
+  ectoderm  population  (Hitoshi,  Seaberg  et  al.  2004).  SaRNA  transfected 
cultures showed that saRNA had no significant impact on the experimental culture’s early 
development compared with the differentiation media itself, both pluripotent markers and  
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neuronal progenitor fgf5 marker expressions suggest that saRNA does not impact the shift 
away from pluripotency or on early differentiation towards a neuronal lineage. 
Analysis of contaminating mesoderm and endoderm markers, brachyury and sox17, indicated 
that all conditions resulted in a drop in expression in hESCs and hiPSC (Figure 54, A/B & D/E).  
Nestin was observed to increase significantly in both hESC and hiPSC by D24 (Figure 54, C & F) 
confirming again that the cultures moved towards an ectoderm lineage (Suzuki, Namiki et al. 
2010). Again, saRNA transfection had no effect on germ layer marker expression above that of 
the  differentiation  media,  suggesting  no  involvement  in  lineage  commitment  and  early 
differentiation. 
Neuronal marker gene analysis showed increased levels of sox1, en1 and nurr1 (Figure 55) in 
both hESC and hiPSC cultures, this implies that cultures are differentiating and developing 
down the neuronal lineage and moving towards the midbrain cell type (Sacchetti, Carpentier et 
al. 2006). Unfortunately, otx2 in both cell types by D38 were lower than the original expression 
levels at D0. This finding is a similar result from Chapter 4, and emphasizes the need for further 
optimisation of the patterning process. Otx2 being the ‘master’ anterior-posterior patterning 
module  gene  (Omodei,  Acampora  et  al.  2008)  implies  it  is  an  essential  step  in  the 
differentiation of DA neurons.  
saRNA transfected hESC cultures exhibited a slight increase relative to the control arms for a 
number of the neuronal markers assessed (nurr1, en1 and sox1), suggesting that transfection 
may be increasing gene expression within the cell population. This was not the case in hiPSC 
where no difference was observed. These results confirm that all conditions are able to form 
neuronal populations that express a number of the desired neuronal markers but no significant 
effect on gene expression was caused by transfection with saRNA. It also suggests that the 
population being created may not be the A9 midbrain neuronal population, indicated by the 
loss of otx2 expression which has been shown by Chung et al. to be a marker for the efficient 
generation of DA neurons (Chung, Moon et al. 2011).  
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Analysis of DA target genes in hESC and hiPSC confirmed the findings of Chapter 4, showing 
that the DA differentiation protocol generates foxa2
+/lmx1a
+/TH
+ populations. The inclusion of 
saRNA within the differentiation protocol did not result in significant changes in the majority of 
genes assessed. Although it was observed that marginally higher expression levels for target 
genes:  TH,  lmx1a  and  DRD  (Figure  56)  were  found  in  hESC  cultures  when  transfected, 
suggesting that the saRNAs did impact slightly on expression levels. Further optimisation of the 
process could result in significant results. Foxa2 expression in hESC cultures was observed to 
be  significantly  impacted  by  transfection  over  that  of  UT  cultures  (Figure  56,  A).    Foxa2 
expression was also of note due to the disappointing findings of Chapter 4, where expression 
was negative by D24. Foxa2 expression in this investigation was observed across all conditions, 
potentially  resulting  from  the  age  of  the  cultures.  hiPSC  showed  no  significant  difference 
between UT and saRNA transfected cultures for foxa2, lmx1a and DRD expression, however 
did show significantly enhanced expression for TH in saRNA transfected cultures over that of 
UT (Figure 56, G). hiPSC expression of foxa2 was shown never to exceed that of D0 confirming 
results from Chapter 4 and implying that hiPSC, specifically MSUH001 may not be suitable for 
this type of cell manipulation.  
These findings though not significant, suggest that saRNA transfection has some impact on the 
gene expression. It is possible that the effects of the saRNA in our findings are overshadowed 
by the total population mRNA expression. This is a limitation of the analytical technique (qPCR) 
employed within this work.  
6.6.4  Confocal analysis of saRNA transfected cultures versus UT cultures 
qPCR allowed us to assess gene expression at a population level but not at the individual cell 
level,  confirming  qPCR  findings  using  immunocytochemistry  was  important,  reflecting  the 
translation  of  mRNA  to  protein  and  the  locality  of  foxa2  and  TH  up-regulation.  Confocal 
microscopy confirmed that both UT DA differentiation and saRNA incorporation generated 
neuronal (β-III-Tubulin
+) cell types from both hESC and hiPSC (Figure 57, A-D & E-H). It was  
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observed  that  all  treatments  produced  β-III-Tubulin
+/TH
+  cells,  confirming  neuronal 
differentiation had been achieved, and also confirmed results from the qPCR analysis, showing 
that  TH  was  being  translated  to  the  protein  level.  Immunocytochemistry  staining  of 
differentiated cultures also confirmed the presence of Foxa2
+/TH
+ cells within the cultures 
following 14 days in DDM (Figure 58), however co-association was found to be rare (Figure 
59/Figure 60). This low level of co-expression and the lack of otx2 gene expression indicated 
that the cells generated within this work were not all the targeted A9 midbrain DA neurons 
desired.   
Quantification of Foxa2
+ and TH
+ cells and their co-expression was attempted using confocal 
microscopy and Volocity software (Figure 59, Figure 60). Representative images were taken 
from four locations on the neurospheres from all culture conditions and this was repeated for 
all three biological replicates. This work confirmed that Foxa2
+ and TH
+ cells were present in all 
cultures but co-staining (Foxa2
+/TH
+) was found only rarely. saRNA transfection appeared to 
increase the level of Foxa2 protein expression but reduced TH protein levels relative to UT 
cultures.  Results  were  so  varied  that  significant  conclusions  could  not  be  drawn.    These 
findings indicated that though the protocols with and without saRNA could differentiate hPSC 
toward a DA (Foxa2
+/TH
+) lineage, consistency within the protocol had not been achieved. 
6.6.5  The potential of reducing the saRNA incorporated into the protocol 
To  understand  the  individual  impact  of  the  saRNA  and  to  assess  the  importance  in  their 
inclusion we undertook an investigation that removed foxa2 saRNA from the work. Foxa2 gene 
expression was shown to be impacted the greatest when cultures were transfected with all 
saRNA. It was hypothesised that any changes observed were due to the foxa2 saRNA targeting 
that specific target gene. 
qPCR analysis showed that pluripotent marker gene expression dropped in hESC and hiPSC 
mimicking  previous  findings  (Figure  64).  Fgf5  expression  behaved  atypically  during  this 
experiment with reductions in expression observed in all conditions (Figure 65). The expression  
 
180 
 
of  neuronal  genes  was  low  when  compared  with  previous  findings,  with  nurr1  and  otx2 
showing very little change from D0 levels in hESC and negative expression in hiPSC (Figure 66), 
contradictory to findings in the previous work (Figure 55).  
In addition, DA marker gene expression was contrary to previous experiments: in previous 
work, foxa2 in hESC and TH in hiPSC showed significant differences in expression for cultures 
transfected with saRNA (Figure 56, A & G) whereas in the reduced saRNA work, differences 
were not found (Figure 67, A & G). These findings suggest a vital role for the foxa2 saRNA in 
the protocol. This result compliments the work of Kriks et al. which suggests that a number of 
factors can be required to induce the desired response, not just one factor is always the 
master trigger (Kriks, Shim et al. 2011).  
These results may also indicate variability in the quality of the starting material or in the 
reagents used. Cell types were continuously cultured from frozen samples and maintained 
over time in feeder-based cultures, the inherent age of the cultures could impact on their 
performance (Xie, Hiona et al. 2011). It is possible that the reduced saRNA experiment was 
performed on cells that were different genetically (due to age or cryopreservation) to those 
used in the previous experiments, impacting results. Karyotyping was periodically undertaken 
(outsourced) for the cell lines used within this work, this was done to assess the karyotypic 
stability  of  the  cell  lines,  but  this  did  not  control  against  point  mutations  or  genetic 
modification.  Moreover,  RNAi  research  has  shown  that  uncharacterised  off-target  effects 
might play a role in determining gene expression responses (Jackson and Linsley 2010). The 
reagents used may have also been affected over time, chemical and growth factors were 
stored in their respective recommended conditions and freeze-thaw was kept to a minimum 
during this work, although effects outside of our control could have led to the degradation of 
reagents, impacting on results. These are all aspects that would need to be understood and 
mitigated if this technology is to progress towards the clinic.  
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6.6.6  Aggregate transfection efficiency 
Transfection  data  from  adhered  cultures  indicated  that  the  enhancement  in  target  gene 
expression in cultures transfected with saRNA should be significant. And yet cell aggregates 
showed neutral to low impact of saRNA on gene expression. To understand this contradiction, 
we  artificially  formed  aggregates  of  known  cell  volumes,  either  1,000  or  2,000  cells  per 
aggregate using aggrewell technology (Figure 68).  Aggregates were transfected with the siGLO 
transfection control over 3 days and then dissociated and quantified using flow cytometry. This 
work  showed  that  the  size  of  the  aggregate  influenced  the  transfection  efficiency  of  the 
protocol and it is logical that the larger the aggregate the fewer cells are exposed to the 
transfection reagent, reducing the efficiency of the reagent (Figure 69).  This observation may 
explain the low level of influence of the saRNA and would be an interesting area for future 
work.  I  propose  that  due  to  our  protocol  being  based  on  aggregate  technology  and 
neurosphere expansion, only a small proportion of the cells on the surface were exposed to 
the lipid based regent and saRNA. Cells within the aggregate core will have not been in contact 
with the saRNA and so unaffected, resulting in the population gene study results (qPCR) being 
overshadowed by the mass of unaffected cells in the centre of the aggregates, influenced only 
by the media conditions. 
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6.7  Conclusion 
hPSC  can  be  successfully  transfected  using  nanofectin  in  adhered  culture  and  this  is 
translatable to suspension culture. The functionality of saRNA in adhered hiPSC was found to 
have the greatest effect on target gene expression when all saRNA were used in conjunction. 
Unfortunately  when  this  technology  was  used  on  aggregates  during  differentiation, 
transfection  was  inefficient  and  failed  to  promote  greater  effects  beyond  that  of 
differentiation media alone. New strategies to penetrate beyond the outer surface layers of 
the aggregates need to be explored. Lipid-based transfection methods may not be optimal for 
aggregates  due  to  transient  functioning  of  saRNA  and  due  to  the  need  for  continuous 
application, disassociating the cells is not an option.  
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CHAPTER 7 - THE EFFECT OF INITIAL SEEDING DENSITY ON PLURIPOTENT 
AND  NEURONAL  GENE  EXPRESSION  DURING  11  DAYS  OF  NEURONAL 
PRIMING 
This independent section of work was designed to investigate the effects of initial cell seeding 
density (ICSD) on the expression of neuronal genes by two hPSC populations, hESC (Shef6) and 
hiPSC (MSUH001), during an 11 day neuronal priming protocol.  
7.1  Introduction 
In order to successfully address the challenges of cell therapy manufacture at an industrial 
scale, it is important to ensure all stages of the bioprocess are optimised firstly at the bench 
scale. The initial stage of many expansion or differentiation processes involves the plating of 
the cell population onto an appropriate substrate for attachment and growth. The substrate 
has  been  shown  to  be  critical  for  culture,  for  example  hPSCs  are  often  plated  onto  iMEF 
(Thomson, Itskovitz-Eldor et al. , Reubinoff, Pera et al. 2000) or specially adapted for survival 
and growth on acellular materials such as matrigel (Xu, Inokuma et al. 2001). In addition to 
substrate,  ICSD  can  have  a  significant  impact  on  cell  behaviour  and  is  reported  to  alter 
proliferation and differentiation responses of various adult cells during 2D culture (Peh, Toh et 
al. 2013) and 3D culture for tissue engineering purposes (Oh, Lee et al. 2012). In the case of 
hPSC it has been shown that passaging hESC colonies at a lower density of 1:8 results in a 
higher degree of spontaneous differentiation versus those passaged at a higher density of 1:3 
(Heng, Liu et al. 2006). Using mouse 46C embryonic stem cells, Veraitch et al. demonstrated 
that lower ICSD specifically enhanced neuroectoderm differentiation, identified by enhanced 
sox1 expression (Veraitch, Scott et al. 2008).  
For these reasons ICSD should be addressed when investigating the scalable expansion of 
therapeutic  cell  lines  to  achieve  the  necessary  clinical  quantities.  As  cell  therapy  culture 
develops from lab scale to manufacturing scale, it will be important to address ICSD in both an  
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adherent and suspension-based system, this may be in the form bioreactor or micro-carrier 
bead culture (Abbasalizadeh, Larijani et al. 2012, Bardy, Chen et al. 2013). Scalable expansion 
obstacles are not just the case for primary somatic cell populations, where expansion is held 
back  by  limited  replicative  potential  and  biological  changes  accompanying  cell  aging 
(Salehinejad,  Alitheen  et  al.  2013),  but  also  for  pluripotent  cell  lines  that  are  prone  to 
karyotypic abnormalities with extended periods in culture (Pera 2011, Steinemann, Gohring et 
al. 2013). Understanding the impact of ICSD will allow researchers to optimize and potentially 
reduce  the  starting  material  needed  to  produce  a  cellular  therapeutic,  which  will  be  of 
substantial benefit to the regenerative medicine industry. 
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7.2  Aim 
The aim of this study was to determine the impact of ICSD on the expression of key genes 
during neuronal induction of hPSC lines. Work was based on established protocols, which use 
smad signalling inhibition along with DA factors to induce neuronal differentiation (Chambers, 
Fasano et al. 2009, Kriks, Shim et al. 2011) and mapped the gene expression profile associated 
with  the  shift  away  from  a  pluripotent  state,  during  neuronal  priming  and  induction  of a 
specialised phenotype over the first 11 days of differentiation. 
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7.3  ICSD Results 
7.3.1  ICSD confluence analysis 
Confluence analysis of the hESC culture population (Figure 70, A & B) showed that over the 
first 4 days of culture, each ICSD showed distinct cell coverage in comparison to the other ICSD 
investigated, however, by D6 this difference had disappeared and all cultures reached 100% 
confluence.  No  significance  was observed  between  the  three  ICSD; 10k/cm
2,  18k/cm
2  and 
25k/cm
2 at any time point.  
A similar trend was observed with the hiPSC population (Figure 70, C) with cell confluence 
steadily  increasing  over  the  culture  period,  no  significance  was  observed  across  the  ICSD 
investigated.  
From these findings it was decided that neuronal priming would commence at D3, although no 
significance was observed, distinct cell densities (associated with the different ICSD) could be 
observed in both cell types. 
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Figure 70 - hPSC ICSD confluence over 7 days 
A) Representative bright-field images of hESC confluence over the initial 6 days of expansion (Scale bar = 400µm). 
B) hESC and C) hiPSC confluence analysis performed over 7 days, 20 representative images of each cell density 
were taken in duplicate, daily. Confluence was assessed using Method for Automated Confluence Estimation 
software (Error bars represent SEM, n=2 (day 1-4) n=1 (day 6-7)). 
7.3.2  ICSD impact on culture population gene expression 
hPSCs  were  cultured  according  to  the  protocol  described  in  materials  and  methods.  Cell 
samples were harvested at D0, D5 and D11 and assessed using qPCR, allowing us to track the 
changes in gene expression throughout the priming protocol. 
7.3.3  Influence of ICSD on hPSC pluripotent gene expression 
qPCR analysis of pluripotent mRNA expression of both nanog and oct4 showed that neuronal 
priming  with  smad  inhibition  resulted  in  significant  reductions  of  nanog  and  oct4  gene 
expression across all ICSD, in both hPSC types. hESC and hiPSC expression of nanog was shown 
to decrease >1.9
-1ΔΔCq and >1
-2ΔΔCq fold relative to D0 by D5 (Figure 71, A, D). At D5 hESC 
nanog  expression  indicated  that  lower  ICSDs  resulted  in  a  greater  decrease  in  expression 
relative to 25k/cm
2, this trend did not continue to D11. In both cell types this reduction in 
expression was maintained through to D11. Oct4 expression exhibited a stepwise reduction in  
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expression for both cell types. D5 expression showed significant decreases in expression with 
hiPSC  showing  the  greatest  reduction.  This  trend  carried  on  through  to  D11  where  hiPSC 
showed a >1
-3ΔΔCq compared with hESC reduction of >1.2x10
-2ΔΔCq (Figure 71, E, B). 
Expression of sox2 unlike nanog and oct4 was shown to increase in both cell types (Figure 71, 
C, F). hESC analysis showed that higher ICSDs resulted in significantly greater expression of 
sox2 relative to D0. At D5, 25k/cm
2 exhibited significantly higher levels of expression relative to 
other  ICSD  investigated,  and  by  D11,  both  18k/cm
2  and  25k/cm
2  showed  similar  and 
significantly higher expression levels relative to 10k/cm
2.  
 
 
Figure 71 - qPCR analysis of the influence of ICSD on pluripotent gene expression during neuronal 
priming  
qPCR analysis of pluripotent mRNA expression over the course of neuronal priming, D0 through to D11. hESC and 
hiPSC  expression  of    nanog  (A/D),  oct4  (B/E)  and  sox2  (C/F)  are  shown  relative  to  D0  expression.  Data  was 
normalised using GAPDH, Ubiquitin-C and β-Actin expression (* p< 0.05 and ** p<0.01. Bars = Mean ± SEM. n=3).  
 
189 
 
7.3.4  Influence of ICSD on hPSC fgf5 gene expression 
hESC expression of fgf5 was shown to significantly increase by D5 and continued to increase 
for the duration of the protocol at the three ICSDs. However, both 18k & 25k/cm
2 increased 
significantly whilst 10k/cm
2 did not over the remaining 6 day period to D11 (Figure 72, A). 
Expression of fgf5 in hiPSC increased relative to D0 but did not continue to increase over time. 
At both the time points, fgf5 expression was higher in 25k/cm
2 ICSD (Figure 72, B).  
 
Figure 72 - qPCR analysis of the influence of ICSD on fgf5 expression during neuronal priming 
qPCR analysis of fgf5 mRNA expression over the course of neuronal priming, D0 through to D11. (A) hESC and (B) 
hiPSC expression of fgf5 is shown relative to D0 expression. Data was normalised using GAPDH, Ubiquitin-C and β-
Actin expression (* p< 0.05 and ** p<0.01. Bars = Mean ± SEM. n=3). 
7.3.5  Influence of ICSD on hPSC sox1 and pax6 gene expression 
hESC early neuronal marker sox1 expression (Figure 73, A) was enhanced over time for all ICSD 
to D11. At D11, 10k/cm
2 was shown to have enhanced expression relative to the two higher 
ICSD.  Pax6  expression  also  increased  throughout  the  duration  of  the  protocol,  with  no 
distinction identified between the ICSD by D11 (Figure 73, B).   
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Figure 73 - qPCR analysis of the influence of ICSD on hESC sox1 and pax6 expression during neuronal 
priming 
qPCR analysis of hESC mRNA expression over the course of neuronal priming, D0 through to D11. Expression of (A) 
sox1 and (B) pax6 are shown relative to D0 expression. Data was normalised using GAPDH, Ubiquitin-C and β-Actin 
expression (* p< 0.05 and ** p<0.01. Bars = Mean ± SEM. n=3).  
Sox1 and pax6 expression in hiPSC (Figure 74, A & B) increased significantly over the course of 
the experiment.  
 
Figure 74 - qPCR analysis of the influence of ICSD on hiPSC sox1 and pax6 expression during neuronal 
priming 
qPCR analysis of hiPSC mRNA expression over the course of neuronal priming, D0 through to D11. Expression of (A) 
sox1 and (B) pax6 are shown relative to D0 expression. Data was normalised using GAPDH, Ubiquitin-C and β-Actin 
expression (* p< 0.05. Bars represent Mean ± SEM. n=3).   
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7.3.6  Influence of ICSD on hPSC otx2 and foxa2 gene expression 
Expression of otx2 within the hESC population was shown to significantly increase over the 
course of the culture period when compared with D0. At D11, 10k/cm
2 was shown to have 
significantly  greater  expression  than  that  of  the  two  higher  ICSD  (Figure  75,  A).  hiPSC 
expression of the otx2 gene (Figure 75, C) was observed to increase for the first 5 days and 
then drop significantly to D11. Similar to the experiment with hESC, expression of otx2 in hiPSC 
was not observed to increase past 1
1ΔΔCq. In hESC (Figure 75, B) and hiPSC (Figure 75, D), 
foxa2 expression was shown to fall over the course of the culture period relative to D0.   
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Figure 75 - qPCR analysis of the influence of ICSD on otx2 and foxa2 gene expression during neuronal 
priming 
qPCR analysis of otx2 and pax6 mRNA expression over the course of neuronal priming, D0 through to D11. hESC and 
hiPSC expression of  otx2 (A/C) and pax6 (B/D) are shown relative to D0 expression. Data was normalised using 
GAPDH, Ubiquitin-C and β-Actin expression (* p< 0.05 and ** p<0.01. Bars = Mean ± SEM. n=3). 
7.3.7  Influence of ICSD on hPSC TH and lmx1a gene and protein expression 
hESC expression of TH was observed to increase over the course of the priming protocol. At 
D11  it  was  shown  that  the  lowest  ICSD,  10k/cm
2,  showed  significantly  greater  expression 
compared to the other ICSD ( 
Figure 76, A). Expression of lmx1a (  
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Figure 76, B) was shown to increase relative to D0 but by D11, 25k/cm
2 was shown to decrease 
significantly relative to D5 and the other ICSD investigated; 10k/cm
2 was observed to have the 
highest levels of lmx1a at D11. Immunocytochemical staining for hESC was inconclusive. 
 
Figure 76 - qPCR analysis of the influence of ICSD on hESC TH and lmx1a expression during neuronal 
priming 
qPCR analysis of hESC mRNA expression over the course of neuronal priming, D0 through to D11. Expression of (A) 
TH and (B) lmx1a are shown relative to D0 expression. Data was normalised using GAPDH, Ubiquitin-C and β-Actin 
expression (* p< 0.05 and ** p<0.01. Bars = Mean ± SEM. n=3).  
While expression of TH in hiPSC was shown to increase throughout the protocol, no trends 
could be identified associated with ICSD (Figure 77, A). Expression of TH was confirmed at a 
protein level, with a few cells showing more developed phenotypes (Figure 77, C). At D11 it 
appeared that there were more TH
+ cells present at the lowest ICSD (10k/cm
2) but within the 
higher ICSD, mature neuronal phenotypes were present. 
Expression of lmx1a was shown to increase to D5, however, by D11 expression of lmx1a fell 
significantly  for  all  ICSD.  No  distinction  could  be  made  between  the  ICSD  (Figure  77,  B). 
Staining showed wide spread expression of lmx1a though no difference could be observed 
across the ICSD (Figure 77, C).   
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Figure 77 - qPCR and immunocytochemical analysis of the influence of ICSD on hiPSC TH and lmx1a 
expression during neuronal priming 
qPCR analysis of hiPSC mRNA expression over the course of neuronal priming, D0 through to D11. Expression of (A) 
TH and (B) lmx1a are shown relative to D0 expression. Data was normalised using GAPDH, Ubiquitin-C and β-Actin 
expression (* p< 0.05 and ** p<0.01. Bars = Mean ± SEM. n=3). C) Immunocytochemical staining of hiPSC expression 
of TH and Lmx1a at D5 and D11 (Scale bars = 100µm)  
7.3.8  Passage methods tested on hiPSC line  
This work assessed the ability of the neuronal priming protocol in influencing neuronal gene 
expression of hPSC and its ability to drive hPSC towards a neuronal lineage. To exploit this 
protocol and any ability to drive neuronal gene expression, it was imperative that cultures 
could  next  be  passaged.  Over  the  11  days  in  the  priming  culture,  cultures  had  become 
confluent with no further capacity to expand. Two methods of passaging were trialled on hiPSC  
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within this work, mechanical and enzymatic; with enzymatic being the most appropriate for 
bioprocessing in the future because it can be carried out in a closed system and did not require 
manual manipulation. 
Mechanical passaging with a sterile pastette was trialled, with and without ROCK inhibitor. The 
representative images shown in Figure 78, A, show a high level of cell death with very low 
adherence of cells to the culture plastic 2 days after passaging. The addition of ROCK inhibitor 
did not reduce cell death when compared with the culture without ROCK treatment.  
Enzymatic  passaging  was  also  trialled  with  Tryple  Express,  a  gentle  disassociated  enzyme 
favoured within the laboratory and appropriate for use alongside qPCR analysis. Cells were 
incubated for 5min (Figure 78, B), with and without ROCK inhibitor, and 10min (Figure 78, C) 
without ROCK inhibitor. All protocols resulted in low cell viability and low cell adhesion as 
represented by the bright-field images.  
 
196 
 
 
Figure 78 - Passaging methods trialled on hiPSC cultures 
Representative  bright  field  images  of  hiPSC  cultures  at  D11,  passaged  mechanically  (using  scraper,  A)  or 
enzymatically for set time periods, (B) 5min and (C) 10min.  Cells were either passaged with or without ROCK 
inhibitor supplemented into the media to help prevent spontaneous cell death. Images were taken 2 days post 
passaging (Scale bars = 100µm). 
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7.4  Discussion 
Through the use of in-house confluence analysis software (Jaccard, Griffin et al. 2014), we 
were able to accurately assess the cell density of cultures seeded at three different ICSD over 
the first 6 days of culture. Using this we identified a specific time point that we felt would 
allow us to assess the impact of ICSD on neuronal priming of hPSC cultures. 
Analysis  of  both  hESC  and  hiPSC  cultures  identified  D3  as  the  optimal  day  to  start  the 
experiment. This time point resulted in distinct and reproducible densities; ~40%, ~60% and 
~80% for ICSDs 10k/cm
2, 18k/cm
2 and 25k/cm
2 respectively. Both cell lines followed this trend, 
although  hiPSC  were  observed  to  expand  quicker  than  hESC  resulting  in  slightly  higher 
densities at D3. 
To  allow  us  to  assess  the  impact  ICSD  on  the  level  of  pluripotency  and  neuronal  gene 
expression a sample was taken at D0, to act as the internal control and all gene expression 
levels are shown relative to this. During experimentation samples were taken at D5 and D11, 
to capture the impact of ICSD over the duration of the experiment.  
Pluripotent gene expression analysis showed a significant drop in expression of nanog in hESC 
and hiPSC (Figure 71, A, D), as was reported by Chambers et al. when using a similar protocol 
to achieve an 80% yield in neuronal progenitors (Chambers, Fasano et al. 2009). Nanog within 
hESC was observed to show significantly lower expression in 10k & 18k/cm
2 when compared to 
25k/cm
2.
  Oct4  was  also  shown  to  reduce  significantly  over  time  in  both  cell  types,  again 
replicating results shown by Chambers et al. Oct4 reduction in both cell types increased over 
time with significant reductions being shown to D5 and then to D11, this indicates that oct4 
was either slower to be impacted by the smad inhibition or was more abundant within the 
pluripotent population than nanog (Figure 71, B/E). These results indicate that the cultures 
moved  away  from  expressing  genes  associated  with  maintained  pluripotency  towards  a 
differentiated  state.  Moreover,  this  drop  in  expression  was  accompanied  by  a  concurrent 
increase in expression of fgf5 (Figure 72), indicating differentiation to the late epiblast stage  
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and early ectoderm phase (Pelton, Sharma et al. 2002). This expression increase was found to 
be greatest in the higher ICSD investigated, suggesting a role of ICSD in fgf5 expression. Lower 
expression in the lower ICSD at D11 may suggest that these populations may have matured 
faster  than  the  higher  ICSDs,  and  passed  the  point  of  expression  when measured.  This  is 
corroborated by the expression of more mature neural and neuronal markers, sox1, otx2, TH 
and lmx1a by D11 in 10k/cm
2 cultures. 
Sox2 expression was also assessed within the cohort of pluripotency genes. It was shown that 
the highest expression resulted from the highest ICSD investigated in hESC; however this trend 
was not reflected in hiPSC results (Figure 71, C, F) which showed no difference in expression 
relating to ICSD. Increased expression of sox2 in both hPSC cultures is associated with the 
acquisition of a neuronal progenitor phenotype (Graham, Khudyakov et al. 2003) and further 
supports a shift away from pluripotency towards the ectodermal/neuronal lineage. The higher 
ICSD of 25k/cm
2 led to higher population-wide expression of fgf5, however, combined with the 
increased expression of later neuronal markers at lower ICSD, it is possible that in the higher 
ICSD  investigated,  a  higher  proportion  of  the  population  stay  in  this  late  epiblast/early 
ectoderm  stage,  whereas  at  10k/cm
2,  stagnated  expression  of  fgf5  possibly  indicated 
differentiation past the epiblast stage (Figure 72). 
Sox1  an  early  neuroectoderm  marker  showed  significant  increases  in  expression  over  the 
course of the protocol, with 10k/cm
2 showing significantly greater expression by D11 in hESC 
(Figure  73,  A).  Enhanced  expression  of  sox1  was  also  observed  in  hiPSC,  though  no 
differentiation could be discerned associated with ICSD (Figure 73 & Figure 74). Pax6, an early 
neuroectoderm marker and key gene in the development of neural tissue (Walcher, Xie et al. 
2013) also showed significant increases in expression when compared to the control in both 
cell  types  (Figure  73  &  Figure  74).  These  findings  replicated  findings  by  Chambers  et  al 
(Chambers, Fasano et al. 2009), that smad inhibition moved hPSC towards a neural lineage and  
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strengthen  previous  findings  in  this  work,  that  these  cultures  are  moving  away  from  a 
pluripotent state and towards a neuronal phenotype.  
The suggestion that lower fgf5 expression in hESCs at 10k/cm
2 indicates a move down the 
ectoderm lineage is enforced by the significant difference in sox1 expression observed at D11. 
This trend was repeated for otx2 at 10k/cm
2 where higher expression was noted compared to 
the other ICSDs (Figure 75), possibly indicating more rapid differentiation towards mature 
neuronal  states  at  lower ICSD.  This  supports  previous observations  in mouse  ESCs,  where 
increased  neuroectoderm  differentiation  was  noted  at  lower  ICSDs  (Veraitch,  Scott  et  al. 
2008). Expression of neuronal genes by hiPSCs was not as prominent as those observed for 
hESCs, with relative expression of the majority of genes screened never showing greater than 
1x10
2ΔΔCq  increase.  This  may  indicate  a  reluctance  of  the  cell  type  to  move  down  the 
ectoderm lineage. In the case of hiPSCs, the reduction in otx2 expression over time (Figure 75, 
C) would also suggest that differentiation is not toward a mid-neural tube phenotype. 
This assumption in hiPSCs is supported by the expression profile of TH and lmx1a (Figure 77), 
with TH showing significantly reduced expression at both 18k & 25k/cm
2  from D5 to D11 and 
lmx1a expression showing a significant drop across all ICSDs within the hiPSC populations. 
Protein analysis of these cultures showed a contradictory story with hiPSC exhibiting mature 
TH phenotypes in 18 & 25k/cm
2 (Figure 77, C). In the case of hESCs, the trend for TH and lmx1a 
(Figure  76)  was  similar  to  that  found  for  the  other  pro-neuronal  genes;  the  lowest  ICSD 
(10k/cm
2) led to significantly greater expression of TH and lmx1a than the higher ICSDs. The 
highest ICSDs showed the only significant drop in lmx1a expression observed in hESCs (Figure 
76, B), enforcing the hypothesis that lower ICSD and level of confluence at the commencement 
of differentiation can improve the efficiency of lineage specification that is needed to drive 
towards a DA neuronal cell phenotype.  
Foxa2 gene expression did not behave as expected and was observed to decrease in both cell 
types, rather than increasing, as was the case for TH and lmx1a. This observation is thought to  
 
200 
 
be a result of the smad signalling inhibition, blocking differentiation towards the endoderm 
lineage of which foxa2 is associated (Burtscher and Lickert 2009). 
To develop the potential of this protocol within the bioprocess of a product, we investigated 
the ability of hiPSC cultures to be passaged. hiPSC were used at this stage due to their greater 
availability and robustness compared to hESC. Mechanical and enzymatic passaging methods 
were trialled; these were supplemented with or without ROCK inhibition to reduce cell death. 
These techniques were tested three times and it was found that cultured cells could not be 
passaged. At this stage it was decided to discontinue this line of work, pursuing suspension 
culture as a more viable bioprocess alternative. 
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7.5  Conclusion 
This work showed that low ICSD resulted in an overall improved neuronal differentiation in 
hESCs, with greater expression of a number of neuronal genes including TH and lmx1a. hESCs 
had a greater propensity than hiPSCs to differentiate towards an ectoderm cell type, when 
assessing population-wide gene expression. Even though differences were evident between 
the two pluripotent cell lines, this data provides evidence that ICSD can affect target gene 
expression and hence differentiation during neuronal lineage commitment.  
The positive response under the protocol was limited by the inability to passage the resulting 
cultures.  A  number  of  avenues  were  explored  to  overcome  this  hurdle  but  we  were  not 
successful in passaging the cells and we moved instead to use a suspension-based system that 
showed true potential in scalability and bioprocessing.  
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CHAPTER 8 - FINAL DISCUSSION 
The CTI is a rapidly growing market with an estimated value in 2012 of $7Bn (Mason, McCall et 
al. 2012). This is an exciting area of research, not just because of the potential financial value 
being created but mainly the number of clinical indications that it could address. These include 
orphan  indications  like  Stargardt’s  macular  dystrophy,  to  widespread  conditions  such  as 
ischemic stroke and PD (Trials.gov 2013). The CTI may provide the opportunity to make a step 
change in the provision of healthcare; providing a cure rather than symptomatic control for a 
number of conditions, resulting in long-term relief to patients and their loved ones. 
This thesis studied stem cells from two classes of cell: (i) autologous cells (omnicytes) and (ii) 
allogeneic  cells  (hESC  and  hiPSCs).  In  particularly,  this  work  focused  on  their  respective 
potential to specifically derive neuronal cell populations, and the factors that enhance the 
yield of these populations. This study, performed within a framework, investigated the use of 
omnicytes in the generation of neurons for the treatment of acute ischemic stroke and the use 
of hPSC in the differentiation of DA neurons for the treatment of PD. 
These two conditions are attractive targets for cell therapy, due to their impact on individuals 
and  society,  with  the  number  of  affected  people  anticipated  to  become  greater  with  the 
ageing population. They are also natural targets because existing therapies are limited in their 
application. 
There are very few interventions for ischemic stroke currently available. A pharmacological 
intervention, rt-PA (Albers, Bates et al. 2000), has a treatment window of 6hrs and mechanical 
interventions (Bose, Henkes et al. 2008, Cohen, Itshayek et al. 2011) that require surgeons to 
physically  remove  the  embolism  following  stroke.  The  timing  requirements  of  these 
treatments means a majority of patients do not receive treatment, resulting in a high level of 
mortality or serious disabilities following the onset (Deb, Sharma et al. 2010). An alternative 
treatment option is high on the agenda. In-vivo studies have shown the potential of HSCs 
within an ischemic environment, resulting in enhanced neovascularization and neurogenesis  
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along with reduced scaring (Taguchi, Soma et al. 2004). This study investigated the use of 
omnicytes, a sub-population of the HSC population, to efficiently derive functional neurons, 
which  could  then  be  administered  to  replace  lost  cells  and  function  to  aid  endogenous 
recovery. 
PD is not a terminal condition but does result in a gradual and irreversible deterioration of the 
patient,  with  symptoms  worsening  as  the  disease  progresses  (UK  2010,  UK  2013). 
Pharmacological and surgical treatments that are currently available for this condition, do not 
slow or prevent the progression of the disease but serve only to control symptoms. Because 
PD is caused predominantly by the loss of a specific cell type within the substantia nigra, A9 DA 
neurons (German, Manaye et al. 1989), it is a particularly attractive target for cell therapy. 
Trials  involving  the  transplantation  of  foetal-derived  DA  grafts  have  previously  shown 
promising results (Lindvall and Kokaia 2009). The goal of this work was to use autologous 
derived cells, rather than grafts, to differentiate DA neurons, in-vitro, under quality controlled 
and efficient protocol to provide improved and a widely available treatment for patients.   
This  thesis  investigated  the  potential  of  omnicytes  and  hPSCs  to  generate  neuronal  cell 
populations. It also investigated the potential of a novel RNA technology, saRNA, to affect the 
transient up-regulation of specific target genes with the intention of increasing the yield of DA 
neurons from hPSC. 
8.1  The use of omnicytes in neuronal differentiation 
Omnicytes were discovered in 1994 as a subpopulation of the CD34
+ cell population. They 
were speculated to contain the regenerative capabilities of the CD34
+ population due to their 
morphology and gene expression i.e. they had the potential to differentiate into all 3 germ 
layer lineages (Gordon 1994, Gordon, Levicar et al. 2006), similar to that of hESC.  
This thesis investigates whether omnicytes have the capability to differentiate into neuronal 
populations due to the endogenous expression of a number of neuronal genes; and aimed to 
generate specialized neurons once proof of principal had been achieved.   
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A number of methods were investigated to exploit the proposed potential of omnicytes and 
achieve  neuronal  differentiation,  including:  media  manipulation  using  smad  signalling 
inhibition (Chambers, Fasano et al. 2009) and growth factor manipulation (Jiang, Henderson et 
al. 2003); as well as the inclusion on microRNA to effect change at a molecular level.  
We were able to show that by using ‘expansion mix’ it was possible to expand the starting 
population six-fold, thereby establishing a population to interrogate our hypothesis. We also 
showed that during expansion, the majority of target neuronal genes, including, sox1, sox2 and 
otx2 were stably expressed, indicating a neuronal primed population suitable for testing our 
hypothesis. 
Manipulation of the expanded omnicyte population using different media was observed to be 
largely unsuccessful, although it was shown neuronal genes including sox1 and otx2 could be 
sustained over the culture period and some cells adhered to the culture surface and changed 
in morphology. We were unable to induce the expression of pax6 (Bel-Vialar, Medevielle et al. 
2007), a marker gene considered essential in moving this differentiation process forwards 
through to mature neurons (Chambers, Fasano et al. 2009).  
Due to lack of results from media manipulation, we attempted to use microRNA in an effort to 
manipulate  the  omnicytes  at  a  molecular  level  and  induce  neuronal  differentiation.  We 
focused this work on two microRNA, miR124 and miR9. These microRNAs have now been 
found by Yoo et al. to transdifferentiate human fibroblasts into functional neurons (Yoo, Sun et 
al. 2011), though our work on omnicytes was less successful. Results were highly variable and 
largely negative.  
We showed that patient variability and cryopreservation impacted on the consistency of the 
results. The response of cells to manipulation using these protocols depended heavily on the 
source cell origin and preservation techniques, and indicated that further work on this cell type 
would be hindered until a consistent and reliable source of cells could be ascertained.  
 
205 
 
Due to the high level of patient variability observed and rarity of the cell type restricting their 
use, it was decided that the research would refocus on readily available cell sources (hESC and 
hiPSC). The work performed on these cell sources, hPSC, would include the use of a novel RNA 
technology, saRNA. 
8.2  Aggregate-based differentiation of dopaminergic neurons from hPSC 
To allow us to investigate the potential of saRNA and their ability to increase the yield of 
differentiated  neuronal  populations  we  first  needed  to  produce  the  desired  neuronal 
population in-vitro. The focus of the research moved towards PD and the differentiation of DA 
neurons.  
We  showed  that  the  cell  populations  (hESC  and  hiPSC)  we  were  using  were  pluripotent, 
through their marker expression at both a genetic and protein level. We also showed that 
these  cells  were  able  to  generate  cells  of  the  3  germinal  layers,  through  spontaneous 
differentiation, affirming their status as pluripotent.  
Results showed that the methodology used in this project reduced key pluripotency genes 
along  with  contaminating  germ  layer  markers  in  both  hESC  and  hiPSC.  The  protocol  also 
induced up-regulation of neuronal progenitor genes, sox2 and fgf5 indicating a move toward 
the ectoderm linage, which was confirmed by expression of  sox1. Further interrogation of 
neuronal genes showed that the protocol was able to up-regulate key DA genes including; 
nurr1, otx2, en1, TH, DRD, lmx1a and foxa2 in hESC, indicating success in driving hESC towards 
a DA neuronal cell type. The protocol was shown to be less successful for hiPSC cultures, with a 
number of key genes (nurr1, otx2 and foxa2) not being expressed during the differentiation 
process, indicating a need for further optimization of the patterning process or the use of a 
different cell type.  
These findings were examined at the protein level for both cell types, with expression of 
nestin, TH and foxa2 following maturation being observed. The ability of these differentiated 
cultures  to  respond  to  stimuli  and  express  dopamine  was  also  confirmed  and  quantified  
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through ELISA, indicating that we had been successful in generating functional DA neurons 
from both cell types. Results from hiPSC at a molecular and protein level did not correspond, 
highlighting a key limitation of this work, using qPCR; this will be discussed in more detail in 
the limitations section. 
Experiments  were  also  performed  to  understand  the  impact  of  extended  culture  on  DA 
differentiation and gene expression. This was done by extending the time aggregates were 
cultured in suspension or by doubling the length of time neurospheres were stuck down and 
matured. Analysis showed that extending the time in suspension or extending stick down time 
had a detrimental impact on a number of the key target genes expressed, namely foxa2 and 
lmx1a. It was hypothesized that the resultant reduction in gene expression may be a result of 
the increased size of the aggregates in extended culture; and that as aggregates grow, necrotic 
death occurs within the core. This occurs because nutrients, growth factors and oxygen cannot 
penetrate to the whole cell population. This hypothesis is supported by work published by Van 
Winkle et al., that found that cell aggregate size impacts on the ability of factors to perfuse to 
the  core,  resulting  in  starvation  (Van  Winkle,  Gates  et  al. 2012).  This  result suggests  that 
extended culture without a feasible passaging method is not advisable. 
8.3  Potential of saRNA in dopaminergic differentiation 
Building on these finding using an aggregate-based differentiation programme, we re-focused 
to increase the yield through the incorporation of saRNA. The aim of this work was to enhance 
the expression of three key DA marker genes, foxa2, lmx1a and TH (Kriks, Shim et al. 2011), 
and impact on the expression of associated genes, resulting in the enhancement of DA neuron 
yield. 
The initial optimization using cancer cell lines and omnicytes proved inconclusive. We expect 
the lack of consistency in results to be due to the insensitive nature of rtPCR and the inherent 
variability of omnicytes as mentioned above.   
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Optimization of saRNA in adherent hiPSC cultures, in contrast, resulted in enhanced expression 
of all target genes; a compilation of all saRNA transfected together resulted in the greatest 
increase in target gene expression.  
Following the transfection of the suspension-based DA differentiation cultures for 24 days, 
hESC culture’s expression of sox1, nurr1 and en1 were revealed to be slightly enhanced in 
transfected cultures relative to UT cultures. These findings were further strengthened by the 
increase in DA marker expression (TH, foxa2, lmx1a and DRD) observed in saRNA transfected 
cultures. Although not statistically significant these results indicated that saRNA transfection 
was impacting on gene expression. Contrary to this, hiPSC were found not to respond to saRNA 
manipulation, confirming finding from the previously work that the particular hiPSC line being 
used may not be an appropriate cell type for the differentiation of DA neuronal populations 
and the incorporation of this technology. Neuronal differentiation was confirmed at a protein 
level (β-III-Tubulin
+ and TH
+) for both cell types.   
Through  protein  analysis  cells  were  found  to  express  TH
+  and  foxa2
+  across  the  whole 
neurosphere but to assess the whole population was impractical resulting in the targeting of 
stain rich areas but this inherently skewed findings. Greater levels of foxa2 were shown to be 
present in both cell types when transfected with saRNA. Contrary to this, TH expression was 
found to drop following transfection. Although this demonstrates an impact of the saRNA, 
because  of  the  method  of  analysis,  and  the  inherent  biased  nature  of  the  procedure,  no 
conclusions could be drawn at a protein level. 
Work done to understand the individual impact of the saRNA, found that foxa2 saRNA had a 
vital  role  in  the  protocol.  Key  genes  that  had  previously  shown  a  slight  increase  when 
transfected with all saRNA (foxa2/TH/lmx1a), did not show this response when transfected 
without the foxa2 saRNA. This finding suggested synergistic action of the saRNAs; to induce the 
desired response, multiple factors may need to be applied (Kriks, Shim et al. 2011).  
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Through  this  work  it  was  hypothesized  that  aggregate  size  may  impact  on  transfection 
efficiency, in so directly impacting on saRNA efficiency. Larger aggregates would show lower 
transfection efficiency when compared to smaller aggregates due to the mechanism of action 
of  the  lipid-based  transfection  reagent  (endocytosis).  Although  this  experiment  was  not 
performed  to  statistical  significance,  results  suggest  that  aggregate  size  does  impact  on 
transfection efficiency. It is thought that by using a transfection reagent that functions via cell-
lipid  endocytosis,  only  the  surface  layer  cells  were  affected  by  the  reagent.  In  smaller 
aggregates the surface cells represent a larger proportion of the whole cell population. To 
maximize transfection efficiency, aggregates either need to be disassociated to a single cell 
layer then transfected and re-aggregated, which is not feasible or a mechanism to control 
aggregate size employed. 
8.4  Impact of ICSD on neuronal priming 
Investigating the impact of ICSD was an independent piece of work within the thesis. It was 
undertaken to understand the impact of ICSD on neuronal priming.  
We showed that lower ICSD resulted in faster up-regulation of pro-neural genes including, 
otx2,  TH  and  lmx1a.  However,  higher  ICSD  (25k/cm
2)  showed  greater  expression  of  early 
neuronal progenitor markers (sox2 and fgf5), over the same culture period.  These findings 
suggest  delayed  differentiation  within  higher  ICSDs;  this  may  the  result  of  a  ‘cell  niche’ 
environment. This work could not be pursued as it was found that passaging the cultures was 
not  possible,  but  this  work  does  have  implications  on  the  wider  regenerative  medicine 
industry. It demonstrates a need to account for ICSD when designing any new differentiation 
process as it could impact on differentiation efficiency. 
8.5  Limitations  
There were a number of limitations that were identified whilst carrying out this research. Here, 
they are identified, along with prospective solutions in future work:  
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i.  The  endogenous  gene  expression  of  omnicytes  would  suggest  that  they  have  the 
potential to  differentiate into  different  lineages.  The  advantage of  this  is  that  the 
source  cell  type  could  be  obtainable  from  the  patient,  negating  the  need  for 
immunosuppression. However, the current availability of the cell type limits the ability 
to develop this technology and as shown within this work, patient variability, disease-
type and preservation techniques impact on the performance of the cells. To address 
this, a consistent source of cells needs to be identified; CD34
+ cells can be acquired 
commercially, providing a source of consistent quality to develop this work.   
ii.  It has been shown that the use of lipid-based transfection reagents within this work 
impacted on the ability to transfect the whole cell population. Nanofectin functions via 
cell-lipid endocytosis; this means that only cells on the surface of the aggregates are 
influenced  by  the  saRNA  being  transported  by  the  nanofectin.  To  achieve  optimal 
transfection, cell aggregates need to be disassociated into single cells, transfected and 
re-aggregated; because saRNAs only provide transient expression this process would 
be required every 3 days; this is not feasible as it would impact on cell viability, and 
would hinder scale-up. To address this limitation, the implementation of a continuous 
or gradual transfection method would be required, this may be in the form of retro-
viral transfection as done with siRNA (Devroe and Silver 2002) or the use of slow 
release nanoparticles as is being developed for the distribution of growth factors by 
Zhang et al. (Zhang, Zhou et al. 2014). These methods would allow the transfection of 
the saRNA to be continuous within the cell population or delay the release of the 
saRNA until the nanoparticles have diffused to the core of the aggregate. 
iii.  The use of an aggregate-based system, though having the potential for scale-up does 
also present some issues that need to be addressed. It has been shown by Van Winkle 
et al. (Van Winkle, Gates et al. 2012) that aggregate size has a direct impact on oxygen, 
growth factors and nutrient diffusion into the aggregates. In this method, because 
there is no way to passage (in a closed system), the aggregate size was not controlled,  
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resulting in increasingly larger aggregates. This inherently results in aggregates over 
the optimal size, reducing the diffusion of factors to the whole population. To address 
this, aggregate size needs to be standardized at D0. This could be achieved through the 
use of aggrewell technology, which enables the synthesis of uniform aggregates. This 
would ensure that aggregates are uniformly impacted by reagents and conditions. For 
the  continuous  control  of  aggregate  size  a  bioreactor,  including  impeller  could  be 
incorporated (Olmer, Lange et al. 2012). 
iv.  The main analysis method utilized within this work was PCR, both rtPCR and qPCR. 
Although  these  techniques  allow  the  analysis  of  gene  modification  within  the 
experimental sample, in this work gene expression analysis was limited to the whole 
cell  population.  As  observed  a  number  of  times  within  this  thesis,  molecular  and 
protein  results  did  not  reflect  each  other,  this  is  likely  to  be  a  result  of  whole 
population gene expression obscuring the expression of the smaller, differentiated 
population. To investigate this further and to gain an accurate understanding of the 
changes induced using these protocol, single-cell qPCR should be incorporated. It is 
important for the future development of cell products that the desired markers are 
expressed homogenously throughout the cell population; this will not be illuminated 
using qPCR whole population analysis.  
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CHAPTER 9 - FINAL CONCLUSION 
This  thesis  studies  a  number  of  methods  for  driving  omnicytes  down  a  neuronal  lineage; 
including, adapting the length of the culture and changing the timing of the manipulation, both 
by signalling pathway manipulation and molecular modification. The experiments did not show 
the changes in gene expression thought to be indicative of a neuronal population switch. 
Further, it was found that the results were not consistent, with no two replicates producing 
the  same  reading.  Although  we  expect  that  the  lack  of  consistency  is  a  result  of  patient 
variability and the impact of storage method (cryopreservation), the lack of consistency and 
the general nonappearance of changes in gene expression following manipulation suggest that 
omnicytes are not a strong cell source for cell therapy development.  
The investigation also studied cancer cell manipulation and the utilization of hPSC. DA-like 
neurons were derived from hPSC using a suspension-based aggregate differentiation protocol. 
Down-regulation of pluripotent and germ layer genes and up-regulation of key neuronal and 
dopaminergic genes were observed. The products of this protocol also expressed a number of 
neuronal and DA protein markers and responded to stimuli to release dopamine, indicating 
that the protocols successfully derived functional DA-like neurons though the generation of A9 
dopaminergic neurons was not confirmed.  
After establishing a baseline of in-vitro DA-like neurons, the thesis studied the potential of 
saRNA to increase yield. Results were disappointing. In adhered culture, notable expression 
changes  were  observed  when  transfected  with  all  saRNA,  though  once  utilized  within 
aggregate culture these changes were insignificant: slight up-regulation was observed in hESC 
transfected  cultures  in  key  genes  such  as  nurr1,  sox1,  en1,  TH,  foxa2  and  lmx1a,  but  no 
significance was found. It was hypothesized that the low impact of saRNA was a result of the 
low  penetration  of  the  saRNA  into  the  cell  aggregates.  Further  work  will  be  required  to 
develop  this  protocol  and  the  method  of  transfection  addressed  to  ensure  the  saRNA 
penetrates beyond the outer surface of the aggregates and affects the whole cell population.   
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Alongside the derivation of neuronal populations, an independent experiment investigated the 
impact  of  ICSD  on  neuronal  priming.  We  showed  that  lower  ICSD  resulted  in  improved 
neuronal priming, with enhanced expression of a number of neuronal genes including TH and 
lmx1a in hESC. It was observed that hESCs have a greater propensity to differentiate towards 
an ectoderm cell type, indicating that that hiPSC (MSUH001) are not a suitable cell type for the 
development of neuronal cell therapy development.  
This work has shown that though omnicytes express a number of markers indicating their 
potential to differentiate into all germ layers and be a prime starting material for cell therapy 
products; the reliable sourcing of this cell type needs to be addressed, so to mitigate the 
effects of patient variability and storage during product development. This body of work has 
also  provided  evidence that  saRNA  can  be  used  within  an  aggregate-based differentiation 
protocol to enhance gene expression and impact on DA yield. Up-regulation of key genes can 
be induced, though transfection efficiency needs to be addressed prior to this being fully 
realized.  
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CHAPTER 10 - FUTURE WORK 
This investigation has highlighted a number of limitations in moving this technology forwards 
and  towards  a  viable  product  for  commercial  manufacture.  Future  work  should  focus  on 
incorporating saRNA into the DA differentiation protocol.  
The following investigations could be used to take this work further: 
1. Understand how aggregate size impacts on the efficiency of transfection, incorporating 
new  techniques  and  technologies  to  mitigate  the  identified  limitations  of  lipid-based 
reagents. 
In the development of an aggregate-based differentiation system it will be essential that future 
work understands the impact of aggregate size on: cell viability; the ability for aggregates to 
differentiate;  growth  factor,  oxygen  and  nutrient  perfusion;  and  transfection  efficiency. 
Through work reported by Van Winkle et al. (Van Winkle, Gates et al. 2012) we know that 
different growth factors and cytokines differ in their ability to penetrate cell aggregates, for 
this reason a full analysis of the material being used within this protocol is required. To address 
these  issues  technology,  for  example,  slow  release  nanoparticles  could  be  investigated  to 
deliver  various  factors  including  saRNA,  allowing  factors  to  penetrate  further  into  the 
aggregates. 
2. Incorporate alternative analytical techniques at the individual cell level to understand the 
impact of the saRNA at a molecular and protein level. 
To  fully  understand  the  impact  of  new  processes  and  additives  on  the  end  product  it  is 
important to assess at the whole-population, as well as the individual-cell level. This work was 
limited by our ability to only assess at the whole-population level. To take this work forwards, 
analytical  techniques  including  Fluorescence-activated  cell  sorting  (FACS)  to  understand 
protein expression at a population level and individual-cell qPCR to fully elucidate the impact 
of  the  protocols  at  the  single-cell  level  should  be  utilized.  Prior  to  the  generation  of  any  
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therapy it is imperative that the full effects of the protocol being utilized are understood, and 
that homogenous cell differentiation is occurring. These protocols could eventually serve as 
screening methods for product release.  
3. Develop a technique for the isolation and purification of differentiated DA neurons. 
Following the confirmation and proof of principal of the technology a purification technique is 
required to provide high resolution purification as to generate the end product for patient 
treatment. It is important that this method is able to effectively remove contaminating cell 
types, although not to the detriment of the final end product recovery (Weil 2014). It will be 
important that this is addressed early in the development of the therapy as to not create an 
unnecessary  bottleneck  later  in  the  progression  of  the  product.  This  could  involve  the 
incorporation of FACS for specific antigens. 
4.  Incorporate  the  use  of  an  impeller  driven  bioreactor  to  allow  complete  and  uniform 
control of the aggregate culture environment, controlling aggregate size and enabling the 
scale-up. 
Once proof of principle is achieved, this research will need to move from static flasks into an 
impeller  driven  bioreactor  (enabling  the  technology  to  progress  from  the  bench-top  to 
bedside).  The  bioreactor  would  allow  the  cellular environment  to  be  controlled  (including 
monitoring pH, oxygen, waste gases, and nutrient and growth factor levels) and contained 
within a closed-system, thereby reducing the risk of infection. An impeller allows the user to 
control of aggregate size (Olmer, Lange et al. 2012), which in turn would allow optimal size to 
be maintain, allowing sufficient perfusion of growth factors, nutrient, oxygen and saRNA to the 
core of the aggregate.  
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